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List of abbreviations 
AE atopic eczema  
ANOVA analysis of variance 
APCI atmospheric pressure chemical 
ionization  
aSMASE acid sphingomyelinase  
ATR attenuated total reflectance 
a.u.  arbitrary unit 
AUC area under the curve 
BCA bicinchoninic acid 
BSA bovine serum albumin 
CCD charge-coupled device 
CER ceramide  
CERS ceramide synthase  
CHOL cholesterol  
ED electron diffraction 
ELA2 elastase 2 
ELOVL elongation of very long chain fatty 
acids  
FEG field emission gun 
FFA free fatty acid  
FLG filaggrin gene 
FTIR Fourier transform infrared 
spectroscopy  
FWHM full width half maximum  
hex hexagonal 
HPLC high performance liquid 
chromatography  
IS internal standard 
KLK kallikrein  
LB lamellar body  
LC-MS liquid chromatography-mass 
spectrometry  
LEKTI lympho-epithelial Kazal-type-related 
inhibitor  
LPP long periodicity phase  
MCT  mercury-cadmium-telluride  
MUFA mono-unsaturated fatty acid  
NeS Netherton syndrome  
NMF natural moisturizing factor  
orth orthorhombic 
PAR2 proteinase-activated receptor 2  
PCA 2-pyrrolidone-5-carboxylic acid 
PPAR peroxisome proliferator-activated 
receptor  
S/N signal to noise ratio  
SAXD small angle X-ray diffraction  
SB stratum basale 
SC stratum corneum  
SCD stearoyl-coenzyme A desaturase  
SCORAD scoring atopic dermatitis 
SD standard deviation 
SEM standard error of the mean 
SG stratum granulosum  
SPINK5 serine protease inhibitor Kazal-type 5  
SPP short periodicity phase  
SS stratum spinosum 
TEM transmission electron microscope 
TEWL transepidermal water loss  
TSLP thymic stromal lymphopoietin 






AdS α-hydroxy fatty acid amide-linked to a dihydrosphingosine base 
AH α-hydroxy fatty acid amide-linked to a 6-hydroxysphingosine base 
AP α-hydroxy fatty acid amide-linked to a phytosphingosine base 
AS α-hydroxy fatty acid amide-linked to a sphingosine base 
EOdS esterified ω-hydroxy fatty acid amide-linked to a dihydrosphingosine base 
EOH esterified ω-hydroxy fatty acid amide-linked to a 6-hydroxysphingosine base 
EOP esterified ω-hydroxy fatty acid amide-linked to a phytosphingosine base 
EOS esterified ω-hydroxy fatty acid amide-linked to a sphingosine base 
NdS non-hydroxy fatty acid amide-linked to a dihydrosphingosine base 
NH non-hydroxy fatty acid amide-linked to a 6-hydroxysphingosine base 
NP non-hydroxy fatty acid amide-linked to a phytosphingosine base 












1. Function and structure of the skin 
The function of the skin is to act as an effective barrier against unwanted 
environmental influences as well as to prevent excessive water loss from the body. 
The skin consists of the epidermis and dermis as well as the subcutaneous fat tissue 
(Figure 1)1. 
 
Figure 1. Schematic overview of human skin and its different layers.  
Adapted from: http://www.dermnetnz.org. 
 
1.1 The epidermis 
The epidermis is the outermost layer of the skin and can be divided into four 
distinctive layers, characterized by different stages of differentiation. These include 
the stratum corneum (SC), stratum granulosum (SG), stratum spinosum (SS), and 
stratum basale (SB). The SG, SS and SB are part of the viable epidermis (thickness 
50-100 μm), while the SC (thickness 10-20 μm) is part of the non-viable epidermis.  
The SB is the innermost layer of the viable epidermis and consists of the 
proliferating cells of the skin. All the keratinocytes (the most prevalent cell type in 
the epidermis) are derived from these cells. The keratinocytes transiently migrate 
and differentiate from the SB towards the SC, after which they are finally released 
from the skin surface, a process called desquamation. During the differentiation, 
which starts in the SS, the keratinocytes flatten out and begin to assume the 
dimensions which are characteristic for the dead cells of the SC, the corneocytes. As 
the cells flatten they become filled with keratin. In the SG enzymes are activated 
that start to degrade the viable cell components such as the nuclei and organelles. 
The SG also contains many membrane-coating granules called lamellar bodies 
(LBs), in which glucosylceramides, sphingomyelin and phospholipids are stored. 
These are precursors of the SC ceramides (CERs) and free fatty acids (FFAs). 
The lipid and hydrolytic enzyme content of the LB is released via  
exocytose at the SG/SC interface. The SC consists of corneocytes which are 
embedded in a lipid matrix and acts as the main barrier for diffusion of substances 




1.2 Structure of the stratum corneum 
SC contains 10 to 25 corneocyte layers which are embedded in lipid bilayers and are 
oriented parallel to the skin surface. The corneocytes are filled with water  
and microfibrillar keratin. The corneocytes are surrounded by a cornified cell 
envelope which consists of a densely crosslinked layer of proteins. A monolayer of 
non-polar lipids is esterified to the cornified envelope. This monolayer forms  
the matrix for the intercellular lipid bilayers. This envelope minimizes the uptake  
of most substances into the corneocytes. The structure of the SC is often referred to 
as a “bricks in mortar” structure, in which the corneocytes are the bricks and the 
lipids are the mortar. 
There are two possible penetration routes for a compound diffusing into 
intact human skin: the transappendageal route and the transepidermal route. The 
first route involves transport via the sweat glands, sebaceous glands and hair 
follicles. This route circumvents penetration through the SC and is considered to be 
a route less contributing to the transport of the compounds compared to the 
transepidermal route. This is based on its relatively small surface area of 0.1% of 
the total skin area5. The transepidermal route can occur either via the transcellular 
(intracellular) or intercellular pathway. The latter has been suggested to be the 
most important route for drugs since the above described cornified envelope is 
highly impermeable for compounds6. Therefore, the intercellular pathway has been 
suggested to be the preferred route for most compounds. Several studies report 
that the transport of compounds is mainly directed along the intercellular SC 
lipids7-9. For that reason the lipids play an important role in the skin barrier 
function, and alterations in lipid composition and/or organization may play a role 
in a decreased skin barrier function. 
 
1.3 Stratum corneum lipid composition 
The intercellular lipid matrix mainly consists of CERs, cholesterol (CHOL) and 
FFAs in an approximately equimolar ratio10-12. CERs consist of a sphingoid base  
to which a fatty acid is linked. To date, 12 CER subclasses have been identified in 
human SC13,14. They differ from each other by their head-group architecture  
and acyl chain length. The sphingoid moiety can be dihydrosphingosine (dS), 
sphingosine (S), phytosphingosine (P) or 6-hydroxysphingosine (H). The fatty acid 
moiety is non-hydroxylated (N) or α-hydroxylated (A) with chain lengths  
of predominantly 24 to 26 carbon atoms. Furthermore, the acyl-CERs possess  
a unique molecular architecture: a very long ω-hydroxy fatty acid (EO) with a  
chain length of 30-34 hydrocarbon atoms to which linoleic acid (C18:2)  
is esterified. Figure 2 shows the molecular structure of the 12 CER subclasses 






Figure 2. Structure and nomenclature of CERs present in human SC. All CERs consist of a polar head 
group and two long carbon chains. The polar head group varies in molecular architecture (at the carbon 
positions marked in red), resulting in 12 different subclasses in human SC. Both chains in every CER 
subclass show varying carbon chain lengths (marked by red arrows). Each CER subclass is denoted by 
its sphingoid base (blue) and fatty acid chain (gray) resulting in 12 CER subclasses. The abbreviations 
are as follows: For the sphingoid base: dihydrosphingosine (dS), sphingosine (S), phytosphingosine (P), 
6-hydroxysphingosine (H). The various acyl chains are denoted by: non-hydroxy fatty acid (N),  
α-hydroxy fatty acid (A) and esterified ω-hydroxy fatty acid (EO). This results in the 12 CER subclasses 
notations: [NdS], [AdS], [EOdS], [NS], [AS], [EOS], [NP], [AP], [EOP], [NH], [AH], [EOH].  
 
The CER synthesis takes place in 4 steps. The variety in CER subclasses is 
generated in the final 2 steps. These last 2 steps start with the lipid 
dihydrosphingosine, which is acylated by one of the 6 CER synthases 
(CERS1-6)15-17. Each CERS has a specificity for the fatty acid chain length and 
degree of saturation that it attaches to the dihydrosphingosine16. In the last step the 
dihydrosphingosine based CER is converted to either sphingosine, 
phytosphingosine or 6-hydroxysphingosine. The de novo synthesis occurs at the 
cytosolic leaflet of the endoplasmatic reticulum. After the final synthesis step the 
CERs are transferred to the Golgi apparatus. There they are transferred into either 
glucosylceramides by linkage of glucose to the primary hydroxyl group of the CERs 
or to sphingomyelin by linkage of a phosphorylcholine group to this hydroxyl 
group15. During movement of the cells into the direction of the skin surface the 
glucosylceramides and sphingomyelin are stored into the cells mainly in lamellar 
bodies. At the viable epidermis-SC interface sphingomyelin and glucosylceramides 




hydrolysis of the phosphorylcholine from sphingomyelin. Cleavage of the glucose 
group from glucosylceramides is catalyzed by the enzyme β-glucocerebrosidase. 
Glucosylceramides are precursors of all 12 CER subclasses in human SC while 
sphingomyelin is the precursor of CER [AS] and CER [NS]18-21. 
FFAs mainly consist of saturated carbon-chains with lengths varying 
between 14 and 32 carbon atoms. The most abundant chain lengths are 24 and 26 
carbon atoms22,23. FFAs are generated by the catabolism of phospholipids that are 
extruded from the lamellar bodies by phospholipases24. After synthesis of FFAs 
with a chain length of 16 carbon atoms by fatty acid synthase, elongation is 
performed by 7 elongases (ELOVLs1-7)25-27. Each ELOVL has its own fatty acid 
chain length specificity. Stearyl-CoA desaturase catalyzes saturated FFAs to  
mono-unsaturated FFAs or poly-unsaturated FFAs28.  
 
1.4 Stratum corneum lipid organization 
Human SC consists of a unique lamellar arrangement of the intercellular lipids 
(Figure 3). Small angle X-ray diffraction (SAXD) studies on human SC revealed the 
presence of a 13 nm lamellar phase, referred to as the long periodicity phase (LPP). 
Besides a 13 nm lamellar phase, a second lamellar phase has also been identified. 
The periodicity of this phase is approximately 6 nm and is therefore indicated  
as the short periodicity phase (SPP)29-31. In contrast to the SPP, the LPP is only 
identified in the SC and not in other biological membranes, which suggests that the 
LPP phase plays an important role in the barrier function of the skin32. Because  
of their unusual long esterified fatty acid chain, the acyl-CERs are able to span  
a layer and extend into another adjacent layer. These long-chain CERs are  
therefore thought to link the different lipid layers in the LPP. The long  
ω-hydroxy chain also induces strong Van der Waals interactions. Both  
aspects contribute to the stability of the 13 nm lamellar phase. CER [EOS] even has 
shown to be crucial for the formation of the LPP33. 
The packing of the lipids within the lamellae is referred to as the lateral lipid 
organization (Figure 3). With increasing packing density this is either liquid, 
hexagonal or orthorhombic. In healthy human SC, the lipids form mainly an 
orthorhombic lipid organization at skin temperature, although also domains with a 
hexagonal or liquid organization exist22,34.  
2. SC hydration 
The hydration level of the SC is regulated by the natural moisturizing  
factor (NMF)35. NMF is composed of filaggrin-derived amino acids (e.g. 
pyrrolidone carboxylic acid and urocanic acid), specific sugars and salts. The amino 





Figure 3. Overview of lamellar and lateral organization in human stratum corneum.  
(1) The outermost layer of the epidermis, the stratum corneum (SC), consists of dead cells (corneocytes) 
embedded in a lipid matrix, also referred to as the bricks (corneocytes) and mortar (lipids) structure  
(2). The intercellular lipids are arranged in layers (lamellae) (3), with two coexisting lamellar phases 
(4). These lamellar phases have a repeat distance of 6 nm (referred to as the short periodicity phase 
(SPP)) or 13 nm (referred to as the long periodicity phase (LPP)). The lateral organization (5) is the 
plane perpendicular to the direction of the lamellar organization. There are three possible arrangements 
of the lipids: a very dense, ordered orthorhombic organization, a less dense, ordered hexagonal 
organization, or a disordered liquid organization.  
 
filaggrin36-38. This degradation process of filaggrin results in production of most of 
the NMF and depends on the SC water level, which in turn is partially dependent 
on the presence of NMF39, leading to a vicious cycle. The presence of NMF in the 
SC is not only important for hydration, but also maintenance of pH40. Changes in 
pH can have an effect on hydrolytic enzymes and effect enzymes that are involved 





3. Atopic eczema 
Atopic eczema (AE, also called atopic dermatitis) is a chronic relapsing 
inflammatory skin disease that is characterized by a broad spectrum of  
clinical manifestations such as dryness, erythema and pruritus42,43. The diagnosis 
of AE is based on a constellation of clinical findings, there is no pathognomonic 
biomarker for diagnosis.  
AE almost always starts in infancy and tends to resolve or improve 
remarkably by the age of 5 and it persists into adult life in approximately 15% of the 
cases44. AE can have a considerable effect on the quality of life; it can interfere with 
sleep due to itching and can therefore affect mental development and physical 
growth. As the disease is visible to the environment (Figure 4), patients can also 
have problems in their social life45.  
 
 
Figure 4. Patient with atopic eczema. Lesional (red) as well as non-lesional (normal appearing) skin 
can be observed. 
 
The past 20 years the prevalence of AE is increasing and is now almost affecting 
20% of children in developed countries, while in adults this is 5-10%46-48. A high 
percentage of AE patients develop other atopic diseases such as asthma and peanut 
allergy, referred to as the atopic march49.  
AE is triggered by a multifactorial setting including environmental factors 
(e.g. stress and infections) as well as genetic factors50. AE patients have several 
barrier abnormalities, including an increased transepidermal water loss (TEWL), 
increased surface pH and reduced SC hydration51-55. Even the non-lesional 
(‘clinically unaffected’) skin is not normal: it is frequently dry and has a high 
irritant skin response. Furthermore, an increased TEWL was observed in these skin 
regions indicating a decreased skin barrier function52-54. 
Two different subtypes of AE exist, the intrinsic and extrinsic form of AE.  
In the extrinsic subtype (~80% of all patients) allergic sensitization to an  
external antigen with subsequent allergen specific IgE production occurs. The  
other subgroup of patients has low serum IgE levels. These patients have the 




The etiology of AE is complex, it is a multifactorial disease, an interplay between 
genetics, environmental factors and immunological dysfunction.  
 
There are two hypotheses proposed concerning the mechanism of AE: 
i) The so called ‘inside-to-outside’ hypothesis in which AE is considered to 
be an immunological disorder. This view holds that the primary defect 
resides in a Th2-driven immunologic disturbance with epithelial barrier 
dysfunction as a consequence of this inflammation. The keratinocytes 
play a crucial role in the inflammatory response as they are 
immunologically active cells producing cytokines and chemokines56. 
Features of a Th2-driven immune response are local production of 
cytokines like IL-4, IL-5, IL-13, IL-17 and IL-22 (all Th2 cytokines), 
production of allergen-specific IgE, and activation of eosinophils and 
mast cells57. The secreted cytokines induce the production of thymic 
stromal lymphopoietin (TSLP), which can activate dendritic cells and 
stimulate the production of high levels of Th2 cytokines by human mast 
cells58,59. In chronic lesions there is a shift from solely a Th2 cell 
cytokine milieu to an environment of both Th2 and Th1 cell type 
cytokines like IFN-γ60.  
ii) The other hypothesis is the ‘outside-to-inside’ view in which the barrier 
abnormality is not a secondary phenomenon, but the ‘driver’ of the 
disease activity in AE61-63. The immunological aspects are secondary to 
the epithelial barrier dysfunction. In 2006 an important finding was 
reported, namely that AE is associated with filaggrin mutations64. As 
filaggrin is a barrier protein heavily involved in SC formation this is a 
major breakthrough in the validation of the outside-inside hypothesis as 
will be explained in the next paragraph. The extent of the permeability 
barrier abnormality correlates with disease severity and clinically  
non-lesional skin sites display impaired barrier function. A defect skin 
barrier may therefore facilitate the transport of allergens and irritants 
into the skin resulting in activation of both innate and adaptive immune 
system and inflammation54,65-67. This on turn may exacerbate the barrier 
defects which leads to a vicious circle. 
Nowadays, accumulating evidence shows that the mechanisms in both hypotheses 
interplay and/or may reflect the heterogeneity of AE. 
 
3.1 Filaggrin loss-of-function mutations and AE 
In 2006, Palmer et al. reported that two common polymorphisms (R501X and 
2282del4) in the filaggrin gene (FLG) are strong predisposing factors for AE64. 
Since then, more than 45 FLG mutations have been identified, including many 




associated with asthma, contact dermatitis, allergies (e.g. peanut, nickel) and are 
causal for ichthyosis vulgaris, a disorder of keratinization that is characterized by 
dry and scaly skin, decreased skin barrier function and often also by features of 
AE74-79. Between 8% and 48% of AE patients are carriers of FLG mutations80. 
FLG is located in the epidermal differentiation complex, a cluster of 
approximately 60 genes involved in epithelial differentiation, on chromosome 1q21. 
This group of genes is involved in the terminal differentiation of keratinocytes81. 
FLG encodes profilaggrin, a large insoluble polyprotein that is the  
major constituent of keratohyalin granules35,82,83. Profilaggrin is cleaved into  
10-12 copies of the filaggrin peptide84. Filaggrin is a component of the cornified 
envelope in SC. It associates with keratin filaments and contributes to their 
alignment, facilitating compaction of cells into squames82. Filaggrin is metabolized 
into a pool of free amino acids including histidine and glutamine which are  
further converted to urocanic acid (UCA) and 2-pyrrolidone-5-carboxylic acid 
(PCA), respectively38. Together with specific salts and sugars these free amino  
acids are referred to as NMF, which is important for SC hydration35. NMF acts as  
a very efficient humectant, by absorbing atmospheric water and dissolving it in  
the SC thereby allowing this layer to remain hydrated85. Expression of FLG  
and subsequent hydrolysis of filaggrin peptides into NMF are influenced by  
the properties of the microenvironment, including local pH, external humidity  
and transepidermal water loss86. 
Several studies have shown the correlation between FLG mutation status and 
NMF levels: AE patients that were carriers of FLG mutations had significantly 
lower NMF levels compared to non-carriers87,88. In addition, within the subgroup of 
FLG mutation carriers it is possible to distinguish between AE patients with 
homozygous (i.e. double null alleles) and heterozygous (1 null allele) FLG 
mutations by studying the NMF levels88. 
Howell et al. found that inflammation has an effect on filaggrin:  
Th2 cytokines down-regulate filaggrin expression89. They report that lesional  
skin of AE patients exhibit lower levels of filaggrin expression compared to non-
lesional skin in the same patient. 
Various studies report on the skin barrier function as assessed by TEWL  
and the presence of FLG mutations, however the role of FLG mutations in the 
barrier dysfunction as measured with TEWL is yet inconclusive; several  
studies report that TEWL did not associate with FLG genotype subgroups88,90-92. 
However, Gruber et al. report filaggrin dose dependent alterations in skin barrier 
function in ichthyosis vulgaris patients: TEWL did not differ significantly between 
controls without FLG mutations and carriers of heterozygous mutations, but  
was significantly increased in carriers of homozygous FLG mutations compared  
to controls93. These findings imply that the role of filaggrin in the impaired  




SC lipids, may play a role in the barrier dysfunction of AE patients. 
  
3.2 SC lipids in AE 
3.2.1 Lipid composition 
The total amount of SC lipids was found to be decreased in non-lesional as well as 
lesional skin94. There is contradicting evidence about the lipid ratios in the 
literature: Di Nardo et al. observed that the CER/CHOL ratio is reduced in  
non-lesional AE skin51. However, other studies do not report a decrease in CER 
content in non-lesional AE skin90,94-97.   
The first study on the CER composition in skin of AE was performed by 
Imokawa et al.94. They observed that CER [EOS] was reduced in SC of both  
non-lesional and lesional AE compared to control SC. A significant decrease in CER 
[NP] and CER [EOS] levels in SC of AE patients in the presence and absence of 
lesional skin lesions have also been reported51. In addition, an increased level of 
free CHOL was detected in this study. The level of CER [NP] significantly 
correlated with skin barrier function. Other studies also report reductions in CER 
[EOS], CER [EOP], CER [EOH], CER [NH] or CER [NP] in non-lesional and 
lesional AE SC92,96-98. In addition it was found that CER [AS] is increased in lesional 
AE SC96. These changes in lipid composition all strongly correlated with skin 
barrier function assessed with TEWL96 but did not show a clear relationship with 
the presence of FLG mutations92. 
Until now, most papers report on the CER subclass composition, not on the 
chain length distribution within the CER subclasses. Only one study focused on the 
chain length distribution. An increased level of CERs with very short chains (with a 
total chain length of 34 carbon atoms, referred to as C34) in the CER [NS] subclass 
in lesional AE skin was found96. The increased level in CER [NS] C34 correlated 
significantly with the skin barrier function as measured by TEWL: a higher level of 
short chain CER [NS] C34 correlated with a higher TEWL. The same study reports 
that the presence of long chain acyl-CERs correlates negatively with TEWL. These 
findings indicate that not only CER subclasses, but also the lipid chain length may 
play an important role in the skin barrier function in AE patients.  
Compared to the composition of CERs, hardly no information about the FFA 
composition in AE skin is available. It was reported that the level of very long chain 
fatty acids (more than 24 carbon atoms) was reduced in non-lesional as well as 
lesional skin of AE patients99.  
 
3.2.2 Effect of inflammation on lipid composition in AE 
It has been previously reported that production of cytokines can affect the lipid 
synthesis and therefore the skin barrier in AE100,101. TNF-α and several cytokines 
downregulate filaggrin expression102-105. Downregulation of filaggrin expression 




increase in pH can lead to altered catalytic activities of lipid processing enzymes 
sphingomyelinase and acid β-Glucocerebrosidase that require an acidic pH for 
their optimal catalytic activity106. Furthermore, the enzyme sphingomyelin 
deacylase has an abnormal expression in skin of AE patients107. This enzyme 
hydrolyzes sphingomyelin into sphingosylphosphorylcholine and FFA precluding 
the formation of CERs, therefore lowering CER levels in the SC of AE patients. 
Finally, peroxisome proliferator-activated receptors (PPARs), which are closely 
related to the skin lipid metabolic pathway show a relation to AE108: In AE the 
expression of PPAR-α and PPAR-γ are decreased whereas expression of PPAR-β/δ 
is upregulated109,110. These nuclear receptors promote SC barrier formation by 
stimulation of keratinocyte differentiation, lipid synthesis, lamellar body formation 
and secretion, and increased activity of enzymes required for the extracellular 
processing of lipids. Furthermore, PPARs are suggested to have anti-inflammatory 
properties in skin111-114. 
 
3.2.3 Lipid organization 
As a result of an altered SC lipid composition, the lipid organization in SC of AE 
patients may be altered. To date, only little is known about the lipid organization in 
SC of AE patients. Pilgram et al. used ED to study the lateral lipid organization in 
SC of 3 controls and non-lesional SC of 3 AE patients115. They report an increased 
percentage of hexagonal organized lipids in non-lesional AE SC compared to SC of 
control subjects. Furthermore, they did not compare the lipid organization between 
carriers and non-carriers of FLG mutations. 
Electron microscopic analysis of  biopsies of AE patients using  ruthenium 
tetroxide (RuO4) postfixation revealed a delayed and probably incomplete 
extrusion of lamellar bodies, suggesting that retention of lipids at their synthesis 
site occurs which makes them unavailable to the intercellular lipid matrix of the 
SC116. Abnormalities in lamellar architecture have been found in FLG deficient SC 
of ichthyosis vulgaris patients93. As this finding was FLG dependent, this may 
indicate similar alterations in AE SC.  
Until now, no studies have been carried out in which both the lipid 
composition as well as the lipid organization have been determined in AE patients 
and controls in vivo. From in vitro studies it is known that an altered lipid 
composition results in an altered lipid organization. Long-chain acyl-CERs are 
important for the formation of the LPP in human SC117. In addition, the presence of 
long-chain FFAs is crucial for the formation of an orthorhombic lateral lipid 
organization118. In vitro diffusion studies with lipid mixtures varying in lipid 
composition reveal the importance a proper lipid organization for the barrier 
function118-120. Therefore, it is expected that changes in lipid composition in SC of 
AE patients lead to an altered lipid organization, resulting in a decreased barrier 




4. This Thesis 
As described above, the skin barrier function of AE patients is impaired in  
non-lesional as well as in lesional skin. Although AE is associated with FLG 
mutations, the precise causes of AE-associated barrier dysfunction are not fully 
understood.  
 
4.1 Objectives of this thesis 
The main objective of the research described in this thesis is to address the role of 
the SC lipids in the impaired skin barrier function of AE patients. 
In order to achieve this we investigated (illustrated in Figure 5): 
i) The SC lipid composition in non-lesional and lesional skin of AE 
patients and in SC of control subjects. The levels of the lipid subclasses 
as well as the chain length distribution were examined. 
ii) The lamellar organization and lateral organization in SC of AE patients 
and of control subjects. 
iii) The relation between lipid composition, lipid organization, skin barrier 
function and disease severity. 
iv) The lipid/protein ratio in lesional and non-lesional skin of AE patents 
and control subjects and how this is related to the skin barrier function. 
v) The effect of FLG mutations as well as NMF levels on the SC lipid 
composition, organization and lipid/protein ratio. 
 
 







4.2 Outline of this thesis 
In chapter 2 of this thesis the lamellar lipid organization and CER subclass 
composition in SC of non-lesional skin are reported in a small group of AE patients 
and control subjects. The relation between CER subclass composition and lipid 
organization is examined. 
In chapter 3 a detailed analysis of lipid organization (lamellar as well as 
lateral) and a comprehensive analysis of CER composition in non-lesional SC of a 
large group of AE patients are described. The relation between lipid composition, 
organization and skin barrier function are assessed. In addition, we examine 
whether the lipid properties correlate with NMF, disease severity (Scoring Atopic 
Dermatitis, SCORAD) and presence of FLG mutations. 
In chapter 4 the use of electron diffraction to study the lateral lipid 
organization in non-lesional SC of AE patients and control subjects is reported. The 
occurrence of either a hexagonal or an orthorhombic lateral organization is 
examined and it is studied whether a correlation exists between the lateral 
organization and skin barrier function or presence of FLG mutations. 
In chapter 5 the lipid organization and total lipid composition (including 
FFAs) is provided in non-lesional and in lesional SC of patients with AE. In 
particular, the influence of the lipid chain length on the skin barrier function and 
lipid organization is described. Correlations between the lipid parameters and 
barrier function, disease severity and presence of FLG mutations are investigated. 
In chapter 6 studies are described using confocal Raman spectroscopy to 
determine the lipid/protein ratio in control subjects, non-lesional and lesional SC 
of patients with AE. In addition, the relation between lipid/protein ratio and skin 
barrier function is examined. 
In chapter 7 the lipid organization as well as the lipid composition in 
another inflammatory skin disease, Netherton syndrome, are described. The 
findings are compared to those obtained for AE. 
In chapter 8 the results of this thesis are summarized and suggestions  
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he existence of an impaired skin barrier function in atopic eczema (AE, 
also referred to as atopic dermatitis) has been demonstrated previously, 
revealing the importance of the skin barrier in the pathophysiology of 
AE1. Loss-of-function mutations in the filaggrin gene (FLG) are known to be a 
major risk factor for developing AE2. However, recent findings report a reduced 
skin barrier function irrespective of FLG genotype, suggesting the importance of 
additional factors for an impaired skin barrier in AE1.  
The skin barrier is primarily provided by the stratum corneum (SC), 
consisting of enucleated cells surrounded by lipid regions. SC lipids (primarily 
ceramides (CERs), cholesterol and free fatty acids) form two lamellar phases: the 
short- and long periodicity phase (SPP and LPP, respectively) with periodicities of 
~6 nm and ~13 nm respectively. These periodicities were determined by small 
angle X-ray diffraction (SAXD)3. Barrier properties of the skin may also depend on 
the lipid organization of the SC lipids and an altered lipid composition or 
organization may cause a reduced skin barrier in AE. Several studies report on the 
CER composition in AE patients4,5. In the present study, the CER composition and 
the lamellar lipid organization in SC of AE skin have been simultaneously 
examined. For AE patients, we observe drastic changes in lipid organization which 






The study was conducted in accordance with the Declaration of Helsinki and 
approved by the Ethical Committee of the Leiden University Medical Center. 
Subjects gave written informed consent. 6 Caucasian AE patients (23.3±5.2 years;  
2 males) and 6 Caucasian subjects without (history of) dermatological disorders 
(24.7±7.6 years; 1 male) were included. The subjects did not apply any 
dermatological products to their forearms for at least one week prior to the studies. 
To study the lipid properties irrespective of FLG mutations, we excluded subjects 
with any of the four most prevalent mutations found in European Caucasians: 
2282del4, R501X, S3247X and R2447X, analyzed by genotyping6. 
The lamellar lipid organization was studied using 4 mm biopsies harvested 
from the ventral forearm of non-lesional skin. Local severity of non-lesional AE 
skin was evaluated by local SCORing Atopic Dermatitis (SCORAD)7 and was 0 for 
all patients. SC was isolated by trypsin digestion8 and analyzed by SAXD using a 
microfocus beam (European Synchrotron Radiation Facility, Grenoble, France) 
similarly as described elsewhere9. The CER composition was examined in SC 
harvested by tape stripping non-lesional regions from the ventral forearm (PPS 
tape, Nichiban, Tokyo, Japan) close to the region of the biopsy. Tape strip numbers 
6 to 9 were extracted, pooled and analyzed by liquid chromatography (LC) (Alliance 
2695, Waters Milford, USA) coupled to mass spectrometry (MS) (TSQ-Quantum, 
Thermo Finnigan, San Jose, USA)10,11. The nomenclature of used CERs is described 
previously12. Briefly, CERs contain a fatty acid chain (either an esterified  
ω-hydroxy (EO), α-hydroxy (A) or non-hydroxy (N) fatty acid) linked via an amide 
to a sphingosine chain (either a sphingosine (S), dihydrosphingosine (dS), 
phytosphingosine (P) or 6-hydroxysphingosine (H)), resulting in 12 CER 
subclasses. 
Figure 1a shows 3 SC diffraction patterns representative for control subjects. 
The periodicity of the LPP was obtained from the peak positions3. All control 
subjects show three LPP peak positions (1st, 2nd and 3rd order) at scattering vector 
values (q) 0.50, 1.00 (main peak) and 1.45 nm-1 respectively, corresponding to a 
periodicity of 12.6 nm. The 1st order peak of the SPP also contributes to the main 
peak, which is located at a slightly higher q-value. Figure 1b shows diffraction 
patterns of AE patients. The top diffraction pattern closely resembles those of 
control subjects and is representative for 4 patients. However, two patients 
(marked  and ) show a different pattern: the central curve shows a shift in the 
main diffraction peak to a q-value of 1.06 nm-1 (labeled *). The lower curve shows 
only a single reflection at q=1.20 nm-1 (labeled **). Increased q-values of the peak 
positions signify shorter periodicities of the lamellar phases in SC of those patients. 
The boxplots (Figure 1c) show a small variance between the 6 control subjects, but 






Figure 1. Diffraction patterns of (a) SC of control subjects, (b) non-lesional SC of AE patients and (c) 
boxplots showing the variance of the main peak position in both groups. The inset in the upper right 
corner of (a) schematically represents the lipid organization and shows the periodicity of the LPP 
(d~12.6 nm).  and  indicate patients with an altered SAXD profile (indicated by * and **). # Indicates 
phase separated cholesterol. From the positions of the peaks (q) the repeat distance of the LPP was 
calculated using the equation d=n·2π/qn (n=order of diffraction peak). The main peak is also caused by 
the 1st order diffraction peak of the SPP located at a slightly higher q-values than the 2nd order of the 
LPP. 
 
Figure 2a shows the CER composition analyzed by LC-MS. All 12 CER subclasses 
were observed, including the newly identified CER [EOdS]11. The observed CER 
profile is very similar to that observed in previous studies using a fully quantitative 
method4,13. AE skin showed a significant decrease in the content of CER [NP] 
(P<0.005, student’s t-test) and in the content of long chain CERs (i.e. subclass 
[EO], Figure 2b, P<0.05, two-way ANOVA), which is in accordance to recent 
findings4. The highest reduction in abundance of CER [EO]-subclasses was 
observed in patients showing an altered X-ray diffraction pattern:  and in 
particular  (Figures 1 and 2). Previous studies have shown that the LPP may be 
important for the skin barrier function14: isolated human CERs with a decreased 
CER [EO] level showed a strong reduction in the formation of the LPP15. This 
variation in structure results in a more dominant influence of the 1st order SAXD 
peak of the SPP on the main SAXD peak, which explains the shift in peak position 
in the diffraction patterns of the two AE patients. 
To our knowledge, our studies demonstrate for the first time that a change in 
CER composition can be associated with a change in the lamellar lipid organization 




understanding of the altered SC lipid barrier in AE. 
 
 
Figure 2. LC-MS analysis on human SC CERs obtained from tape strips taken from the ventral forearm. 
To permit semi-quantitative analysis, two deuterated CERs (CER [E(18:2)O(30)S(18)] and CER 
[N(24)S(18)]) were used as internal standards. (a) Bar graph of the relative CER abundance (in 
percentages) of every CER subclass in SC of control subjects (green bars) and non-lesional SC of AE 
patients (maroon bars) (mean±SD, n=12). An unpaired student’s t-test showed a significant difference 
in NP content between control and AE subjects (P<0.005). (b) Boxplots of the relative CER abundance 
(in percentages) of the CER [EO] subclasses, as well showing the individual data points (n=12). Green 
and maroon boxes represent SC of control subjects and non-lesional SC of AE patients, respectively. 
ANOVA showed a significant difference in the total [EO] content ([EOdS]+[EOS]+[EOP]+[EOH]): 
P<0.05. Individual AE patients marked as  and  correspond to the same patients labeled in Figure 1.  
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hallmark of atopic eczema (AE) is skin barrier dysfunction. Lipids in the 
stratum corneum (SC), primarily ceramides (CERs), fatty acids and 
cholesterol, are crucial for the barrier function, but their role in relation 
to AE is indistinct. Filaggrin is an epithelial barrier protein with a central role in the 
pathogenesis of AE. Nevertheless, the precise causes of AE-associated barrier 
dysfunction are largely unknown. In this study, a comprehensive analysis of CER 
composition and lipid organization in non-lesional SC of AE patients and control 
subjects was performed by means of mass spectrometry, infrared spectroscopy and 
X-ray diffraction. In addition, the skin barrier and clinical state of the disease were 
examined. The level of CERs with an extreme short chain length is drastically 
increased in SC of AE patients, which leads to an aberrant lipid organization and a 
decreased skin barrier function. Changes in SC lipid properties correlate with 
disease severity but are independent of filaggrin mutations. We demonstrate for the 
first time that changes in CER chain length and lipid organization are directly 
correlated with the skin barrier defects of non-lesional skin of AE patients. We 
envisage that these insights provide a new therapeutic entry in therapy and 






The skin offers a protective barrier against allergens, irritants, microorganisms and 
prevents excessive transepidermal water loss (TEWL). The barrier function 
strongly relies on the outermost layer of the skin, the stratum corneum (SC), which 
consists of corneocytes embedded in a highly organized lipid matrix1,2. This lipid 
matrix is considered to be important for a proper skin barrier function. 
Ceramides (CERs), cholesterol and free fatty acids are the main lipid classes 
in SC. To date, 12 CER subclasses in human SC have been identified with a wide 
chain length distribution3,4. An explanation of the CER nomenclature is given in 
Figure 1.  
 
Figure 1. Structure and nomenclature of CERs. All CERs bear a polar head group and two long carbon 
chains. The polar head group may vary in molecular architecture (at the carbon positions marked in 
red), resulting in 12 different subclasses in human SC. Both chains in every CER subclass show varying 
carbon chain lengths (marked by red arrows). Each CER subclass is denoted by its sphingoid base 
(blue) and fatty acid chain (gray) resulting in 12 CER subclasses. The abbreviations are as follows: For 
the sphingoid base: dihydrosphingosine (dS), sphingosine (S), phytosphingosine (P),  
6-hydroxysphingosine (H). The various acyl chains are denoted by: non-hydroxy fatty acid (N),  
α-hydroxy fatty acid (A) and esterified ω-hydroxy fatty acid (EO). This results in the 12 CER subclasses 
notations: [NdS], [AdS], [EOdS], [NS], [AS], [EOS], [NP], [AP], [EOP], [NH], [AH], [EOH]. The number 
of total carbon atoms in the CERs (e.g. C34 CERs) is the number of carbon atoms in the fatty acid chain 







The aim of the present study was to determine the chain lengths of each CER 
subclass in non-lesional skin of atopic eczema (AE) patients and to correlate these 
with the lipid organization, skin barrier function and disease severity, see Figure 2. 
 
 
Figure 2. Schematic overview of the SC lipid parameters, clinical parameters and the determinants of 
the filaggrin content discussed in this chapter. These different parameters may all affect the skin barrier 
and are therefore investigated in this study. Arrows indicate possible correlations that are studied 
throughout the manuscript. 
 
AE is a chronic relapsing inflammatory skin disease characterized by a broad 
spectrum of clinical manifestations such as erythema, dryness and intense 
pruritus5,6. AE affects over 15% of Caucasian children and 2-10% of adults, and its 
prevalence is increasing rapidly especially in developed countries7-11. Patients have 
a decreased skin barrier function in lesional and non-lesional skin12-16.  
In previous studies it has been shown that AE is strongly associated with 
mutations in the filaggrin gene (FLG)17-19 but the role of FLG mutations in the 
barrier dysfunction is yet inconclusive20-25. Other factors, such as aberrations in the 
SC lipids, may play a role in the decreased skin barrier in AE12,26,27. In healthy SC, 
lipids form two lamellar phases with repeat distances of approximately 6 and 13 
nm. These are referred to as the short periodicity phase (SPP) and long periodicity 
phase (LPP), respectively28,29. A schematic presentation of the lipid organization is 
provided in Figure 3. Within the lipid lamellae, the lipids have a dense 
(orthorhombic) lateral organization, although a subpopulation of the lipids can be 






Figure 3. Lamellar and lateral organization in human stratum corneum. (1) The outermost layer of the 
epidermis, the stratum corneum (SC), consists of dead cells (corneocytes) embedded in a lipid matrix, 
also referred to as the bricks (corneocytes) and mortar (lipids) structure (2). The intercellular lipids are 
arranged in layers (lamellae) (3), with two coexisting lamellar phases (4). These lamellar phases have a 
repeat distance of 6 nm (referred to as the short periodicity phase (SPP)) or 13 nm (referred to as the 
long periodicity phase (LPP)). The lateral organization (5) is the plane perpendicular to the direction of 
the lamellar organization. There are three possible arrangements of the lipids: a very dense, ordered 
orthorhombic organization, a less dense, ordered hexagonal organization, or a disordered liquid 
organization.  
  
CERs play a crucial role in the lipid organization33 and have a characteristic 
molecular architecture. Several studies have reported significant changes in CER 
subclasses in non-lesional SC of AE patients: reduced CER [NP], increased CER 
[AS] and reduced long chain CERs [EOH] and [EOS]12,23,34-36. Some of these 
changes could be correlated with changes in skin barrier function. However, no 
information was reported on the effect of chain length distribution of CERs on the 
skin barrier, until recently. Ishikawa et al. showed that lesional skin has a 
significantly increased level of short-chain CERs (with a total chain length of  




skin barrier function37. These results suggest that CER chain length may be an 
important factor in skin barrier dysfunction of AE patients. These findings were the 
starting point of the present study in which we performed a detailed analysis on 
CER composition, focusing in particular on the CER chain length distribution in 
non-lesional SC of AE patients in relation to lipid organization and skin barrier 
dysfunction. We studied SC of non-lesional skin as we aimed to monitor the 
changes in lipid properties in the absence of inflammation. We have identified 
several CER subclasses that exhibit an increased level of extremely short C34 
chains in AE and we demonstrate that the overall level of C34 is increased in AE. 
The changes in CER chain length distribution correlated with changes in lipid 
organization, skin barrier function, disease severity and levels of natural 
moisturizing factor (NMF, composed of filaggrin-derived amino acids, their 
metabolites, specific sugars and salts). Changes in CER chain length distribution 
did not correlate with FLG genotype. These results demonstrate for the first time 
that CER chain length is an important factor in skin barrier dysfunction in  
non-lesional skin of AE patients. 
Materials and methods 
Study population and general study setup  
The study was conducted in accordance with the Declaration of Helsinki and was 
approved by the Ethical Committee of the Leiden University Medical Center. All 
subjects gave written informed consent. 15 Caucasian subjects without (history of) 
dermatological disorders (25.0±5.2 years; 5 males) and 28 Caucasian AE patients 
(25.6±5.6 years; 11 males) were included. The group of AE patients consists of  
14 patients with and 14 patients without the presence of common FLG genotype 
mutations (see FLG mutation analysis below). Subjects did not apply any 
dermatological products to their forearms for at least one week prior to the study. 
The study itself was performed in a temperature and humidity controlled room and 
subjects were acclimatized for 45 minutes prior to the measurements. Per subject, 
all measurements were performed on a single day on one of the ventral forearms, 
which was observed by a dermatologist at the start of the study to carefully depict 
an area of non-lesional skin, which was marked accordingly. At this area, NMF 
levels were determined with Raman spectroscopy followed by subsequent tape 
stripping, TEWL and Fourier transform infrared spectroscopy (FTIR) 




At the end of the study day, buccal mucosa cells were collected with a cotton swab 
and SCORing Atopic Dermatitis (SCORAD) was performed by a dermatologist to 
determine the severity of the disease. Finally, a 4 mm biopsy was harvested close to 
the area where all measurements were performed. 
 
FLG mutation analysis 
The influence of FLG mutations on the lipid properties was studied. We screened 
all subjects on the four most prevalent mutations found in European Caucasians 
(2282del4, R501X, S3247X and R2447X), covering around 93% of all FLG 
mutations known to date38. Buccal mucosa cells were collected by rubbing the 
inside of the cheeks with a cotton swab on a plastic stick after rinsing the mouth 
with water. Mutations were determined by genotyping after DNA extraction39. 
 
Skin barrier function assessment by TEWL 
A Tewameter TM 210 (Courage+Khazaka, Köln, Germany) was used to measure 
TEWL on the marked area on the ventral forearm of the subject. The forearm was 
placed in an open chamber and TEWL values were recorded for a period of two 
minutes after which an average reading during the last 10 seconds of the 
measurement was calculated. This procedure was performed before tape stripping 
(baseline TEWL) and after each two tape strips to have an indication of the amount 
of removed SC. 
 
SCORAD 
SCORAD was performed by the dermatologist to determine the severity of the 
disease40. 
 
Determination of NMF levels in SC 
Confocal Raman microspectroscopy (3510 Skin Composition Analyzer, River 
Diagnostics, Rotterdam, The Netherlands) was used to measure NMF in the SC of 
the ventral forearm. The principles and experimental details of this method and the 
procedure have been described elsewhere41,42. Depth profiles of Raman spectra 
were measured at 2 µm intervals from the skin surface to 20 µm below the skin 
surface. In each subject 15 profiles were measured at different spots within the 
marked area on the ventral forearm. Raman spectra were recorded between 400 to 
1800 cm-1 with a 785 nm laser. Laser power on the skin was 25 mW. NMF levels 
relative to keratin were determined from the Raman spectra measured between  
4-8 µm by means of classical least-squares fitting. Relative NMF to keratin levels 
were calculated from the recorded Raman spectra by using SkinTools 2.0 (River 






Tape stripping procedure 
To harvest SC lipids, the following tape stripping procedure was performed on both 
control subjects and non-lesional regions of AE patients: multiple poly(phenylene 
sulfide) tape strips (Nichiban, Tokyo, Japan) were successively applied at the same 
area (4.5 cm2) on the ventral forearm. All tapes were pressed to the targeted skin 
with a pressure of 450 g/cm2 using a D-Squame pressure instrument (Cuderm 
Corp., Dallas, USA). Tweezers were used to remove the tape in a fluent stroke, 
using alternating directions for each successive tape strip. The Squamescan 850A 
(Heiland electronic, Wetzlar, Germany) was used to determine the amount of SC 
removed, in order to obtain a good indication of the depth of each tape strip 
taken43,44. Calibration was performed by a bicinchoninic acid (BCA) assay using 
bovine serum albumin (BSA). The predicted total amount of protein in the SC was 
calculated by plotting 1/TEWL against the cumulative amount of protein removed. 
The intercept with the x-axis is indicative for the total amount of protein in the SC 
according to Kalia43. Tapes 6 to 9 were selected for lipid composition analysis, since 
these tapes do not show surface contamination (observed when analyzing tape 
strips from the surface of the SC). All tapes were punched to a circular area of  
2 cm2, put individually into glass vials containing 1 mL chloroform/methanol/water 
(1:2:½) and stored at -20°C under argon atmosphere prior to lipid extraction. 
 
Lipid extraction and ceramide analysis by LC-MS 
Lipid extraction was performed on 4 tape strips (numbers 6 to 9) of each  
subject. Before lipids were extracted from tape strips by liquid-liquid  
extraction, 2 deuterated internal CER standards (CER [NS] C24 and,  
CER [EOS] C30 linoleate) were added to compare CER levels between control 
group and non-lesional skin of AE patients. Then, a slightly enhanced  
extraction procedure of the commonly used Bligh and Dyer45 method was 
performed on all 4 selected tape strips individually: 3 different ratios of solvent 
mixtures chloroform/methanol/water (1:2:½; 1:1:0; 2:1:0) were used sequentially 
to extract all lipids. A detailed procedure is described elsewhere45,46. Afterwards, 
lipid extracts from all 4 individual tapes were pooled, dried under N2 gas and 
resolved in 100 µl chloroform:methanol:heptane (2½:2½:95) to obtain a total lipid 
concentration around 1.0 mg/mL. Samples were stored at -20°C until use. The 
analysis was performed by liquid chromatography-mass spectrometry (LC-MS) 
using a recently developed LC-MS method described in detail elsewhere4. Briefly, 
10 µl of each lipid sample was automatically injected and separated onto an 
analytical normal phase column (polyvinyl alcohol-bonded column; 100 x 2.1 mm 
i.d., 5 µm particle size, YMC (Kyoto, Japan)) by a gradient solvent system from 
heptane to heptane/isopropyl alcohol/ethanol at a flow rate of 0.8 mL/min using 
an Alliance 2695 high performance liquid chromatography (HPLC) system (Waters 




Thermo Finnigan, San Jose, CA, USA) in atmospheric pressure chemical ionization 
(APCI)-positive mode with a scan range set from 360-1200 amu. The temperature 
of the source heater and heated capillary were set to 450°C and 250°C respectively, 
while the discharge current was set to 5 µA. The CER analysis was performed using 
Xcalibur software version 2.0, and its nomenclature used throughout this article is 
according to Motta47 in which CER subclasses are classified by letter abbreviations 
according to their two individual chains: the sphingoid base (either 
dihydrosphingosine (dS), sphingosine (S), 6-hydroxysphingosine (H) or 
phytosphingosine (P)), chemically linked to the fatty acid chain (either an α-
hydroxy fatty acid (A), an esterified ω-hydroxy fatty acid (EO) or a non-hydroxy 
fatty acid (N)). This results in 12 different CER subclasses, namely [AdS], [AS], 
[AH], [AP], [EOdS], [EOS], [EOH], [EOP], [NdS], [NS], [NH] and [NP]. The CER 
nomenclature and its molecular structure are explained in Figure 1. 
 
Lateral organization and conformational ordering of the lipids 
To obtain information on the lateral organization and conformational ordering of 
the lipids, FTIR spectra were recorded in the same skin region also used for lipid 
analysis. FTIR spectra of the SC were collected after each 2 tape strips using a 
Varian 670-IR spectrometer (Varian Inc., Santa Clara, USA) equipped with a broad 
band mercury-cadmium-telluride (MCT) detector and an external sample 
compartment containing a GladiATR (Pike, Madison, USA) attenuated total 
reflection (ATR) accessory with a single reflection diamond. The spectral resolution 
was 2 cm-1. The instrument was continuously purged with dry N2. Each spectrum 
was an average of 150 scans. For data treatment, the instrument software 
Resolutions Pro 4.1 (Varian Inc., Santa Clara, USA) was used. We calculated 
positions of the CH2 symmetric stretching vibration and second derivatives of the 
scissoring bandwidth as described previously48,49. Shortly, the second derivative 
was calculated and it was baseline-corrected between the endpoints of the 
scissoring region (~1460-1480 cm-1). We calculated the bandwidth at 50% of the 
peak height (full width half maximum, FWHM) and determined CH2 symmetric 
stretching vibration positions of spectra recorded between the removal of 2 to 10 
tape strips. 
 
Biopsy and small angle X-ray diffraction measurements 
After tape stripping, 4 mm biopsies were taken from the ventral forearm close to 
the region of the tape stripping. SC was isolated by trypsin digestion as described 
earlier50. This procedure does not affect the lipid organization in SC51. The SC 
sheets were measured by small angle X-ray diffraction (SAXD) performed at the 
European Synchrotron Radiation Facility (ESRF, Grenoble, France) using station 
BM26B. Prior to the measurements, SC was hydrated over a 27% NaBr solution 




parallel to the primary X-ray beam. SAXD patterns were detected with a Frelon 
2000 charge-coupled device (CCD) detector at room temperature for a period of 10 
minutes using a microfocus beam, similarly as described elsewhere52. Samples were 
checked for evidence of radiation damage and the exposure time to the X-rays was 
kept to a minimum. From the scattering angle, the scattering vector (q) was 
calculated by q=4π sin θ/λ, in which λ is the wavelength of the X-rays at the sample 
position and θ the scattering angle.  
 
Statistical analysis 
Statistical analysis was performed using SPSS Statistics. Non-parametric  
Mann-Whitney tests were performed when comparing 2 groups and stated 
significant when P<0.05. When the effect of FLG was taken into account and trends 
were observed, Kruskall-Wallis tests and eventually an additional Mann-Whitney 
test was performed. Bivariate analysis was performed to analyze which parameters 
showed a significant correlation, and their respective Spearman’s ρ correlation 
coefficients were calculated. Univariate general linear model analysis was 
performed to correlate the biologically and clinically relevant parameters to  
2 independent lipid parameters, as well as the predicted and the observed average 
chain length.  
Results 
Description of study population 
Fourteen out of 28 AE patients were carriers of at least one of the four most 
common FLG mutations (details in Supplemental Table I). Patient and control 
subject characteristics are provided in Supplemental Table II. In addition, two 
control subjects were heterozygous for FLG mutations. Severity of the disease was 
scored by an experienced dermatologist using SCORAD (Figure 4a). AE patients 
showed an elevated TEWL in non-lesional skin compared to control subjects 
(12.2±6.5 gm-2h-1 and 6.5±1.7 gm-2h-1, respectively, P<0.0005, Figure 4b) and lower 
NMF levels compared to control subjects (0.66±0.39 and 1.05±0.20, respectively, 







Figure 4. SCORAD, TEWL and NMF levels in SC of control subjects and in non-lesional SC of AE 
patients. Dot plots showing individual control subjects ( and ) and AE patients ( and ) of the 
measured parameters (a) SCORAD, (b) TEWL and (c) NMF levels. Open and filled data points indicate 
carriers and non-carriers of FLG mutations, respectively. Means are indicated by gray horizontal dashed 
lines and their corresponding values (±SD). Significant differences were observed between control 
subjects and AE patients for both TEWL and NMF. FLG mutations were associated with reduced NMF 
levels in AE patients (P<0.005) but not with SCORAD and TEWL. 
 
Reduced CER chain length correlates with a decreased barrier 
function  
From the LC-MS data, lipid profiles were constructed and examples are shown in 
Supplemental Figure 1. From manual integration of these lipid profiles, the relative 
abundance of all CER subclasses could be calculated, which is shown in 
Supplemental Figure 2. Statistical differences between control subjects and AE 
patients were observed in 7 subclasses: CERs [EOP], [EOH], [NS], [NP], [NH], 
[AS] and [AH] (P<0.05). No difference was observed between carriers and  
non-carriers of FLG mutations. The total CER level in the control group and  
in non-lesional skin of AE patients was not significantly different 37.0±3.6 and 
38.5±2.4 ng/μg protein, respectively (P>0.1). 
The average CER chain length was significantly decreased by 0.64±0.23 total 
carbon atoms in AE patients (mean±SEM; P=0.012, Figure 5a). No difference was 
observed between carriers and non-carriers of FLG mutations (P>0.1). Figure 5a 
shows that in non-lesional skin of AE patients, extremely short C34 CERs were 
increased within several CER subclasses. This was primarily observed in CER 
subclasses [AS], [AH], [NS] and [NH] (Figure 5b, P<0.05). The increase in total 
C34 CERs in AE (P<0.0001) contributes to a reduction in overall chain length. In 
addition, the very long chain CERs belonging to the [EO] subclass are significantly 
reduced, which is primarily caused by significantly decreased levels of CER [EOH] 
and [EOP] (P=0.019 and P=0.040, respectively, Figure 5a and Supplemental 
Figure 2b). Univariate analysis shows that an increased level of C34 CERs and 
decreased level of CERs [EO] largely contribute to a reduction in average CER 
chain length, as can be observed from Figure 5c. The influence of FLG mutations on 
any of the CER chain length parameters was not significant (P>0.1; detailed 





Figure 5. CER composition in SC of control subjects (C) and non-lesional SC of AE patients. (a) Dot 
plot showing the average chain length of all CERs in total; the relative abundance of total C34 CERs; and 
the relative abundance of total [EO] CERs. (b) Dot plots indicating the relative abundance of C34 CER 
species for each subclass. Means are indicated by gray horizontal dashed lines. (c) Scatter plot of 
univariate analysis of the predicted average chain length (by the abundance of C34 CERs and [EO] 
CERs) versus the observed average chain length. Gray dashed line represents the optimal fit (r=0.94): 
Average chain length=(0.33∙C34CERs)+(0.24∙CER[EO]). (d) Scatter plot of univariate analysis of C34 
CER and CER [EO] versus the TEWL. Insets show the residuals of the respective plots. The gray dashed 
line represents the optimal fit (r=0.77): TEWL=8.2+(4.6∙C34CERs)-(0.6∙CER[EO]). Control subjects are 
indicated by  and . AE patients are indicated by  and . Open and filled data points indicate 





The observed changes in CER chain length were compared to changes in barrier 
function as assessed by TEWL. The results in Figure 5d show a strong correlation 
between TEWL and the levels of C34 CERs and CER [EO]: univariate analysis of 
TEWL versus the total C34 CERs and total CER [EO] levels shows a correlation 
coefficient of 0.77 (P<0.0001).  
Correlations between the relative abundances of the various CER subclasses 
with TEWL are shown in Table I. CER [EOH] and CER [AS] are the two subclasses 
which are most significantly associated with TEWL. This again indicates the 
importance of the chain length for the skin barrier in AE: the exceptional long CER 
[EOH] is decreased while CER [AS] (the CER subclass with the highest abundance 
of exceptionally short C34 CERs) is increased. The changes in CER composition are 
irrespective of FLG mutation status (P=0.58).  
 
Table I. Correlation coefficients (r) of the various CER 
subclasses versus TEWL. The table contains all 12 CER 
subclasses as well as the CERs that strongly influence the 
chain length (i.e. total CER [EO] and total C34 CERs). 
CER subclass TEWL 
CER [EOdS] -0.245 
CER [EOS] -0.177 
CER [EOP] -0.434** 
CER [EOH] -0.617*** 
CER [NdS] -0.226 
CER [NS]  0.407** 
CER [NP] -0.483** 
CER [NH] -0.420** 
CER [AdS]  0.214 
CER [AS]  0.650*** 
CER [AP]  0.255 
CER [AH]  0.195 
Total CER [EO] -0.441** 
Total C34 CERs  0.738*** 
Average CER chain length -0.528*** 
Statistical differences on the P<0.01 level are labeled **. 
Statistical differences on the P< 0.001 level are labeled ***.  
 
Altered lamellar and lateral lipid organization correlates with a 
decreased barrier function 
SAXD gives information about the lamellar organization of intercellular lipids in 
SC28 (explanation in Supplemental Figure 3). The lipids form two lamellar phases, 
the SPP and LPP. Figure 6a shows three examples of SAXD curves of SC. The upper 
curve is a typical example from a control subject. The central curve is typical for 
AE. The bottom curve is representative for a subgroup of AE patients with an 
aberrant SAXD profile. The upper two curves show lipid-based features as two 




contributes to all three peaks, while the SPP contributes only to peak II 
(Supplemental Figure 3). In the bottom curve both peaks I and III are absent and 
peak II is shifted to higher q-values. Peaks I and III were not present in 5 out of 28 
patients. As peak I and peak III only attribute to the LPP, this indicates that there is 
a drastic reduction in the presence of the LPP in those patients. 
Figure 6b shows the position of the strong peak (II) in the SAXD curves from 
control subjects (left) and AE patients (right). The peak position shows a larger 
variance within the group of AE patients compared to the group of control subjects. 
The average position of the strong peak is located at significantly higher q-values 
for AE patients as compared to control subjects (1.03 nm-1 and 1.00 nm-1, 
respectively, P=0.046). The position of peak II showed no difference between AE 
patients with and patients without FLG mutations (P=0.76).  
FTIR was used to obtain information on the lateral lipid organization. Two 
types of vibrations were monitored, the CH2 symmetric stretching vibrations and 
the CH2 scissoring vibrations (Supplemental Figure 4). A low (~2848 cm-1) 
wavenumber of the CH2 symmetric stretching vibrations indicates the presence of a 
highly ordered lipid organization (either hexagonal or orthorhombic), while a high 
(~2853 cm-1) wavenumber indicates a liquid disordered phase53. The mean value of 
the position of the CH2 symmetric stretching vibrations of AE patients shows a 
small but significant shift to higher values compared to control subjects (2849.2 
cm-1 versus 2848.8 cm-1, respectively, P=0.0013, Figure 6c). In addition, the 
variance in the group of AE patients is larger than in control subjects. In order to 
distinguish between an orthorhombic (dense) or hexagonal (less dense) lateral 
organization, the bandwidth of the CH2 scissoring vibrations was monitored. A 
narrow bandwidth (typically 8 cm-1) indicates the presence of only a hexagonal 
lipid organization, while a large bandwidth of typically 11 cm-1 is indicative for the 
presence of mainly an orthorhombic organization49.  
The average bandwidth of the scissoring vibrations was significantly lower  
in AE patients compared to control subjects (10.6 cm-1 versus 11.6 cm-1, 
respectively, P=0.010, Figure 6d), demonstrating a reduction of lipids in  
an orthorhombic organization and thus a less dense lipid organization. No 
significant influence of FLG mutations on the lipid organization in AE patients was 
found (P>0.05, Figures 6b-d). 
Univariate analysis was performed between TEWL and two independent 
lipid organization parameters: a lamellar organization component (SAXD peak II 
position) and a lateral organization component (FTIR scissoring bandwidth). The 
correlation coefficient was r=0.76 (P<0.0001, Figure 6e), which demonstrates that 








Figure 6. Lipid organization in SC of control subjects and non-lesional SC of AE patients. (a) The 
upper SAXD curve of a control subject shows the 1st (I), 2nd (II) and 3rd (III) order peak positions of the 
LPP. # indicates phase separated cholesterol. The middle diffraction curve is from an AE patient and 
resembles the pattern of SC of the control subject. The bottom curve of an AE patient shows only the 
presence of peak II. (b) Position of peak II in SAXD curves. (c) Position of the stretching vibrations in 
the FTIR spectrum. (d) Scissoring bandwidth in the FTIR spectrum. Means are indicated by gray 
horizontal dashed lines. (e) Correlation between lipid organization and TEWL. Scatter plot of univariate 
analysis of SAXD peak II position + bandwidth of scissoring vibrations versus the TEWL. The inset 
shows the residuals of this plot. The gray dashed line represents the optimal fit (r=0.76):  
TEWL=-301+(64∙SAXDpeakIIposition)-(2.3∙Bandwith). The correlation coefficient is 0.76. Control 
subjects are indicated by  and . AE patients are indicated by  and . Open and filled data points 
indicate carriers and non-carriers of FLG mutations, respectively. 
 
Altered CER composition correlates with aberrant lipid 
organization 
As CER composition and lipid organization both show a relationship with a 
reduced skin barrier (TEWL), the relation between the lipid parameters are 
summarized in Table II. The levels of C34 CERs and CER [EO] associate with both 
the lamellar organization (SAXD) and lateral lipid organization (FTIR scissoring 
bandwidth and stretching vibrations position). A powerful correlation of 0.71 was 




FTIR) were plotted versus the two components of the CER composition ([EO] CERs 
and C34 CERs). Supplemental Figure 5 illustrates this correlation. 
  
Table II. Correlation coefficients of lipid composition and lipid organization parameters. 
Lipid organization/CER composition parameters Correlation coefficient (r) 
SAXD peak II position vs. total C34 CER content  0.432** 
SAXD peak II position vs. total CER [EO] content -0.393** 
SAXD peak II position vs. average CER chain length -0.370* 
FTIR scissoring bandwidth vs. total C34 CER content -0.669*** 
FTIR scissoring bandwidth vs. total CER [EO] content  0.267 
FTIR scissoring bandwidth vs. average CER chain length  0.386* 
FTIR stretching vs. total C34 CER content  0.607*** 
FTIR stretching vs. total CER [EO] content -0.399* 
FTIR stretching vs. average CER chain length -0.471** 
Statistical differences on the P<0.05 level are labeled *. 
Statistical differences on the P<0.01 level are labeled **. 
Statistical differences on the P<0.001 level are labeled ***. 
 
Altered CER composition and aberrant lipid organization 
correlate with NMF levels and SCORAD 
A detailed overview of correlation coefficients between different parameters  
is presented in Table III. NMF levels correlate (r>0.4, P<0.01) with both lamellar 
and lateral lipid organization as well as with chain length of the CERs.  
SCORAD (disease severity) was associated with CER composition (i.e. total C34 
CERs and total CER [EO] content) and lipid organization (i.e. SAXD peak II 
position and FTIR scissoring bandwidth), with correlation coefficients of 0.56 
(P<0.01) and 0.58 (P<0.01), respectively.  
 
FLG mutations correlate with NMF levels, but not with SCORAD 
and TEWL levels 
NMF levels were significantly lower in FLG mutation carriers than in non-carriers 
(0.45±0.19 and 0.87±0.43, respectively, P<0.01). Both SCORAD and TEWL values 






Table III. Correlations between the various parameters. 
Correlated parameters Correlation coefficient (r) 
TEWL vs. SCORAD  0.560** 
TEWL vs. SAXD peak II position  0.450** 
TEWL vs. FTIR scissoring bandwidth -0.735** 
TEWL vs. FTIR stretching  0.645** 
TEWL vs. total C34 CER content  0.738** 
TEWL vs. total CER [EO] content -0.441** 
TEWL vs. average CER chain length -0.528** 
TEWL vs. NMF -0.643** 
SCORAD vs. SAXD peak II position  0.164 
SCORAD vs. FTIR scissoring bandwidth -0.474* 
SCORAD vs. FTIR stretching  0.534** 
SCORAD vs. total C34 CER content -0.470* 
SCORAD vs. total CER [EO] content -0.238 
SCORAD vs. average CER chain length -0.265 
SCORAD vs. NMF -0.362* 
NMF vs. SAXD peak II position -0.501** 
NMF vs. FTIR scissoring bandwidth  0.697** 
NMF vs. FTIR stretching -0.778** 
NMF vs. total C34 CER content -0.611** 
NMF vs. total CER [EO] content  0.416** 
NMF vs. average CER chain length  0.456** 
Note: the SCORAD indicates the severity of AE, and gives only valid values when AE is diagnosed. 
Therefore all control subjects were excluded in these specific correlations. 
* Correlation is significant at the 0.05 level. 
** Correlation is significant at the 0.01 level. 
Discussion 
We performed an integral analysis of CER composition focusing on the  
chain length distribution of each of the CER subclasses in relation to lipid 
organization and their correlation with skin barrier function (TEWL), disease 
severity (SCORAD), FLG mutations and NMF levels. This provides detailed 
information about the role of lipids in the impaired skin barrier function of  
non-lesional AE skin.  
The results show a reduced average CER chain length in non-lesional skin of 
AE patients. This reduction in chain length can be attributed to an increase in 
extremely short C34 CERs as well as a reduction in very long CER [EO] subclasses. 
The increment in C34 CERs has recently been reported by Ishikawa et al. for a 
single subclass (CER [NS]) in lesional skin of AE patients37. Here we show a largely 




[NH], [AS] and [AH]. In addition, the results show changed levels in some of the 
CER subclasses consistent with previous reports: a decrease in CER [NP] level and 
an increase in CER [AS] level12,34-37,54,55. We did not observe a change in 
CER/protein levels between AE patients and controls. Interestingly, the reduction 
in CER chain length found in the present study had a much stronger impact on the 
skin barrier function than the changes in CER subclass levels: the TEWL increases 
proportionally with decreasing chain length. These findings are in excellent 
agreement with earlier in vitro studies showing that a reduction in chain length of 
CERs has a stronger impact on the lipid organization and permeability than a 
change in the ratio between CER subclasses keeping the chain length 
approximately equal56-58 (and unpublished results M. Oguri, G.S. Gooris, J.A. Bouwstra).  
Di Nardo et al. observed a reduction in CER/CHOL ratio in non-lesional skin 
of AE patients, while other studies do not report a decrease in CER content in  
non-lesional AE skin20,35-37,54. Groen et al. observed that when increasing the CER 
or FFA level while keeping the level of the other two main lipid classes equal, this 
did not affect the permeability in vitro58. Therefore, these studies suggest that the 
CER composition and chain length rather than the ratio between lipid classes does 
play a major role in the increased TEWL in non-lesional skin in patients with AE. 
The increment in C34 CERs and decrement in CER [EO] suggest that elongation of 
the acyl chains is reduced. As the elongase family plays an important role in the 
elongation of fatty acids in the viable epidermis, we hypothesize that the higher 
abundance of C34 CERs may be due to a misbalance in the activity of some of the 
members of the elongase family59,60.  
Several publications report on the lipid organization in AE patients: Pilgram 
et al. reported changes in the lateral packing when comparing three AE patients 
with three controls32. In a recent study, we reported the first results on a very 
limited number of subjects focusing on the lamellar phases and CER subclasses 
without examining the CER chain lengths61. In addition, several studies focused on 
the (delayed or incomplete) lamellar body extrusion process in AE62-64 possibly 
caused by a reduced peroxisome proliferator-activated receptor activation65. In the 
present study we were particularly interested in the influence of CER chain length 
on the lipid organization in AE patients.  
With respect to the lamellar lipid organization, we observed a shift in peak II 
position of the SAXD curves of SC of AE patients. This indicates a reduced value of 
the repeat distances of the lamellar phases and/or a reduced formation of the 
LPP28. The correlation between SAXD peak II position with CER [EO] and C34 
CER levels indicates that changes in these CER levels affect the lamellar 
organization. When focusing on the lateral organization, AE patients show a less 
dense lipid packing compared to controls that correlates strongly with a higher 
level of C34 CERs. This shows that CER chain length is also an important 




lamellar and lateral organization correlate with the increased TEWL levels and thus 
with an abnormal skin barrier function in patients with AE. The findings in this 
study strongly support the hypothesis that in AE patients a reduction in CER chain 
length leads to a change in lipid organization, which in turn leads to an impaired 
barrier function. In addition, the present study shows that this impaired barrier 
function is also correlated to the disease severity as determined by SCORAD, which 
is supported by literature66,67. This may indicate that as a result of inflammation, 
the lipid synthesis is influenced (even at non-lesional sites), and subsequently the 
barrier function is decreased.  
Since FLG mutations are known to be predisposing factors for AE17, an 
interesting question is whether lipid changes are associated with the presence of 
FLG mutations. We screened our subjects for four of the most prevalent FLG 
mutations, accounting for 93% of the European FLG mutation spectrum38. In our 
study cohort there is no evidence that FLG mutations have an effect on CER 
composition and lipid organization. In contrast, in a recent study in ichtyosis 
vulgaris patients68, changes in the lamellar organization were observed between 
patients and controls. In that investigation, however, the majority of the patients 
was homozygote or compound heterozygote with respect to FLG mutations and no 
inflammation was observed in these patients.  
In previous studies, as well as in the current study, AE patients with FLG 
mutations showed significantly reduced NMF levels22,69. Remarkably, in this study 
changes in lipids correlated with NMF levels but not with the presence or absence 
of FLG mutations. This suggests that between FLG gene (genotype) and NMF 
(phenotype), other (translational and environmental) factors may also influence 
NMF levels. These factors may include FLG copy numbers (repeat alleles on the 
FLG gene)70 and interleukin levels, which can downregulate filaggrin expression71. 
Changes in NMF levels are suggested to lead to a change in pH, and together with 
altered interleukin levels and protease activity this may affect enzymes involved in 
CER biosynthesis5,68,72-74 and therefore change the CER composition and lipid 
organization. Thus, despite the fact that we did not find a correlation between the 
lipids and FLG mutation status, filaggrin might play an indirect role in the 
decreased barrier function of AE patients, although the underlying mechanism 
remains unclear. Besides, other barrier proteins may be involved. This will be 
subject of future studies in our group. 
In conclusion, in this study we have shown that the CER chain length is 
altered in AE patients by elevated C34 CERs levels and reduced CER [EO] levels. 
These changes correlate with an altered lipid organization and a decreased barrier 
function in AE patients. In addition, a significant correlation was observed between 
disease severity and change in lipid composition and organization. Our results 
suggest a novel therapeutic entry to repair skin barrier defects in AE patients, 




improve the SC lipid organization and restore the skin barrier function of AE 
patients. 
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Supplemental Figure 1. Representative 3D multi-mass chromatograms of SC CERs of a control 
subject (left) and non-lesional SC of an AE patient (right). All subclasses are indicated by their 
abbreviation. IS indicate the deuterated internal standards (CER classes [EOS] and [NS]) which were 
added to every sample to enable semi-quantitative analysis. 
 
 
Supplemental Figure 2. Bar plot showing the relative abundances of all CER subclasses (a) and only 
the very long [EO] CER subclasses (b) (mean±SEM). Green bars correspond to the control group, while 










Supplemental Figure 3. Lamellar organization in human stratum corneum. The right graph shows a 
typical SAXD profile of human SC. The scattering intensity (I) is plotted as a function of q, which is 
defined by q=2πsin θ/λ, in which λ is the wavelength of the X-rays and θ the angle of the scattered  
x-rays. The X-ray diffraction graph of human stratum corneum is characterized by a high intensity at 
low q-values due to keratin in the corneocytes and a series of peaks. The peaks indicated by I (weak 
peak), II (strong peak) and III (weak peak) are attributed to the LPP. Peak II is also attributed to the 
SPP. The peak indicated by # is due to cholesterol. A schematic drawing of the X-ray curves of the 
keratin, LPP and SPP is also shown on the left. The 1st, 2nd, 3rd, 4th, 5th and 6th order of the LPP (indicated 
by 1L-6L) and 1st and 2nd order of the SPP (indicated by 1S and 2S) . From the positions of the peaks (q) the 
repeat distance of the LPP and SPP can be calculated using the equation d=n·2π/qn (n=order of 
diffraction peak). When comparing the positions of the LPP and SPP to that in the diffraction pattern of 
the SC, peak I and III are only attributed to the LPP, while II is attributed to the LPP (2L) and SPP (1S). 








Supplemental Figure 4. The lateral organization can be measured by Fourier transform infrared 
spectroscopy (FTIR) by focusing on the CH2 scissoring vibrations (1460-1480 cm-1) and the CH2 
symmetric stretching vibrations (2848-2053 cm-1). (a) An orthorhombic organization results in a 
splitting of the scissoring vibrations, while a hexagonal packing results in a single vibration. Therefore, 
an increased bandwidth of the scissoring vibrations is indicative for an increased fraction of lipids 
forming orthorhombic lipid domains. In addition, the CH2 symmetric stretching vibration provides 
information about the conformational ordering of the lipids (b); a lower frequency (~2848 cm-1) 
indicates a fully extended chains (high degree of conformational ordering) of the lipids, whereas a high 
wavenumber (2853 cm-1) is indicative for a liquid organization (low degree of conformational ordering). 
 
 
Supplemental Figure 5. Scatter plot of univariate analysis of the predicted correlation between the 
CER organization (lamellar organization (SAXD) and lateral organization (FTIR)) versus the CER 
composition (the abundance of [EO] CERS and C34 CERs). Gray dashed line represents the optimal fit 
(r=0.713). Control subjects are indicated by  and . AE patients are indicated by  and . Open and 
filled data points indicate carriers and non-carriers of FLG mutations, respectively. 
 
Supplemental Table I. Mutations in the cohort of AE patients. 
 2282del4 R501X R2447X S3247X 
Heterozygous:10 4 4 1 1 
Homozygous: 3 2 1 - - 






Supplemental Table II. Characteristics of the subjects. 
Parameter Control (n=15) AE (n=28) 
Age (years) 25.0±5.2 25.6±5.6 
Female gender 10 17 
Total SCORAD - 28.0±16.1 
TEWL (gm-2h-1)  6.5±1.7 12.2±6.5 
NMF (a.u.)  1.05±0.2  0.66±0.39 
FLG mutation  2 14 
 
Supplemental Table III. Statistical data of the relative abundance of the 12 CER subclasses in control 




















[EOS]  3.76±0.59  3.43±1.52 0.191  3.66±1.79  3.19±1.22 0.550 
[EOP]  1.43±0.36  1.21±0.36 0.040  1.13±0.33  1.29±0.38 0.270 
[EOH]  4.06±0.87  3.21±0.97 0.019  3.17±1.01  3.25±0.97 0.783 
[EOdS]  0.37±0.26  0.29±0.23 0.286  0.30±0.28  0.28±0.17 0.713 
[NS]  6.88±2.57  9.67±3.44 0.003  9.84±4.20  9.51±2.64 0.646 
[NP] 26.5±2.57 19.85±5.16 <0.001 18.49±4.99 21.21±5.14 0.183 
[NH] 14.01±1.94 12.54±2.63 0.033 12.94±2.83 12.14±2.45 0.462 
[NdS]  9.48±3.75  7.86±2.92 0.063  7.80±2.59  7.92±3.32 0.783 
[AS]  4.57±0.68  8.67±3.48 <0.001  8.95±4.24  8.39±2.65 0.963 
[AP] 14.79±4.96 16.73±4.94 0.308 16.95±5.05 16.52±5.02 0.890 
[AH] 13.07±3.46 15.21±3.66 0.028 15.47±3.59 14.96±3.84 0.462 
[AdS]  1.09±0.32  1.32±0.66 0.272  1.30±0.88  1.35±0.36 0.141 
 
Supplemental Table IV. Data of the relative abundance of all C34 CERs between control SC versus 



















CER [AS] C34 0.32±0.11 0.78±0.44 <0.001 0.68±0.48 0.89±0.38 0.089 
CER [AP] C34 0.10±0.02 0.13±0.06 0.058 0.13±0.07 0.13±0.05 0.232 
CER [AH] C34 0.16±0.06 0.34±0.14 <0.001 0.30±0.14 0.39±0.13 0.089 
CER [AdS] C34 0.06±0.04 0.08±0.07 0.337 0.07±0.08 0.09±0.05 0.251 
CER [NS] C34 0.08±0.04 0.25±0.18 0.002 0.22±0.20 0.28±0.17 0.198 
CER [NP] C34 0.06±0.05 0.07±0.06 0.936 0.07±0.04 0.06±0.08 0.141 
CER [NH] C34 0.10±0.04 0.17±0.14 0.045 0.14±0.14 0.20±0.14 0.118 
 
Supplemental Table V. Statistical overview of the relative abundance regarding CER [EO] and CERs 
















CER [EO] (%)  9.62±2.62  8.13±2.47 0.079*  8.26±2.94  8.00±2.00 0.788* 
CERs C34 (%)  0.87±0.26  1.83±0.83 0.00017*  1.62±0.95  2.04±0.68 0.185* 
Average chain length 
(total carbon atoms) 
47.0±0.72 46.4±0.72 0.012** 46.7±0.78 46.4±0.74 0.277** 




























kin barrier impairment is thought to be an important factor in the 
pathogenesis of atopic eczema (AE). The skin barrier is located in the 
stratum corneum (SC), consisting of corneocytes embedded in lipids. 
Ceramides, cholesterol and free fatty acids are the major lipid classes and are 
crucial for the skin barrier function, but their role in relation to AE is indistinct. 
Filaggrin is an epidermal barrier protein and common mutations in the filaggrin 
gene strongly predispose for AE. However, there is no strong evidence that filaggrin 
mutations are related to the reduced skin barrier in AE. 
In this study, electron diffraction is used in order to study the lipid organization of 
control SC and non-lesional SC of AE patients in vivo. An increased presence of the 
hexagonal lipid organization was observed in non-lesional SC of AE patients, 
indicating a less dense lipid organization. These changes correlate with a reduced 
skin barrier function as measured with transepidermal water loss but do not 
correlate with the presence of filaggrin mutations. These results are indicative for 






The barrier function of the skin is located in the stratum corneum (SC) which 
consists of corneocytes embedded in lipids. Several papers report on an impaired 
skin barrier function not only in lesional, but also in non-lesional skin in patients 
with atopic eczema (AE)1-8. AE is an inflammatory skin disease affecting almost 
20% of Caucasian children and 2-10% of adults, with increasing prevalence9,10. 
Patients with active AE have lesional skin regions that appear red, itchy and flaky. 
The causes of AE are still unknown, but its prevalence has been associated with 
loss-of-function mutations of the filaggrin gene (FLG)11-14.  
In human SC, lipids are organized in layers in between the corneocytes, 
forming two lamellar phases with repeat distances of approximately 6 and 13 nm, 
referred to as the short periodicity phase (SPP) and long periodicity phase (LPP), 
respectively15,16. Within these stacked lipid layers, the lipids form mainly a dense, 
orthorhombic lateral organization, although a subpopulation of lipids also forms a 
less dense hexagonal lateral organization, as determined with Fourier transform 
infrared spectroscopy (FTIR) and electron diffraction (ED)17-19. Ceramides (CERs), 
cholesterol and free fatty acids are the three most abundant lipid classes in SC. 
Several studies report that the lipid composition is altered in AE patients compared 
to controls4,20-23. In addition, it was found that the CER chain length is important 
for a proper lipid organization and skin barrier function24,25. 
In the present study we used ED as a tool to examine the lateral lipid 
organization of healthy SC and non-lesional SC of AE patients in vivo. This method 
is used in combination with non-invasive tape stripping. The advantage of ED over 
FTIR is that it provides more detailed information as it samples the lateral 
organization very locally.  
In a previous study Pilgram et al. used ED to study the lipid organization in  
3 controls and 3 AE patients19. However, we recently showed that there is a large 
variation in the lipid organization in patients with AE25. Therefore, a larger number 
of patients is warranted. In addition, in the study of Pilgram et al. the changes in 
lipid organization were not related with the skin barrier function and presence of 
filaggrin mutations19. Therefore, besides the larger patient population, the lateral 
organization was correlated with the skin barrier function as assessed by 
transepidermal water loss (TEWL) and the presence of FLG mutations. 
In our studies we observed a higher abundance of diffraction patterns that 
indicate the presence of a hexagonal lipid organization in non-lesional AE skin 
compared to control SC. These changes in lipid organization correlated with an 
increased TEWL observed in AE patients. The presence of FLG mutations did not 





Materials and methods 
Study population and general study setup  
The study was conducted in accordance with the Declaration of Helsinki and was 
approved by the Ethical Committee of the Leiden University Medical Center. All 
subjects gave written informed consent. 15 Caucasian control subjects without 
(history of) dermatological disorders (25.0±5.2 years; 5 males) and 28 Caucasian 
AE patients (25.6±5.6 years; 11 males) were included. The group of AE patients 
consists of 14 carriers of FLG mutations (see FLG mutation analysis below). 
Subjects did not apply any dermatological products to their forearms for at least 
one week prior to the study.  
 
FLG mutation analysis 
We screened all subjects on the four most prevalent mutations found in European 
Caucasians, covering around 93% of all FLG mutations known to date26: 2282del4, 
R501X, S3247X and R2447X. Buccal mucosa cells were collected by rubbing the 
inside of the cheeks with a cotton swab on a plastic stick after rinsing the mouth 
with water. After DNA extraction mutations were determined by genotyping27. 
Here, subjects with one (or more) of the above mentioned mutations are called 
‘carriers’ of FLG mutations and subjects without the studied mutations are called 
‘non-carriers’ of FLG mutations. 
 
Skin barrier function assessment by TEWL 
A Tewameter TM 210 (Courage+Khazaka, Köln, Germany) was used to measure 
TEWL. The forearm was placed in an open chamber and TEWL values were 
recorded for a period of two minutes after which an average reading during the last 
10 seconds of the measurement was calculated. This procedure was performed 
before tape stripping and after each two tape strips. 
 
Tape stripping procedure 
Multiple poly(phenylene sulfide) tape strips (Nichiban, Tokyo, Japan) were 
successively applied at the same area (4.5 cm2) on the ventral forearm. All tapes 
were pressed to the targeted skin with a pressure of 450 g/cm2 using a D-Squame 
pressure instrument (Cuderm Corp., Dallas, USA). Tweezers were used to remove 
the tape in a fluent stroke, using alternating directions for each successive tape 
strip. The Squamescan 850A (Heiland electronic, Wetzlar, Germany) was used to 
determine the amount of SC proteins removed, in order to obtain a good indication 
of the depth the SC for ED was harvested28,29. After 10 tape strips, grid strips for ED 
analysis were taken. Calibration was performed by a bicinchoninic acid (BCA) assay 
using bovine serum albumin (BSA). The total amount of protein in SC was 




The intercept with the x-axis after extrapolation is indicative for the total amount of 
proteins in the SC according to Kalia28.  
 
Electron diffraction 
Grids (thin bar mesh-700 hexagonal, Agar scientific, Stansted, UK) were dipped 
into a 3% w/v glue/chloroform solution (glue: T406-30, Avery Dennison, Leiden, 
The Netherlands in chloroform: Biosolve, Valkenswaard, The Netherlands). After 
blotting the excess of chloroform with a filter paper, the grids were air dried, 
leaving a sticky layer of glue on the grid bars. 
A total of 12 grids were pressed to the arm during 5 seconds and taken off 
and directly cryo-fixed in liquid nitrogen and stored until use. Upon use, grids were 
put into a pre cooled Gatan 626 cryo holder (Gatan, München, Germany) and 
examined in a FEI Tecnai 200 kV cryo transmission electron microscope (TEM) 
(FEI Company, Eindhoven, The Netherlands) with a Field Emission Gun (FEG) 
source at 200 kV with spotsize 11. No selected area aperture was used. Diffraction 
patterns were recorded at a camera length of 1000 mm.  
A fixed area of approximately 0.78 µm2 was selected for diffraction. This 
small area was chosen in order to decrease the number of exposed lipid crystals  
and therefore increase the possibility of obtaining diffraction spots instead of  
rings. This allows discrimination between the orthorhombic and hexagonal  
lipid organization.  
The electron dose rate was 0.75 e-Å-2s-1. In order to prevent electron beam 
damage and disappearance of diffraction spots an exposure time of 2s was used, 
resulting in a dose of 1.5 e-Å-2. A longer exposure time between 4-6s resulted in 
weaker diffraction patterns and subsequently disappearance of spots. Diffraction 
patterns were digitally recorded on a Gatan 4Kx4K charge-coupled device (CCD) 
camera (Gatan, München, Germany), with binning 2. Pictures were stored as a 
DM3 file and examined with Image J. Spacings of the reflections in the ED patterns 
were calculated using the equation Rd=λL, which is deduced from Bragg’s Law. The 
known ED pattern of gold was used to calibrate the constant factor λL, in which λ is 
the wavelength of electrons and L the camera length. The distance of a recorded 
reflection to the central beam spot (R) was determined with Image J. In this way 
the repeat distance (d) could be calculated. ED patterns were scored independently 
by three persons into five categories as described in the results section.  
 
Statistical analysis 
Statistical analysis was performed using SPSS Statistics. A repeated measurement 
generalized linear model analysis was performed to investigate the difference in the 
ED patterns of control subjects and AE patients as well as the influence of FLG 






ED patterns were obtained from grids taken after removal of 10 tape strips. Figure 1 
shows an example of a TEM picture from a grid containing SC. First, we compared 
the depth at which the grids were taken. For controls, the grids were taken after 
removing 42.5±2.6% of the total mass of SC proteins and in AE patients this was 
46.9±2.5%. This indicates that the grids for ED analysis were taken at a similar SC 
depth in the two groups (P>0.05).  
 
 
Figure 1. Grid containing SC visualized with TEM. The scale bar is 10 μm. 
 
Interpretation of ED patterns 
When the lipids are oriented perpendicular to the incident electron beam  
(Figure 2a) this results in reflections that provide information about the  
lateral lipid organization.  
Figure 2b shows schematic pictures of the arrangement of the lipid acyl 
chains (blue circles) in a hexagonal lattice (left) and an orthorhombic lattice (right) 
when the lipid chains are oriented perpendicular to the incident electron beam. In a 
hexagonal organization the distances between the lattice planes in various 
directions are equal, being 0.41 nm. In the orthorhombic lattice, the lipids are 
denser packed, in which in one direction the lattice planes have a distance of  
0.37 nm, while in the other two directions this distance is 0.41 nm. The 
corresponding diffraction patterns when only one orientation of the crystals is in 
the electron beam are provided in Figure 2c. In a hexagonal organization (middle) 
the three pairs of reflections have interplanar angles of 60o. In the orthorhombic 
lattice the diffraction pattern consists of two reflections with interplanar angles of 
68o and 56o (right). Here, two out of six reflections are located at a larger distance 




When a large number of differently oriented crystals is exposed, the large number 
of spots forms rings (Figure 2d); in a hexagonal arrangement one strong ring at a 
spacing of 0.41 nm is visible (middle). However, the presence of an orthorhombic 
lipid organization cannot be excluded as the outer ring in the orthorhombic pattern 
is less intense than the inner ring. This pattern is therefore referred to as hex*. 
When dealing with an orthorhombic lattice the diffraction pattern consists of two 
strong rings at spacings of respectively 0.41 nm and 0.37 nm (right). As the inner 
reflection is at the same spacing as the hexagonal pattern it is not possible to 
determine whether also a hexagonal lateral packing is present. This pattern is 
therefore referred to as orth*. 
Occasionally, higher order reflections with spacings of 0.22 and 0.24 nm  
are also observed.  
We used an exposure time of 2s (electron dose 1.5 e-Å-2) in order to obtain 
the ED patterns. We confirmed that this did not lead to radiation damage by 
making series of diffraction patterns with exposure times varying between 1 to 10s. 
A too high electron beam intensity damages the lipids leading to disappearance of 
the crystal structure and broadening and fading away of the ED patterns. This 
occurs at exposure times higher than 4s.  
The obtained ED patterns were classified into five groups: 
i) hex: hexagonal; 
ii) hex*: hexagonal, however the presence of an orthorhombic organization 
cannot be excluded;  
iii) hex+orth: combination of hexagonal and orthorhombic organization;  
iv) orth*: orthorhombic, however the presence of hexagonal organization 
cannot be excluded; 








Figure 2. Explanation of hexagonal and orthorhombic lipid organization and corresponding ED 
patterns. (a) Perpendicular orientation of the lipids with respect to the incoming electron beam. In this 
orientation there are various lattice planes that give rise to reflections in the ED pattern simultaneously. 
The positions of these reflections give information about the lateral lipid organization. (b) The ordering 
of the hydrocarbon chains of the lipids. In a hexagonal organization, the spacings between the lattice 
planes are 0.41 nm (left). In the orthorhombic lattice the lipids are tighter organized, resulting in a 
spacing of 0.37 nm in one direction while in the other two directions this is 0.41 nm (right). (c) The 
corresponding diffraction patterns when only a few orientations of the crystals are in the electron beam. 
In a hexagonal (hex) lattice, the three pairs of reflections have interplanar angles of 60o (left). In the 
orthorhombic (orth) lattice the diffraction pattern consists of reflections with interplanar angles of 68o 
and 56o (right). (d) The corresponding diffraction patterns consist of rings, when a large number of 
differently oriented crystals is exposed. In a hexagonal arrangement one strong ring at a spacing of  
0.41 nm is visible (left). However, the presence of an orthorhombic lipid organization cannot be 
excluded as the outer ring in the orthorhombic pattern is less intense than the inner ring. This pattern is 
therefore referred to as hex*. When dealing with an orthorhombic lattice the diffraction pattern consists 
of two strong rings at spacings of respectively 0.41 nm and 0.37 nm (right). As the inner reflection is at 
the same spacing as the hexagonal pattern it is not possible to determine whether also a hexagonal 
lateral packing is present. This category is therefore referred to as orth*. h=hexagonal (blue), 




Figure 3 shows representative examples of ED patterns in each of the above 
mentioned categories. Figures 3a and 3b show three pairs of reflections at 0.41 nm 
which have an interplanar angle of 60o indicative for the presence of mainly one 
hexagonal lattice in the beam area. Figure 3c shows an orthorhombic ED pattern 
with two pairs of reflections at 0.41 nm (red arrows) and one pair of reflections at 
0.37 nm (orange arrows), with interplanar angles of 68o and 56o, respectively. This 
indicates the presence of one orthorhombic orientation in the beam. Figure 3d 
shows an ED pattern of three different orthorhombic lattices that are rotated over 
an angle of 60o relative to each other (indicated by red, green and maroon arrows), 
also demonstrating the presence of only an orthorhombic lateral packing, but now 
in at least three different orientations. In addition to the above mentioned 
categories, combinations of orthorhombic and hexagonal patterns exist. Figures 3e 
and 3f show ED patterns in which both the hexagonal and orthorhombic lattice are 
observed; both reflections with an interplanar angle of 60o (indicative for the 
hexagonal lipid organization, see blue arrows) as well as reflections with 
interplanar angles of 68o and 56o (indicative for the orthorhombic lipid 
organization, see red arrows) are present. In Figures 3g and 3h two rings are 
observed located at 0.41 and 0.37 nm. This indicates that the orthorhombic lipid 
organization is present. However the hexagonal lattice cannot be excluded, as the 
hexagonal pattern consists of a single ring at a spacing of 0.41 nm that might be 
obscured by the inner diffraction ring of the orthorhombic packing. Figures 3i and 
3j show examples of hexagonal ED patterns in which the presence of an 
orthorhombic lipid organization cannot be excluded: only one ring at a spacing of 
0.41 nm is observed. In this case it might be possible that only a few lipids are in 







Figure 3. Representative ED patterns recorded in human SC. (a) and (b). Three pairs of reflections at 
0.41 nm which have an interplanar angle of 60o indicative for the presence of a hexagonal lattice.  
(c) Orthorhombic ED pattern with two pairs of reflections at 0.41 nm (red) and one pair of reflections at 
0.37 nm (orange) with interplanar angles of 66o and 57o. (d) ED pattern in which three differently 
oriented orthorhombic lattices are present in the beam area (indicated by red, green and maroon 
arrows). (e) and (f) Combination of hexagonal and orthorhombic organization. The orthorhombic 
reflections appear as spots (red arrows), the hexagonal reflections appear as arcs (blue arrows). In f, at 
least three different orthorhombic orientations are observed. (g) and (h) Two rings located at 0.41 and 
0.37 nm, indicative for an orthorhombic lipid organization, however the presence of a hexagonal 
organization cannot be excluded. (i) and (j) Ring located at 0.41 nm indicative for a hexagonal lipid 
organization, however the presence of orthorhombic organization cannot be excluded. The obtained ED 
patterns were classified into five groups: hex=hexagonal; hex*=hexagonal, however the presence of an 
orthorhombic organization cannot be excluded; hex+orth=combination of hexagonal and orthorhombic 
organization; orth*=orthorhombic, however the presence of hexagonal organization cannot be excluded; 
orth=orthorhombic. 
 
ED patterns in control SC and SC of AE patients 
Out of 28 patients and 15 control subjects, we could not obtain ED patterns from  
4 AE patients and 3 controls as their grids did not contain sufficient SC. At  
least 50 ED patterns were recorded and scored of all the other subjects. A total of  
956 ED patterns of control subjects were scored, as well as 1662 ED patterns of AE 
patients. Per group, the percentage of ED patterns was calculated for each of the  
5 described categories above. Figure 4a shows the distribution profile of the ED 
patterns that have been obtained from controls (green) and non-lesional SC of AE 




ED patterns were either hex* or orth*. There is a significant increase in the relative 
occurrence of hex* ED patterns in AE patients compared to controls (47.9±3.9% 
and 36.1±4.3%, respectively, P<0.05). A trend was observed for the category orth*: 
this pattern was found less frequently in AE SC compared to controls, although not 
significant (38.1±3.4% and 46.8±3.9%, respectively, P=0.08). For the other 
categories there were no significant differences found: 3.9±1.0% hex in AE 
compared to 4.0±1.0% hex in controls; 3.8±0.9% hex+orth in AE compared to 
6.1±1.5% hex+orth in controls and 6.3±1.3% orth in AE compared to 6.9±1.2% orth 
in controls (all P>0.1). Overall, the orthorhombic organization predominates in 
control SC (categories orth* and orth), whereas in non-lesional AE SC the 
hexagonal ED patterns predominate (categories hex* and hex). Furthermore, we 
determined the spacings of the hexagonal and orthorhombic reflections in  
5 controls and 5 AE patients. In controls these spacings were 0.409±0.01 nm  
and 0.363±0.009 nm, respectively. In AE patients these were 0.412±0.01 nm and 
0.368±0.009 nm. No significant difference in spacing between controls and AE was 
observed (P>0.14). 
When investigating the effect of FLG mutations on the ED patterns, no 
relation was observed between the frequency of occurrence of the various 
diffraction patterns and FLG mutations (P>0.13, Figure 4b).  
Besides scoring the ED patterns into the above mentioned categories, the 
relative number of ED patterns in which cholesterol reflections were observed was 
also determined. Figure 5a shows an example of an ED pattern in which cholesterol 
reflections are visible reflecting the presence of phase separated cholesterol. The 
cholesterol reflections are located at a spacing of 0.51 nm (see arrow). The presence 
of the ring demonstrates that the cholesterol crystals are randomly oriented. Figure 
5b shows the relative number of ED patterns in which cholesterol reflections were 
observed in control SC (green) and SC of AE patients (orange). The percentage of 
ED patterns containing cholesterol reflections was not different between controls 
and AE SC: 15.8±4.2% and 15.6±2.5%, respectively (P>0.85). In addition, there was 
no difference between carriers and non-carriers of FLG mutations in the 







Figure 4. Occurrence of ED patterns in the different categories for controls and AE patients.  
(a) Relative number of ED patterns (±SEM) in control SC (n=12) and non-lesional AE SC (n=24). 
Green and maroon bars indicate control and non-lesional AE SC, respectively. (b) Relative number of 
ED patterns (±SEM, n=12 per group) in carriers and non-carriers of FLG mutations. Red and orange 
bars indicate carriers and non-carriers of a FLG mutation. hex=hexagonal; hex*=hexagonal, however 
the presence of orthorhombic organization cannot be excluded; hex+orth=combination of hexagonal 
and orthorhombic organization; orth*=orthorhombic, however the presence of hexagonal organization 






Figure 5. Presence of cholesterol in ED patterns. (a) Diffraction pattern in which cholesterol reflections 
with spacings of 0.51 nm are observed (see arrow). (b) Percentage of ED patterns in which cholesterol 
spacings were observed in control SC and non-lesional AE SC. Control subjects are indicated by  and . 
AE patients are indicated by  and . Open and filled data points indicate carriers and non-carriers of 
FLG mutations, respectively. Means are indicated by gray horizontal dashed lines and their 
corresponding values (±SD). 
 
Correlation between lipid organization and skin barrier function 
Next, we studied whether these changes in lipid organization result in a reduced 
skin barrier function. As the grid strips for ED analysis were taken after removal of 
10 tape strips, we correlated TEWL values at this depth with ED results. 
Figure 6a shows the TEWL after removal of 10 tape strips. After removal of 
10 strips the TEWL is significantly higher in AE compared to controls:  
16.5±1.6 gm-2h-1 and 9.0±0.7 gm-2h-1 in AE patients and control subjects, 
respectively, P<0.001.  
As in the categories hex and hex* the hexagonal patterns predominates, we 
combined the percentages of these categories in order to study the correlation 
between TEWL and hexagonal lipid organization. In order to study the correlation 
between TEWL and the presence of an orthorhombic lipid organization, we also 
combined the categories orth and orth*, as these categories mainly consist of 
orthorhombic organized lipids. 
The correlation between the relative number of hexagonal ED patterns and 
TEWL is plotted in Figure 6b (r=0.61, P<0.001). From the correlation it becomes 
clear that TEWL is higher when the amount of lipids that is predominantly 




orthorhombic ED patterns is r=-0.52 (P<0.005, Figure 6c), indicating a lower 
TEWL when the amount of lipids with an orthorhombic organization is increased. 
 
 
Figure 6. Correlation between skin barrier function and lipid organization. (a) TEWL in control SC and 
non-lesional AE SC after removal of 10 tape strips. (b) Correlation between TEWL and presence of 
hexagonal ED patterns (r=0.61). (c) Correlation between TEWL and presence of orthorhombic ED 
patterns (r=-0.52). Control subjects are indicated by  and . AE patients are indicated by  and . 
Open and filled data points indicate carriers and non-carriers of FLG mutations, respectively. Means are 
indicated by gray horizontal dashed lines and their corresponding values (±SD). 
Discussion 
We investigated the lipid organization in SC of controls and non-lesional SC of AE 
patients with ED. This technique gives information on the local variation of the SC 
lipid organization. We studied the effect of FLG mutations on the ED patterns and 
correlated the obtained results to the skin barrier function.  
With ED it is possible to study non-invasively the lateral lipid organization of 
SC in vivo. It is used in combination with tape stripping and can therefore give 
information about the lipid organization at various depths in SC. Here, we studied 
the lipid organization after removal of 10 tape strips. In this way we made sure not 
to measure surface contamination or sebum, which may result in a relatively higher 
amount of obtained hexagonal ED patterns30.  
As the lipid organization is dependent on the SC depth19, we first checked 
whether the grids for ED analysis were taken in the same range for both groups. 
The depth range at which the grids were taken for ED analysis was comparable 
between controls and AE patients. This demonstrates that we can directly compare 
the results obtained from the controls with those from the AE patients and that 
observed changes in lipid organization between controls and AE patients are not a 
result of different SC depths at which grids were taken. 
We classified the obtained ED patterns into 5 categories. As the amount of 




patterns for every subject (between 50-120 patterns). In order to ensure equal 
contribution of every subject within each group the total amount of ED patterns per 
subject was included in the statistical model that was used. 
Our results show that the most frequently encountered lateral packing is 
orthorhombic in controls. Orth* was scored most often in controls. In this category 
the presence of a hexagonal lipid organization cannot be excluded, however it is 
very likely that most of the patterns in this category indicate mainly orthorhombic 
organized lipids. We did not observe the orthorhombic packing as frequently as 
previously reported by Pilgram et al.19,30. This difference might be caused by the 
smaller area (0.78 μm2) that was selected for diffraction in our studies compared to 
theirs (1 and 20 μm2). Due to the smaller area selected for diffraction there is a 
higher probability to have only hexagonal organized lipids in the beam, and a lower 
number of exposed lipids. Therefore, in order to detect the outer less intense 
diffraction ring in the diffraction pattern, the fraction of lipids forming the 
orthorhombic lateral packing that is exposed to the electron beam should be higher 
compared to that in the study of Pilgram et al. If this ring is not detectable, the 
pattern is scored as being in the hex* category.  
We observed an increase in the relative number of hexagonal ED patterns  
in non-lesional SC of AE patients, indicating a less dense lipid organization in SC  
of AE patients. These changes in lipid organization can be explained by an  
altered lipid composition in non-lesional SC of AE patients. Previous in vitro 
studies have shown that shorter lipid chains, a lower percentage of free fatty  
acids, and an increase in unsaturated lipid chains induce a hexagonal lipid  
organization31,32 (and unpublished results). Several studies have reported significant  
changes in CER subclass composition between the lipid classes in non-lesional SC 
of AE patients4,20-23. Furthermore, a decreased chain length of CERs and free  
fatty acids as well as a higher degree of unsaturated fatty acids is observed  
in AE24,25 (and unpublished results).  
The occurrence of the ED patterns (rings, arcs) depends on the number of 
lipid crystals that is exposed in the area selected for diffraction; when only a few 
crystals are exposed the diffraction pattern consists of arcs. As we did not observe 
significant differences in the categories orth and hex (both containing ED patterns 
with arcs) between both groups this indicates that there are no large differences in 
the size of the lipid crystals in SC of controls and AE patients.  
The next step was to determine whether changes in lipid organization as 
observed with ED correlate with the impaired skin barrier function in AE. The 
observed correlations show clearly that an increased percentage of ED patterns 
indicating a predominant hexagonal lipid organization corresponds to a higher 
TEWL. In the same line, the increased ED patterns reflecting mainly a dominant 
orthorhombic packing correlated with a lower TEWL. This corresponds excellently 




between the skin barrier function and extent of SC lipids organized in 
orthorhombic lattices. This indicates that the less dense lipid organization in AE 
patients plays a role in the decreased barrier function in these patients. 
ED is a complementary method to FTIR to study the lateral lipid 
organization in SC. In case of ED, the method is sampling the local lateral packing, 
while FTIR is an averaging technique. As a result, ED provides very local 
information on the SC lipid organization. Our previous FTIR results showed a 
significant decrease in the bandwidth of the CH2 scissoring peak in AE SC. This 
bandwidth, the maximum of which is around 12 cm-1, is effected by the fraction of 
lipids forming an orthorhombic packing as well as the size of orthorhombic 
domains34. The maximum bandwidth due to the domain sizes is already achieved 
when the orthorhombic domains are only around 100 lipid chains, thus being still 
rather small. The bandwidth is around 5 cm-1 when all lipids are organized in a 
hexagonal packing34. With ED, more detailed information is obtained about the 
local variability of the lipid organization in SC; it provides information on the 
presence of orthorhombic as well as hexagonal lipid domains, but also lipid 
domains containing a combination of both types of lipid organization. Our results 
demonstrate that in around 6.5% of the patterns only an orthorhombic lateral 
packing is detected in the electron beam, suggesting that areas of at least 0.78 μm2 
with only an orthorhombic lateral packing exist in both AE and control skin. In 
addition such regions with only a hexagonal packing are also observed, but the 
frequency is only ~4% of the total number of patterns in AE and controls. As in our 
studies the majority of the ED patterns consists of rings, this at least suggests that 
the size of the crystal domains in these regions is rather small.  
To date, FLG mutations are a well-known predisposing factor for AE11-14. 
However, until now no clear correlation has been observed between FLG mutations 
and an impaired skin barrier function in AE3,5,35. Subjects were screened for four of 
the most prevalent FLG mutations, accounting for 93% of the European FLG 
mutation spectrum26. Our results show that the distribution of ED patterns and 
thus the lateral lipid organization does not differ between carriers and non-carriers 
of FLG mutations within the group of AE patients. This is in agreement with a 
previous study in which no correlations were found between FLG mutation status 
and lipid organization measured with FTIR25. 
In conclusion, the results described in this paper show that there is an 
increased amount of hexagonally organized lipids in non-lesional SC of AE 
patients. This change in lipid organization leads to a decreased skin barrier 
function as measured by TEWL. The observed changes are not correlated with the 
presence of FLG mutations. Taken together, these results suggest the important 
role of the lipids in the skin barrier and future treatment may aim at normalizing 
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ne of the features of atopic eczema (AE) is a decreased skin barrier 
function. The stratum corneum (SC) lipids – comprised of ceramides 
(CERs), free fatty acids (FFAs) and cholesterol – form a highly ordered 
lipid organization that fulfill a predominant role in this barrier function. Recently, 
the detailed CER composition in non-lesional skin has been investigated in AE 
patients. In the present study we report for the first time i) the extracellular SC FFA 
composition, including chain length and degree of unsaturation, in both lesional 
and non-lesional skin; and ii) how these factors associate with the examined CER 
composition and the impaired skin barrier in AE.  
The results show a clearly distinguishable lipid profile between control skin, 
non-lesional and lesional AE skin. In particular the FFA chain lengths are clearly 
reduced in AE SC, and the changes are much more pronounced in lesional skin 
than in non-lesional skin. The CER composition and lipid organization were also 
examined in lesional skin and compared to previously reported data on  
non-lesional skin. We noticed a strong reduction in CER chain length and a 
reduced density in the lipid organization. Changes in the chain length distribution 
of FFAs and CERs were strongly associated. In addition, we encountered a strong 
association between a reduction in chain length of both lipid classes and the 
increased presence of a less dense lipid organization. The changes in lipid 
organization did also associate with a reduced skin barrier function and were more 
pronounced in lesional skin. 
These changes in composition, organization and barrier function were 
strongly observed in lesional skin but already present in non-lesional skin and 
demonstrate the importance of the FFAs and the lipid chain length for a proper 






Atopic eczema (AE) is a very common skin disease with a current prevalence of  
10-15% in developed countries1-5. AE has multiple manifestations, such as 
erythema, skin dryness and pruritic skin lesions. The etiology of AE is complex: it is 
a multifactorial disease in which genetics, environmental factors, and an immune 
dysregulation all interplay. Although the immunological dysregulation is 
characteristic for AE patients, the skin barrier dysfunction also plays an important 
role6-10. A reduced skin barrier may result in an increased penetration of allergens 
and irritants, thereby provoking an immune response11. A commonly used 
parameter to indicate a (reduced) skin barrier function is transepidermal water loss 
(TEWL). Patients show increased TEWL values at both lesional and non-lesional 
sites, indicating that the skin barrier is affected in both inflamed and non-inflamed 
regions7,8,12.  
In 2006 it was reported – and since then replicated in many studies – that 
loss-of-function mutations in the filaggrin gene (FLG) are a major predisposing 
factor for the development of AE13-16. Filaggrin is a well-known skin barrier protein 
responsible for proper keratin filament alignment17. In addition, filaggrin 
degradation products – i.e. the natural moisturizing factor (NMF) – are important 
to retain the moist and acidic nature of the stratum corneum (SC), which is the 
uppermost layer of the skin where the main barrier of the skin is located18. 
However, the reduced skin barrier in AE cannot fully be explained by FLG 
mutations as 50-70% of all AE patients are non-carriers of such a mutation18, and 
in a number of studies no relation was observed between FLG mutations and the 
impaired skin barrier in AE19-22.  
As the lipids play an important role in the skin barrier – also with respect to 
AE7,23-26 – the aim of this study is to determine the lipid chain length distribution 
and in particular free fatty acid composition in AE and their relation with the skin 
barrier function. The SC consists of corneocytes with a lipid matrix in the 
intercellular regions. The lipids are composed of an approximately equimolar ratio 
of cholesterol, free fatty acids (FFAs) and ceramides (CERs, molecular architecture 
is explained in Figure 1)27-30. These lipids are organized in regularly stacked lipid 
layers23,24,31,32. Within these layers the lipids form a very dense, highly ordered 
packing – the so-called orthorhombic organization – but a subpopulation is also 
present in a less dense – hexagonal – or even liquid organization (Figure 2)33-35.  
In a recent study we examined the CER composition and lipid organization in  
non-lesional skin of AE patients from which it was concluded that a reduction  






These changes in CER composition and lipid organization strongly correlated to the 
degree of skin barrier dysfunction, suggesting that the CER chain length may be a 
key factor for a proper lipid organization and impaired skin barrier function in 
non-lesional AE skin36.  
 
 
Figure 1. Explanation of CER subclasses and CER chain length. CERs are composed of a fatty acid 
chain linked to a sphingosine base. Both chains show a wide distribution in their carbon chains length 
(indicated by the arrows, the numbers represent the general distribution). This results in a wide range of 
the total carbon chain length of CERs, that is, the carbon atoms of the two chains combined. In addition, 
CERs can have an additional functional group at the carbon positions labeled in red, which results in 
the presence of 12 subclasses, denoted as: [NdS], [AdS], [EOdS], [NS], [AS], [EOS], [NP], [AP], [EOP], 
[NH], [AH], [EOH]. 
 
Building on these recent findings in non-lesional skin, this study presents for the 
first time a detailed analysis of the chain length distribution of FFAs in lesional as 
well as in non-lesional AE skin. We focused on the chain length distribution as well 
as on the presence of mono-unsaturated FFAs (MUFAs) and the very sparsely 
studied hydroxy-FFAs. Previously, a wide chain length distribution has been 
observed in healthy subjects ranging from mainly 16 to 36 carbon atoms37-39. To the 
best of our knowledge, only one study reports FFA chain length in AE patients 
mentioning the very long chain fatty acids only40. They report a decreased presence 
of FFAs longer than 24 carbon atoms. Based on our detailed FFA analysis, we 
studied the association of changes in chain length distribution of the FFAs with the 
chain length distribution of the CERs, as literature reports a common synthetic 




AE patients is shortened, which is in conjunction with a reduced CER chain length. 
Finally, we examined possible correlations between changes in chain length profiles 
of the FFAs (and CERs) versus: 
i) a modulation in lipid organization; 
ii) a reduction in skin barrier function monitored by TEWL; 
iii) the presence of FLG mutations. 
 
 
Figure 2. Lateral organization in human stratum corneum. (1) The outermost layer of the epidermis, 
the stratum corneum (SC), consists of dead cells (corneocytes) embedded in a lipid matrix, also referred 
to as the bricks (corneocytes) and mortar (lipids) structure (2). The intercellular lipids are arranged in 
layers (lamellae) (3,4). The lateral organization (5) is the plane perpendicular to the direction of the 
lamellar organization. There are three possible arrangements of the lipids: a very dense, ordered 






Materials and methods 
General study setup 
The study is in accordance to declaration of Helsinki and approved by the Ethics 
Committee of the Leiden University Medical Center. The study includes  
15 Caucasian control subjects (25.0±5.2 years; 5 males) and 28 Caucasian AE 
patients (25.6±5.6 years; 11 males) of which 11 did show lesional skin sites at the 
day in which all measurements were performed. Subjects did not apply any 
dermatological products to their forearms for at least one week prior to the study. 
Patients were screened by the four most prevalent mutations found in the 
European population (2282del4, R501X, S3247X and R2447X): 14 patients and  
2 control subjects appeared as carriers of a FLG mutation. Various measurements 
to study the lipid composition and organization are described in more detail below. 
All measurements were performed both non-lesional skin and lesional skin  
(if present) on the ventral forearms. A dermatologist marked an area of 4.5 cm2 on 
the ventral forearm of the control subjects or on non-lesional and, if present, 
lesional skin on the ventral forearms of AE patients. On this area, the TEWL  
was measured using an open chamber Tewameter TM 210 (Courage+Khazaka, 
Köln, Germany) device. Values were recorded for a period of two minutes  
after which an average reading during the last 10 seconds of the measurement  
was calculated. This procedure was performed before tape stripping (baseline 
TEWL) and after each two tape strips. 
SC lipids were obtained by tape stripping. In between each 2 tape strips, 
Fourier transform infrared spectroscopy (FTIR) measurements were performed to 
study the lipid organization. In order to determine FLG mutations buccal mucosa 
cells were collected by rubbing the inside of the cheeks with a cotton swab on a 
plastic stick after rinsing the mouth with water. Mutations were determined by 
genotyping after DNA extraction13. 
 
Tape stripping procedure and LC-MS analysis 
SC lipids were harvested using multiple poly(phenylene sulfide) tape strips 
(Nichiban, Tokyo, Japan). Successive tapes were pressed on the marked area using 
a pressure device and were removed in one fluent stroke using tweezers. To avoid 
contamination of surface lipids (e.g. sebum), tape strips 1-5 were discarded and 
only tapes 6 to 9 were used for lipid analysis of non-lesional skin and – if possible – 
from lesional skin. The tapes were punched to an area of 2 cm2 and stored in 
chloroform/methanol/water (1:2:½) at a dark, cold (-20°C) and dry environment 
under argon atmosphere. Afterwards, lipid extraction of all samples was performed 
using a adapted procedure of the Bligh and Dyer method described by Thakoersing 
et al.43. Lipids were reconstituted in chloroform/methanol/heptane (2½:2½:95) 




a recently developed LC-MS method for analysis of both CERs and FFAs28,44 (and van 
Smeden et al., unpublished data). Figure 1 explains the nomenclature (according to Motta et 
al.45) and variation in chemical structure for these CER subclasses. 
Prior to the analysis of the FFA composition, a particular problem for the 
quantification of FFA C16:0, C17:0, C18:0 and C18:1 was encountered. These 
endogenous lipids are also present in the tape strips used to harvest the SC, thereby 
interfering with the analysis of SC FFAs (van Smeden et al., unpublished data). However, it was 
possible to correct for the amount of these lipids on the tape. This procedure is 
explained in detail in the supplement (Supplemental Figure 1 and Supplemental 
Table I).  
 
Lateral lipid organization by FTIR and its principles 
FTIR spectra were recorded after each two tape strips in order to obtain 
information on the lateral organization and conformational ordering of the lipids.  
A Varian 670-IR spectrometer (Varian Inc., Santa Clara, USA) equipped with a 
broad band mercury-cadmium-telluride (MCT) detector and an external sample 
compartment containing a GladiATR (Pike, Madison, USA) attenuated total 
reflection (ATR) accessory with a single reflection diamond was used. The spectral 
resolution was 2 cm-1. The instrument was continuously purged with dry N2. Each 
spectrum was an average of 150 scans. For data treatment, the instrument software 
Resolutions Pro 4.1 (Varian Inc., Santa Clara, USA) was used. Positions of the  
CH2 symmetric stretching vibrations and scissoring bandwidth were calculated as 
described previously46,47. Shortly, the second derivative was calculated and it  
was baseline-corrected between the endpoints of the scissoring region  
(~1460-1480 cm-1). We calculated the bandwidth at 50% of the peak height (full 
width half maximum, FWHM) and determined CH2 symmetric stretching vibration 
positions of spectra recorded between the removal of 2 to 10 tape strips. The width 
of the peak is indicative for the size and amount of orthorhombic lipid domains48. 
The stretching peak position indicates whether lipids are present in either a highly 
ordered organization (low peak position at ~2848 cm-1) or a disordered/liquid 
phase (high peak position ~2853 cm-1).  
 
Data analysis 
All statistical outcomes were determined using SPSS Statistics 17.0. In general, data 
was not Gaussian distributed and therefore non-parametric Mann-Whitney tests 
are more appropriate when 2 groups were compared, and Spearman’s ρ correlation 
coefficients are shown. Jonckheere trend tests were performed to assess 
significance of trends between control, non-lesional and lesional SC. Differences 
were considered significant when P<0.05. For some subjects in some of the 
parameters, data could not be determined and therefore missing. These data points 




possible to obtain 4 tape strips. In that case we used merely 2 or 3 tapes. This is one 
of the reasons why we do not report absolute data on the lipid composition, but 
rather relative values. Another important reason for presenting relative data is 
because the lipid composition is compared to the lipid organization. The latter is 
depending on the relative amounts of the former, rather than absolute amounts. 
We therefore chose for presenting relative data. 
Results 
Altered FFA composition in SC of AE patients 
AE patients showed – in both lesional and non-lesional skin – an increase in 
MUFAs at the expense of hydroxy-FFAs (Figure 3a), whereas the total level of 
saturated (non-hydroxy) FFAs was unchanged. In lesional skin, changes in levels of 
the various FFA subclasses are more pronounced than in non-lesional skin. For the 
saturated FFAs, the chain length distribution is notably changed: very long chain 
FFAs (≥24 carbon atoms) were strongly reduced whereas shorter FFAs – in 
particular C16:0 and C18:0 – were increased (Figure 3b). These changes in FFA 
chain length distribution were more pronounced in lesional SC, but already of 
significance in non-lesional skin. The MUFAs showed higher levels of short FFAs 
C16:1 and C18:1 in non-lesional and lesional skin compared to the control  
(Figure 3c). Hydroxy-FFAs ≥18 carbon atoms were decreased, predominantly in 
lesional skin (Figure 3d). All these changes resulted in a significant decrease in 
average FFA chain length in non-lesional as well as lesional AE skin compared to 
controls (20.3±0.9, 18.2±0.6 and 21.4±0.4 carbon atoms, respectively, P<0.001, 
Figure 3e). FFA profiles of AE patients from both lesional and non-lesional skin 
were compared per subject (pairing), and the average FFA chain length was always 
lower in lesional skin compared to non-lesional skin (Supplemental Figure 2).  
No effects were observed of FLG mutation status on the FFA composition, neither 
in the FFA chain length, nor in the abundance of hydroxy-FFAs or  
MUFAs (P>>0.1, Table I). 
 
Altered CER chain length in SC of AE patients 
We compared changes in the FFA composition of AE patients in both lesional and 
non-lesional sites to changes in CER composition. From all CER subclasses, the 
overall CER chain length distribution was determined in non-lesional and lesional 
skin (Figure 4a). Chain lengths of all CER subclasses showed a broad distribution 
mainly between 32 and 54 carbon atoms. Exceptions were the acyl-CERs, which 
showed a range between 64 and 74 carbon atoms. This is mainly due to the 
additional fatty acid moiety attached to these CERs. In AE patients, the level of long 




(<42 carbon atoms) was increased. Differences are most pronounced for lesional 
skin, but were also significantly altered in non-lesional skin. Among the short 
CERs, in particular the CERs with 34 carbon atoms (C34 CERs) are increased in AE 
(Figure 4b). To obtain more information on which CER subclasses were involved in 
this strong increase in C34 CERs, we also analyzed the level of all CER subclasses. 
The relative abundance of the 12 individual CER subclasses (see Figure 1) in 
lesional skin were combined with those in non-lesional skin previously reported36. 
The most prominent changes in lesional skin are an increase in CER [NS] and CER 
[AS], and a decrease in CER [NP] (Supplemental Figure 3). The CER chain length 
distribution shows a progressive increase in C34 CERs, predominantly in the CER 
[NS] and CER [AS] subclasses, and a reduction of almost 50% was observed for the 
long chain acyl-CERs in lesional AE SC (see Figures 4b and 4c). Together, this 
results in a significant reduction of the average CER chain length in both in  
non-lesional and lesional AE SC compared to controls (P<0.012, Figure 4d). 
A direct intra-subject comparison (paired statistics) between lesional and 
non-lesional skin from the same patient showed a lower average CER chain length 
in lesional skin as compared to the non-lesional skin sites (Supplemental Figure 2). 
Since we also observed this trend for the FFAs, we calculated the total lipid chain 
length and compared lesional skin with non-lesional skin sites (Figure 5). From 
these paired observations we noticed for each individual a reduction in total lipid 
chain length at lesional skin sites compared to non-lesional skin sites. 
No indications were found that FLG mutations have an effect on the lipid 
composition in AE patients (Table I). No significant changes were observed 
between subjects with and without a FLG mutation for either lesional and  
non-lesional skin: neither in the level of acyl-CERs (P>0.1), nor in the average CER 








Figure 3. FFA data on controls, non-lesional AE SC and lesional AE SC (labeled as green, orange and 
blue bars, respectively). The total amount of all FFAs was set to 100%. (a) Bar plots showing the relative 
abundance of the FFA subclasses (saturated, mono-unsaturated (MUFA), hydroxy-FFA) in control SC, 
non-lesional and lesional AE skin. There is a significant increase and decrease in trend for the 
abundance of MUFAs and hydroxy-FFAs, respectively, for controls, non-lesional and lesional AE SC 
(P<0.03). (b-d) Chain length distribution of saturated FFAs, MUFAs and hydroxy-FFAs, respectively, in 
control SC, non-lesional and lesional AE SC. There is a significant trend of increasing abundance of 
saturated FFAs with chain lengths of 16 and 18 carbon atoms between controls, non-lesional and 
lesional AE SC (P<0.001). There is a significant trend of decreasing abundance of saturated FFAs with 
chain lengths between 22 and 30 carbon atoms (except C23) between controls, non-lesional and lesional 
AE SC (P<0.04). There is a significant trend of increasing abundance of MUFAs with chain lengths of  
16 and 18 carbon atoms between controls, non-lesional and lesional AE SC (P<0.04). There is a 
significant trend of decreasing abundance of MUFAs with chain lengths between 20 and 30 carbon 
atoms (except C22, C23 and C24) between controls, non-lesional and lesional AE SC (P<0.05). There is 
a significant trend of decreasing abundance of all hydroxy-FFAs except C16 between controls, non-
lesional and lesional AE SC (P<0.04). The total relative amount of these three FFA classes is 100%. 
Controls, non-lesional AE skin and lesional AE skin are shown in green, orange and blue respectively. 
Error bars represent the SD. The scatter dot plot in (e) shows the average FFA chain length. Horizontal 
dashed lines indicate the mean value ±SD. Control subjects are indicated by /. Non-lesional skin and 
lesional skin of AE patients are indicated by / and /, respectively. Non-carriers and carriers of a 
FLG mutation are represented by filled and open data points respectively. 
 
 




















































































































































































































































































































































































































































































































































































































































































































































































































Figure 4. CER data on controls, non-lesional AE and lesional AE (labeled as green, orange and blue 
bars, respectively). The total amount of all CERs was set to 100%. (a) Bar plots showing the relative CER 
chain length distribution of all subclasses combined. There is a significant trend of increasing 
abundance of CERs with chain lengths of 32-40 carbon atoms between controls, non-lesional and 
lesional AE SC (P<0.001). There is a significant trend of decreasing abundance of CERs with chain 
lengths of 46-50 carbon atoms between controls, non-lesional and lesional AE SC (P<0.04). There is a 
significant trend of decreasing abundance of CERs with chain lengths of 65-72 carbon atoms between 
controls, non-lesional and lesional AE SC (P<0.05). The relative abundance of the C34 CERs and  
acyl-CERs are shown in (b) and (c), respectively. There is a significant trend of increasing abundance of 
CERs [NS], [NP], [NH], [AS], [AP] and [AH] between controls, non-lesional and lesional AE SC 
(P<0.01). There is a significant trend of decreasing abundance of CERs [EOS], [EOP], [EOH] and total 
amount of acyl-CERs between controls, non-lesional and lesional AE SC (P<0.01). 100% orresponds to 
the amount of all 12 subclasses combined. Error bars represent the SD. ND means not detected. The 
scatter dot plot in (d) illustrates the average CER chain length. Horizontal dashed lines indicate the 
mean value ±SD. Control subjects are indicated by /. Non-lesional skin and lesional skin of AE 
patients are indicated by / and /, respectively. Non-carriers and carriers of a FLG mutation are 





Figure 5. (a) Dot plots of the calculated total lipid chain length (FFAs+CERs) for all three groups. 
Horizontal dashed lines indicate the mean value ±SD. (b) Paired plot of the calculated total lipid chain 
length of a selected subset of patients of which both non-lesional and lesional skin was analyzed. Control 
subjects are indicated by /. Non-lesional skin and lesional skin of AE patients are indicated by / 
and /, respectively. Non-carriers and carriers of a FLG mutation are represented by filled and open 
data points, respectively. 
 
Relationship between FFA and CER composition 
As presented in Table II, the average CER chain length correlates to the average 
FFA chain length (r=0.60, P<0.001). More precisely, a high abundance of short 
chain FFAs (<23 carbon atoms) is accompanied by a high abundance of short chain 
CERs (<42 carbon atoms), whereas an increased presence of long chain FFAs  
(>23 carbon atoms) correlates to an increase in long chain CERs (>42 carbon 
atoms), as illustrated by the correlation map in Supplemental Figure 4 and in 
Supplemental Table II. 
 
Table II. Spearman correlation coefficients of lipid composition and lipid organization parameters. 
Correlated parameters Correlation coefficient (r) 
Average CER chain length versus average FFA chain length  0.596* 
Average CER chain length versus stretching peak position -0.567* 
Average CER chain length versus scissoring bandwidth  0.517* 
Average FFA chain length versus stretching peak position -0.683* 







Altered lipid composition in AE patients corresponds to a less 
ordered lipid organization 
We investigated whether the observed changes in SC lipid composition in  
AE affect the lipid organization in these patients. The lateral lipid organization  
was assessed by attenuated total reflectance Fourier transform  
infrared spectroscopy (ATR-FTIR), primarily focusing on lesional skin of  
AE patients. Principles of ATR-FTIR measurements are explained in the  
materials and methods section. The stretching peak position in AE patients  
was located at a higher wavenumber compared to control subjects in both  
non-lesional as well as lesional AE SC (P<0.001; Figure 6a). This indicates that  
the organization of SC lipids in AE patients is less ordered compared to  
control subjects. The difference in stretching peak position between lesional  
and non-lesional skin was not significant (P=0.083).  
To obtain information about hexagonal or orthorhombic organization of the 
SC lipids, the scissoring bandwidth was determined. Lesional SC of AE patients 
shows a scissoring bandwidth of 9.1±1.9 cm-1, which is significantly lower than  
the bandwidth in non-lesional skin of AE patients (10.6±1.3 cm-1) and in  
control skin (11.6±0.8 cm-1; P<0.001; Figure 6b). This indicates that  
the subpopulations of lipids in a highly ordered orthorhombic phase are  
less dominantly present in lesional skin in AE compared to non-lesional skin of  
AE patients and control subjects.  
Regarding the influence of FLG mutations, a significant difference  
was observed for the scissoring bandwidth in lesional skin between AE  
patients with and without a FLG mutation: P=0.016. This was not found for the 
stretching peak position (P>0.05). 
Table II shows that the average CER chain lengths correlate to a high extent 
with the change in lateral lipid ordering (|r|>0.51; P<0.001), and the correlation of 
FFA chain length with the change in lateral lipid ordering is even stronger 
(|r|>0.68; P<0.001). Supplemental Figures 5a and b show this correlation between 
FFA chain length and FTIR scissoring bandwidth in more detail (r=0.73; P<0.001): 
It becomes clear that FFAs with chain lengths ≤20 relate to a lower FTIR 
bandwidth (more hexagonal lipid organization) whereas FFAs with chain lengths 








Figure 6. Scatter dot plots of (a) the FTIR CH2 stretching peak position and (b) the FTIR CH2 
scissoring bandwidth for all three groups: control, AE – non-lesional and AE – lesional. Horizontal 
dashed lines indicate the mean value±SD. Control subjects are indicated by /. Non-lesional skin and 
lesional skin of AE patients are indicated by / and /, respectively. Non-carriers and carriers of a 
FLG mutation are represented by filled and open data points respectively. 
 
Skin barrier function shows a high affinity with lipid chain 
length and lipid ordering 
Supplemental Figure 6 shows that the TEWL is significantly increased in  
non-lesional as well as lesional AE SC compared to controls (12.2±6.5 gm-2h-1, 
27.6±11.6 gm-2h-1, 6.5±1.7 gm-2h-1, respectively, P<0.0005). Figure 7a shows that 
the increase in TEWL associates very well with the average lipid chain length: a 
reduction in average chain length corresponds to an increase in TEWL (r=-0.80, 
P<<0.001). Short lipid chain FFAs and CERs (<20 and <41 carbon atoms, 
respectively) correlate positively with TEWL, whereas long lipid chains (>23 and 
>42 carbon atoms for FFAs and CERs, respectively) are negatively  
correlated (Figures 7b and c). Also for the lipid organization a high correlation  
with TEWL was observed for both the scissoring bandwidth and the stretching  
peak position (Figures 7d and e): a decrease in lipid ordering corresponds to  
an increase in TEWL. 
Discussion 
As there is increasing evidence that SC lipids play a role in the impaired barrier 
function of AE7,26, we investigated the lipid chain length distribution in SC of AE 







Figure 7. (a) Correlation plot in which the lipid chain length of all individual subjects is plotted versus 
the TEWL. The dashed line indicates the optimal fit through the data. (b) and (c) present bar plots in 
which each individual chain length of respectively FFAs and CERs is plotted versus their respective 
spearman correlation coefficients with TEWL. The dashed line indicates the moving average (period=3). 
(d) and (e) are correlation plots of the TEWL vs either the stretching peak position or the scissoring 
bandwidth, respectively. The dashed lines indicate the optimal fit through the data. Non-carriers and 
carriers of a FLG mutation are represented by filled and open data points respectively. Control subjects 






A clear shift to shorter SC lipid chain lengths was observed in AE patients for both 
CERs and FFAs. Short chain FFAs (≤20 carbon atoms) showed a negative 
correlation with FTIR bandwidth, and long chain FFAs (≥24 carbon atoms) showed 
a positive correlation with FTIR bandwidth. Previous in vitro studies with lipid 
model systems have shown that the formation of the hexagonal organization is 
strongly enhanced by a decreased FFA chain length49. This leads to the conclusion 
that the FFA chain length is an important determinant for the lipid organization in 
AE: short chain FFAs enhance the formation of a hexagonal lipid organization 
whereas long chain FFAs enhance the formation of an orthorhombic lipid 
organization. Furthermore, we observed an increased level of MUFAs in SC of AE 
patients, which also correlated to the presence of a hexagonal lipid organization in 
in vitro studies (unpublished data). 
The reduction in FFA chain length matches the presence of shorter CERs: AE 
patients showed a shift from long chain CERs (≥43 carbon atoms) towards short 
chain CERs (≤42 carbon atoms). It has been reported that the sphingosine base in 
CERs is on average about 18-20 carbon atoms long50. Using these numbers in 
estimating the acyl chain length in the CERs, our results suggest that CERs having 
an approximate acyl chain length of ≥22 carbon atoms (42 minus 18 to 20 carbon 
atoms) are decreased in SC of AE patients. This matches our observations in the 
decreased levels of FFAs ≥22 carbon atoms. In addition, the high levels of C34 
CERs in AE patients correspond to an acyl chain length similar to the 16 carbon 
atoms of the FFA. The level of this particular FFA is also highly elevated in these 
patients. These correlations between CERs and FFAs demonstrate for the first time 
that the acyl chain length in CERs correlates with the FFA chain length, which is a 
strong argument for a common synthetic pathway41,42.  
The reduction in long chain FFAs corresponds to a reduction in long-chain 
acyl-CER levels in AE. These acyl-CERs are also crucial for a proper organization of 
the lipids: in vitro studies have shown that a reduced level of acyl-CERs results in a 
less thermostable orthorhombic organization51. The reduced amount of acyl-CERs 
in AE patients could also play an important role in the decreased skin barrier 
function, as permeability studies have shown that a reduced level of acyl-CERs 
results in increased permeation52 or could even lead to neonatal death by epidermal 
dehydration in mice completely lacking acyl-CERs39. Therefore, not only the 
changes in FFA composition, but also reduced levels of acyl-CERs may contribute 
to the increased hexagonal organization and impaired skin barrier function in AE. 
TEWL is a commonly accepted measure of skin barrier integrity. The results 
demonstrate that the increase in TEWL is strongly associated with the decreased 
lipid chain length. In other words, an increased abundance of short lipid chains 
contributes to an increased TEWL in AE, whereas an increased presence of long 
chain lipids corresponds to lower TEWL values. In addition, the increased TEWL 




organization in AE. This raises the question whether the changes in lipid chain 
length are causative for the changes in lipid organization and increased TEWL. 
Previous in vitro studies by Groen et al. with model lipid membranes demonstrate 
that a shorter FFA chain length leads to an increased permeability of benzoic acid49. 
These findings provide new fundamental insights for possible barrier repair: 
the presence of long-chain lipids may be crucial for the lipid organization  
and therefore a proper skin barrier function. A possible treatment to compensate 
for the reduced long chain lipids may therefore focus on topical application of  
long-chain lipids. Our observed relation between the FFAs and CERs also imply 
that normalization of the FFA chain length distribution in AE skin will also 
contribute to normalization of the CER chain length distribution in these patients. 
As discussed below, most probably the elongase enzyme family will play  
an important role here. 
One of the challenges is to unravel the changes in the biochemical  
synthesis of the lipids that are responsible for the altered SC lipid composition in 
AE, as this may result in new targets for normalizing the skin barrier function.  
The shift to a shorter FFA chain length distribution suggests that FFA elongation is 
hampered to some extent. It is known that elongation of FFAs ≥C16 occurs by  
a series of elongases, ELOVLs1-7, all having a certain selection towards a specific 
FFA chain length42,53. Currently, little is known about these elongases in the 
epidermis. It has been reported, however, that ELOVL1, -3, -4 and -6 are  
expressed in mammalian skin54. Only ELOVL4 is identified in the epidermis on a 
protein level and plays a crucial role in the elongation of FFAs ≥C2439,55. Our data 
on AE shows a decrease in FFAs ≥C24, from which we hypothesize  
that the ELOVL4 protein level and/or activity may be decreased in  
AE patients. Although no information has been reported on humans with respect to 
AE, two studies in ELOVL4 knockout mice demonstrate a strong reduction in  
very long chain FFAs, supporting our hypothesis39,56. In addition, the  
loss of functional ELOVL4 in mice has been related to a reduced level of  
hydroxy-FFAs, in particular long chain hydroxy-FFAs39. Interestingly, in our  
study a reduced level of hydroxy-FFAs is also observed. As we also observed 
increased levels of FFAs with 16 and 18 carbon atoms, ELOVL6 and ELOVL1,  
which are the major enzymes involved in elongation of respectively FFAs>C16  
and FFAs>C18, may also be reduced in activity in the epidermis of patients  
with AE. Furthermore, if the elongation of these short chain FFAs is hampered,  
an alternative metabolic pathway may also become more important.  
This pathway involves the synthesis of MUFAs by stearoyl-coenzyme A desaturases 
(SCDs)57. Indeed, an increased level of MUFAs with chain lengths of  
16 and 18 carbon atoms is observed in SC of AE patients that may be caused  
by an increased activity of SCDs. Another aspect that should be considered  




reports have reported an altered level of sebaceous lipids in AE, which may affect 
the SC barrier function in these patients58-60. 
Eleven AE patients had both lesional and non-lesional sites at their ventral 
forearms. We could therefore perform an intra-subject comparison of non-lesional 
and lesional skin. The shift to shorter FFA and CER chain lengths was more 
pronounced in lesional skin compared to non-lesional skin. These changes in lipid 
composition can mainly be attributed to inflammation, although increased levels of 
cutaneous microbes (e.g. Staphylococcus Aureus), genetic mosaicism17 or 
environmental factors could also play a role. Cytokines, which play a role in 
inflammation, are capable of interfering to a large extent with the lipid synthesis in 
multiple ways. They have shown to be involved in:  
i) reduced levels of enzymes involved in CER synthesis (e.g.  
β-glucocerebrosidase and acid sphingomyelinase), thereby affecting the 
CER composition61.  
ii) peroxisome proliferator-activated receptors (PPARs), which are closely 
related to the skin lipid metabolic pathway and show a relation to AE62: 
PPAR-α and PPAR-β/δ are respectively down- and upregulated in AE 
patients63,64. These nuclear receptors promote SC barrier formation and 
are suggested to have anti-inflammatory properties in skin65-68.  
iii) TNF-α and several other cytokines, which downregulate filaggrin 
expression69-71. This may result in lower NMF levels, thereby affecting 
the local pH. It has been suggested that such a pH change may alter the 
lipid synthesis in the epidermis72. This is emphasized by the importance 
of environmental factors that can also raise the pH of the skin, of which 
washing the skin with soap and other detergents may be most 
important73,74. 
 
Downregulation of FLG expression may be a factor interfering with FLG mutations 
and lipid parameters. This can explain the absence of a correlation between  
FLG mutations and lipid parameters. This suggests that mutations in the FLG 
genotype have no direct effect on the metabolic skin lipid pathways, but  
can indirectly affect these pathways via the FLG breakdown products (NMF)36. 
Most enzymes involved in lipid synthesis are pH dependent, and changes in  
NMF levels caused by FLG mutations may therefore indirectly lead to a dysfunction 





Summarizing, we analyzed the SC lipid chain length distribution in  
non-lesional and lesional skin of AE patients. The results demonstrate an  
increased presence of short chain FFAs and a decreased presence of long-chain 
FFAs in SC of AE patients. These changes are in line with the changes observed  
for the CERs, and lead to an altered lipid organization and decreased skin barrier 
function in AE. The outcomes of this study do not only give more insights  
in fundamental SC lipid knowledge, but also suggest possible new targets for future 
drug therapy for both lesional and non-lesional AE skin. 
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Quantitative analysis of FFA C16:0 and C18:0, correcting for tape 
strip contamination 
Recently we published a method that enables analysis of FFAs by LC-MS and 
applied that method on tape stripped SC. However, endogenous C16:0, C17:0, 
C18:0 and C18:1 FFAs are abundantly present on control tapes (blanks), thereby 
interfering with the results. To correct for the amount of these four endogenous 
lipids on tape, it was not possible to simply subtract a certain amount of these 
lipids as the tape appeared to be too inhomogeneous for a reliable correction: we 
observed that the amount could vary ~100 fold. Therefore, a more comprehensive 
correction method was needed that corrects for these 2 lipids for each individual 
tape strip.  
 
 
Supplemental Figure 1. Tape strips were analyzed to obtain information on the amount of 
endogenous lipids that interfere with data from SC lipids, and how to correct for this contamination. 
Data are presented as scatter dot plots and their correlations of (a) endogenous FFAs C16:0 versus 
C18:0 (R2=0.991) analyzed from control tape strips. (b) exogenous ions m/z 365.3 amu versus 393.3 
amu. Data points include control tape strips as well as tapes from all subjects. 
 
Although the variation in absolute amounts of endogenous lipids is very high, we 
observed that the ratio of these lipids is always the same. In example, C16:0 is 
always linearly correlated to the amount of C18:0, which can be appreciated from 
Supplemental Figure 1a. We also analyzed two peaks which appear in blank tape 
strips but not in human SC, possibly exogenous lipids. Again, a very high 
correlation was observed between the amounts of the two unidentified peaks 
(Supplemental Figure 1b). The amount of these two lipid peaks also correlates very 
well (but not perfectly) to the amount of the four endogenous FFAs (Supplemental 




interfere with SC from in vivo subjects, we could calculate the predicted amount of 
endogenous lipids C16:0, C17:0, C18:0, C18:1. Indeed, we were able to successfully 
correct for the amount of contamination of these lipids. However, we mention that 
the methodological error does increase since we did not observe perfect 
correlations: Since the r2-values of the correlations are around 0.85-0.95, the 
expected increment in error is around 10%. Nevertheless, either taking into account 
or completely leaving out the C16:0 and C18:0 data did not change any of the 
conclusions that could be drawn from the data. 
 
Supplemental Table I. Correlation coefficients (r2) between the endogenous lipids and the two 
exogenous lipids. 
 Correlation coefficient (r2) 
Endogenous lipid 
Exogenous ion 1 
(m/z=365.3 amu) 
Exogenous ion 2 
(m/z=393.3 amu) 
C16:0 0.917 0.852 
C17:0 0.862 0.855 
C18:0 0.942 0.903 
C18:1 0.944 0.890 
The correlation coefficients state the accuracy in which the amount of the two exogenous ions (m/z 
365.3 and 393.3 amu) are correctly predicting the amount of endogenous lipids related to the tape. In 
general, exogenous ion 1 was chosen to predict the amount of endogenous lipids, as the correlation 
coefficient was higher compared to exogenous ion 2. 
 
Additional lipid composition data 
 
Supplemental Figure 2. Paired data of non-lesional and lesional AE skin for the FFA chain  
length, CER chain length, stretching peak position and bandwidth. P-values are calculated from the 
Wilcoxon signed rank test. Non-lesional skin and lesional skin of AE patients are indicated by /  








Supplemental Figure 3. Relative CER composition of each subclass for control (green),  
AE – non-lesional (orange), and AE – lesional (blue). 
 
 
Supplemental Figure 4. Correlation map of CERs and FFAs. On the horizontal axis are the individual 
CER chain lengths, whereas on the vertical axis are the individual FFA chain lengths. Strong negative or 
positive correlations are depicted in blue or red, respectively. Gray strokes indicate the tipping point of 
the chain length correlations; in other words, where positive correlations turn into negative correlations 
and vice versa. 
 
Supplemental Table II. Correlations between short/long CERs vs short/long FFAs  
  FFAs <C23 FFAs >C23 
CERs <C42  0.496* -0.541* 
CERs >C42 -0.429*  0.481* 
Spearman correlations showing that short CERs correlate positively with short FFAs and negatively with 






Supplemental Figure 5. (a) Correlation plot in which the FTIR scissoring bandwidth of all 
individuals is plotted versus the mean FFA chain length. The gray dashed line indicates the optimal 
linear fit. Control subjects are indicated by /. Non-lesional skin and lesional skin of AE patients are 
indicated by / and /, respectively. Open and filled data points indicate carriers and non-carriers 
of FLG mutations, respectively. (b) Bar plots demonstrating the correlation between each individual 
FFA chain length (x-axis) versus the scissoring bandwidth. Positive correlation coefficients indicate that 
these FFAs contribute to a more ordered lateral lipid packing, whereas FFAs with negative correlation 
coefficients contribute to a less ordered packing of the lipids. The dashed line indicates the moving 
average (period=3).  
 
 
Supplemental Figure 6. TEWL levels in control subjects, non-lesional SC and lesional SC of AE 
patients. Control subjects are indicated by /. Non-lesional skin and lesional skin of AE patients are 
indicated by / and /, respectively. Open and filled data points indicate carriers and non-carriers 
of FLG mutations, respectively. Means are indicated by gray horizontal dashed lines and their 
corresponding values (±SD). Significant differences were observed between control subjects and  





















he barrier function of the skin is primarily provided by the stratum 
corneum (SC), the outermost layer of the skin. Skin barrier impairment is 
thought to be a primary factor in the pathogenesis of atopic eczema (AE). 
Filaggrin is an epidermal barrier protein and common mutations in the filaggrin 
gene strongly predispose for AE. However, there is no strong evidence  
that filaggrin mutations are related to the reduced skin barrier in AE. It was 
recently shown that the SC lipid composition and organization play a role in  
the reduced skin barrier in AE. 
We determined the dry SC mass per surface area of controls and AE patients 
as well as the ratio between lipid and protein bands in the Raman spectra being a 
measure for the lipid/protein ratio in SC. The results show that the dry SC mass per 
skin area is altered only in lesional SC of AE patients compared to control subjects. 
Much more pronounced was the observed reduction in the lipid/protein ratio in SC 
of AE patients, both in lesional and non-lesional SC. These changes correlate with 
the barrier function, and may indicate that the lipid/protein ratio plays a role in the 






Atopic eczema (AE) is a chronic relapsing inflammatory skin disease characterized 
by erythema, pruritus and xerosis. AE is currently affecting over 15% of Caucasian 
children and 2-10% of adults, and its prevalence is increasing1-4. Eczematic lesions 
have a red, flaky appearance and cause severe itching. There is increasing evidence 
that AE is related to an impaired skin barrier function5,6. AE is strongly associated 
to mutations in the filaggrin gene (FLG) which encodes the barrier protein 
filaggrin7. Filaggrin has a role in the alignment of keratin filaments, facilitating the 
flattening of keratinocytes during terminal cornification8. In addition, filaggrin is 
metabolized into hygroscopic molecules, together with specific salts and sugars 
referred to as the natural moisturizing factor (NMF), which is important for SC 
hydration9. Despite the fact that an impaired barrier function has been 
demonstrated in adult AE patients, the precise role of filaggrin for the skin barrier 
function is not completely understood and compelling evidence that FLG mutations 
are the cause of the reduced barrier function in AE is missing10-12.  
The primary function of the skin is to reduce epidermal water loss and to 
prevent the penetration of harmful agents by acting as a permeability barrier to the 
environment. This barrier is provided by the stratum corneum (SC), the outermost 
layer of the skin. It contains nonviable corneocytes oriented parallel to the skin 
surface. The corneocytes are surrounded by a cornified cell envelope, consisting of 
a densely cross-linked layer of proteins. This envelope reduces the uptake of most 
substances into the corneocytes and therefore redirects the transport of most 
substances along the intercellular regions13. The intercellular regions are filled with 
highly organized lipids with a characteristic composition and organization. For this 
reason, lipid composition and organization are considered to be crucial for an 
adequate skin barrier function. The major lipid classes in the SC are ceramides 
(CERs), fatty acids and cholesterol.  
In previous studies, changes have been observed in the CER composition of 
non-lesional as well as lesional SC of AE patients5,14-18. Changes in several of the 
CER subclasses correlate with a reduced skin barrier function as measured by 
transepidermal water loss (TEWL). More recently, strong evidence was observed 
that besides changes in CER subclasses, the CER chain length plays a prominent 
role in the impaired barrier function of AE skin: in non-lesional SC of AE patients, 
both CER chain length and skin barrier function were significantly reduced19. 
Besides the lipid composition and organization, the lipid/protein ratio in the 
SC as well as the SC thickness may affect the skin barrier function. The aim of the 
present study was to determine the lipid/protein ratio in SC of control subjects and 
AE patients. In addition, the dry SC mass per surface area was determined, being a 
measure for SC thickness. Subsequently, these parameters were related to the 




The results show that the dry SC mass per surface area is altered in lesional AE SC 
but not in non-lesional AE SC, as compared to controls. The lipid/protein ratio is 
lower in both non-lesional and lesional SC in AE compared to that in SC of control 
subjects. The lipid/protein ratio correlates strongly with TEWL values. Therefore, 
besides lipid composition and organization, the lipid/protein ratio may be an 
important factor in the impaired skin barrier function in AE patients.  
Materials and methods 
Study population and study setup 
The study was approved by the Medical Ethics Committee of the Leiden University 
Medical Center and conducted in accordance with the Declaration of Helsinki 
Principles. All subjects gave written informed consent. Twenty-eight Caucasian AE 
patients (25.6±5.6 years; 11 males) and fifteen Caucasian control subjects without 
(history of) dermatological disorders (25.0±5.2 years; 5 males) were included. In 
the AE group, 14 patients were carrier of at least one prevalent FLG null allele. At 
the time of the study, 11 out of 28 AE patients suffered from eczematic lesions on at 
least one of the ventral forearms. The subjects did not apply any dermatological 
products to their forearms for at least one week prior to the study. Measurements 
were performed in a temperature and humidity controlled room, in which the 
subjects were acclimatized for 45 minutes prior to the measurements. All 
measurements were performed on a single day. A dermatologist marked an area 
(~4.5 cm2) of non-lesional skin and, if applicable, an area (~4.5 cm2) of lesional 
skin on the forearm of each AE patient at the start of the study day. The Raman 
measurements were performed on these marked areas. After the Raman 
measurements, the same skin areas were tape stripped while TEWL was monitored 
after each two tape strips. At the end of the study day, buccal mucosa cells were 
collected with a cotton swab for FLG genotyping.  
 
FLG mutation analysis 
All subjects were screened for any of the four most prevalent mutations found in 
the European Caucasian population (2282del4, R501X, R2447X, S3247X), as 
described earlier19. 
  
Skin barrier function assessment 
TEWL was monitored using a Tewameter TM 210 (Courage+Khazaka, Köln, 
Germany). The marked area on the subjects’ ventral forearm was placed in an open 
chamber, and TEWL values were recorded for a period of at least two minutes after 
which an average reading was calculated from the last 10 seconds of the 




and after each second tape strip, to assure proper monitoring of the changes in skin 
barrier function. 
 
Confocal Raman microspectroscopy 
Confocal Raman microspectroscopy (3510 Skin Composition Analyzer, River 
Diagnostics, Rotterdam, The Netherlands) was used to determine the lipid/protein 
ratio in SC of the ventral forearm. The principles of Raman spectroscopy and the 
procedure have been described elsewhere20,21.  
Spectra were recorded in the high wavenumber spectral region  
(2500-4000 cm-1) using a 671 nm laser. The spatial resolution was 5 cm-1. Laser 
power on the skin was 20 mW. Spectra were obtained from the skin surface to a 
depth of 40 μm with 2 μm steps. This was repeated on 15 different locations within 
the marked area. In order to avoid interfering Raman signals from skin surface 
contamination such as sebum and to avoid influences of washout effects and 
desquamation near the skin surface as well as to avoid Raman signals from the 
viable epidermis, we determined the lipid/protein ratio between depths of 4-10 μm 
in the SC. This was done by calculating the ratio of the integrated signal intensity 
from 2866 to 2900 cm-1 (CH2 asymmetric stretching of lipids) and from 2910 to 
2966 cm-1 (CH3 symmetric stretching of proteins, the same region as taken for the 
protein band for determination of the water concentration in skin20) and taking 
into account a linear baseline between the integration boundaries. The calculated 
signal ratio between the lipid and protein bands is referred to as the lipid/protein 
ratio. Calculations were performed using SkinTools 2.0 (River Diagnostics, 
Rotterdam, The Netherlands). 
 
SC isolation and lipid extraction  
In order to obtain Raman spectra of human SC lipids and extracted human SC, 
human SC was isolated by trypsin digestion as described elsewhere22. The SC lipids 
were extracted according to a modified Bligh and Dyer23 procedure with the 
addition of 0.25M KCl to extract polar lipids.  
 
Tape stripping procedure 
Multiple poly(phenylene sulfide) tape strips (Nichiban, Tokyo, Japan) were 
successively applied at the same area (4.5 cm2) on the marked area of the ventral 
forearm. All tapes were applied on the targeted skin and pressed for 5 seconds at 
450 g/cm2 using a D-Squame pressure instrument (Cuderm Corp., Dallas, USA). 
Tweezers were used to remove the tape in a fluent stroke, using alternating 
directions for each subsequent tape strip. The Squamescan 850A (Heiland 
electronic, Wetzlar, Germany) was used to determine the dry SC mass removed by 





The calibration procedure of the Squamescan was as follows. Immediately after 
measuring the absorption of the tape strip with the Squamescan, the tapes were 
incubated and shaken overnight in 1 mL 1M KOH, after which the extracts were 
neutralized with 79 μl 12M HCL. The final pH of the extract was set between 7.2-7.4 
with 1M HCl and/or 1M KOH. Subsequently, 50 μl of the extract was added to 200 
μl bicinchoninic acid (BCA, Pierce BCA, Protein Assay, Perbio Science BV,  
Etten-Leur, The Netherlands), followed by heating for 2 hours at 37oC and 
determination of the absorption at 562 nm (OD562). In this way we obtained 
corresponding OD562 values of the tape extracts with known Squamescan values. 
Sheets of isolated human SC with known weight (between 10-1000 μg, size  
~0.05-1 cm2) were incubated overnight and treated as described above, resulting in 
a calibration curve of dry SC mass against OD562. With this curve we converted 
Squamescan values of the tapes via their OD562 values into dry SC mass, which 
resulted in a calibration curve of Squamescan values against dry SC mass. In 
addition, 1/TEWL was plotted against the cumulative amount of tape stripped SC. 
Here, the intercept with the x-axis obtained by extrapolation is a measure for the 




Statistical analysis was performed using SPSS Statistics version 17.0. As the data 
show a non-normal distribution, non-parametric Mann-Whitney tests were 
performed for comparison of different groups with a significance level of P<0.05. 
For the paired comparison of non-lesional and lesional SC, a Wilcoxon signed rank 
test was used. Bivariate analysis and Spearman’s ρ correlation coefficient were used 
to analyze correlations between parameters.  
Results  
From the TEWL values and the cumulative amount of stripped SC, the dry SC  
mass per skin area was calculated. Figure 1 shows typical examples of 1/TEWL 
against the cumulative amount of tape stripped SC of three AE patients.  
The abscissa intercept by extrapolation is indicative for the dry SC mass per cm2.  
In the examples in Figure 1, the dry SC mass varies between 1195.2 μg/cm2 and 






Figure 1. Three examples of 1/TEWL plotted against the cumulative amount of tape stripped SC. The 
intercept of the line with the x-axis is indicative for the dry SC mass per cm2. 
 
Figure 2a shows the dry SC mass per surface area in control SC  
(1619±400 μg/cm2), non-lesional SC of AE patients (1407±340 μg/cm2), and 
lesional SC of AE patients (1200±168 μg/cm2). There was neither a significant 
difference between controls and non-lesional skin of AE, nor between non-lesional 
and lesional AE skin (P>0.08). However, there was a difference between controls 
and lesional skin of AE (P=0.01). Open and filled circles indicate non-carriers and 
carriers of FLG mutations, respectively. There was no difference in dry SC mass 
from AE patients that were carriers and non-carriers of a FLG mutation (P>0.1). In 
Figure 2b, 1/TEWL values are plotted as function of the dry SC mass per surface 
area (μg/cm2). The correlation coefficient between these parameters is r=0.67. 
Raman spectroscopy was used to examine the lipid/protein ratio in the SC. 
Figure 3a shows high wavenumber (2500-4000 cm-1) Raman spectra of SC (blue), 
extracted SC (containing no lipids, mainly protein, green), and extracted SC lipids 
(red), respectively. The spectrum of SC exhibits peaks at 2850 cm-1, 2880 cm-1 and 
2930 cm-1. The spectrum of the extracted lipids contains two characteristic peaks 
located at 2850 cm-1 and 2880 cm-1. In contrast, the extracted SC spectrum consists 
of only one peak located at 2930 cm-1. Figure 3b shows a typical example of a high 
wavenumber Raman spectrum of a control subject at a skin depth of 4 μm. The 







Figure 2. (a) Dry SC mass per surface area (μg/cm2) in control subjects, non-lesional SC of AE patients 
and lesional SC of AE patients. Means are indicated by gray horizontal dashed lines and their 
corresponding values (±SD). (b) Correlation between 1/TEWL and dry SC mass per cm2 in control 
subjects and AE patients. Non-carriers and carriers of FLG mutations are represented by filled and open 
data points, respectively. Control subjects are indicated by /. Non-lesional skin and lesional skin of 
AE patients are indicated by / and /, respectively.  
 
 
Figure 3. (a) High wavenumber Raman spectrum of SC (upper, blue), extracted SC (middle, green) 
and extracted SC lipids (lower, red). (b) Raman spectrum between 2500-4000 cm-1 of control SC at a 
depth of 4 μm. Peaks at 2880 cm-1 and 2930 cm-1 (both colored orange) belong to the lipids and 
proteins, respectively. 
 
Figure 4a shows the lipid/protein ratio as a function of depth (between 0 and  
40 μm), with a maximum between 0 and 4 μm and a gradual decrease deeper than 
8 μm. Figure 4b shows the average lipid/protein ratio between 4 and 10 μm in the 
SC in control SC, non-lesional AE SC, and lesional AE SC. Non-lesional skin of AE 
patients shows a significantly lower lipid/protein ratio than the skin of control 
subjects (0.24±0.05 and 0.28±0.03, respectively, P<0.005). In lesional skin, the 
lipid/protein ratio is even further reduced (0.19±0.03, P<0.001).  
Figure 4c shows the intra-subject comparison between lesional and  
non-lesional skin. In 9 out of 11 AE patients, the lipid/protein ratio is lower in 




The lipid/protein ratio in AE patients showed no difference between carriers and 
non-carriers of FLG mutations (0.24±0.04 in non-carriers and 0.23±0.06 in 
carriers (P>0.1) for non-lesional AE SC; and 0.19±0.02 in non-carriers and 
0.18±0.04 in carriers (P>0.1) for lesional AE SC). 
 
 
Figure 4. Lipid/protein ratio in control subjects and AE patients. (a) Lipid/protein ratio in the range of 
0-40 μm. The green, orange and blue lines indicate the average (±SD) of control SC, non-lesional AE 
SC and lesional AE SC, respectively. (b) Average lipid/protein ratio between 4-10 μm in the SC of the 
individual patients and controls. Means are indicated by gray horizontal dashed lines and their 
corresponding values (±SD). (c) Paired lipid/protein data of non-lesional and lesional AE skin.  
Non-carriers and carriers of FLG mutations are represented by filled and open data points, respectively. 
Control subjects are indicated by /. Non-lesional skin and lesional skin of AE patients are indicated 




The relationship between skin barrier properties and lipid/protein ratios is 
presented in Figure 5, showing the correlation between 1/TEWL and the 
lipid/protein ratio in control subjects and in non-lesional and lesional SC of AE 
patients. The correlation coefficient between 1/TEWL and lipid/protein ratio was 
0.86 (P<0.001).  
 
 
Figure 5. Correlation between lipid/protein ratio and 1/TEWL in control subjects and AE patients. 
Non-carriers and carriers of FLG mutations are represented by filled and open data points, respectively. 
Control subjects are indicated by /. Non-lesional skin and lesional skin of AE patients are indicated 
by / and /, respectively. 
Discussion 
In this study, we determined the lipid/protein ratio in SC of control subjects and in 
non-lesional as well as lesional SC of AE patients. In addition, the dry SC mass per 
surface area was determined in control subjects and in non-lesional skin of AE 
patients. Finally, we studied the correlations of these parameters with the skin 
barrier function as assessed by TEWL. 
The Raman spectra of extracted SC lipids and extracted SC demonstrate that 
the ratio between the peaks located at 2880 cm-1 and 2930 cm-1 is an excellent 
measure for the lipid/protein ratio in SC: the contribution of the lipids to the  
2930 cm-1 peak as well as the contribution of the proteins to the 2880 cm-1 peak  
is negligible. The selected peak boundaries of the 2930 cm-1 peak were based on 
those used for the protein band for determination of the water concentration  
in skin20. A change of the baseline by broadening the peak boundaries did not have 





We observed that the lipid/protein ratio is significantly lower in non-lesional as 
well as lesional SC of AE patients, compared to SC of control subjects. This may be 
partly explained by changes in the SC lipid composition: previous studies have 
shown that the lipid composition is altered in AE patients as compared to 
controls5,14-19,25. Some studies revealed that the level of long-chain CERs is reduced 
in non-lesional AE skin and the level of very short chain CERs (with a total chain 
length of 34 carbon atoms, referred to as C34 CERs) is increased16,19. However, the 
level of C34 CERs and long-chain CERs in non-lesional AE skin are together 
accounting for about 10 mol% of the total CER content in non-lesional skin19. 
Assuming an equimolar CER:CHOL:FFA ratio this is only 3 mol% of the total 
lipids, whereas the lipid/protein level has decreased by ~14% in non-lesional AE 
and ~32% in lesional AE. Hence the changes in C34 CERs, long-chain CERs and 
total CER level may not account for the complete reduction in lipid/protein ratio, 
which indicates another, yet unknown factor. The reduced lipid/protein ratio may 
be partly explained by a delayed or incomplete lamellar body extrusion process 
caused by an altered peroxisome proliferator-activated receptor (PPAR) activation, 
which has been reported for AE26-28. PPARs can be activated by lipids, and these 
nuclear hormone receptors may possibly be a link for the observed changes in both 
the lipid chain length and lipid/keratin ratio29,30. 
We could perform an intra-subject comparison of non-lesional and lesional 
skin as eleven subjects had both skin types on their ventral forearms. In most cases 
the lipid/protein ratio was lower in lesional compared to non-lesional skin. These 
differences within a subject may primarily be attributed to inflammation, the 
presence of microbes and/or an altered pH. These factors may affect the lipid 
synthesis31,32 and therefore result in a lower lipid/protein ratio in lesional AE skin. 
A measure of SC thickness is the total dry SC mass per surface area, which 
was determined by extrapolation of 1/TEWL versus the cumulative mass of tape 
stripped SC. Between non-lesional AE skin and control skin no significant 
difference in the dry SC mass per surface area was observed, which indicates that 
SC thickness was comparable for both groups. In lesional AE SC the total dry SC 
mass per surface area was lower compared to controls. In line with our results, 
Voegeli et al. have reported a decreased SC thickness in lesional AE SC33. They 
suggested increased serine protease activity in lesional SC of AE patients as a 
possible explanation for the observed differences. We noticed that SC thickness 
does affect the TEWL values and thus the skin barrier function as observed by the 
correlation between the total dry SC mass per surface area and TEWL.  
An alternative method to determine SC thickness is based on the water 
concentration profile in the SC measured by confocal Raman spectroscopy34-37. The 
advantage of Raman spectroscopy is that it enables the direct monitoring in vivo 
without damaging the SC. The method determines the actual SC thickness, which 




we were interested in variations in the SC thickness as a result of changes in dry SC 
mass per surface area independent of variations in water content of the SC. As the 
total amount of tape stripped dry SC mass and subsequent extrapolation does not 
change upon swelling, we used this method to determine the dry SC mass per 
surface area. In order to obtain a calibration curve we extracted small pieces of SC. 
During extraction of the SC, it is possible that not all proteins were extracted. 
Therefore, the amount of SC per tape strip may be slightly overestimated. 
Both SC thickness and lipid/protein ratio are factors that affect the TEWL. 
However, the correlation between lipid/protein ratio and TEWL was much stronger 
than the correlation between dry SC mass per surface area (as a measure of  
SC thickness) and TEWL. This may suggest that the level of lipids in SC plays  
a more prominent role in the skin barrier function than the dry SC mass. In  
the same line, our previous study shows a strong correlation between CER chain 
length and skin barrier function19. 
FLG mutations are the largest risk factor for the development of AE7,38 
known to date. However, in this study the presence of FLG mutations was not 
associated with lipid/protein ratio or dry SC mass per surface area in AE patients. 
In our previous study it was concluded that FLG mutations do not influence CER 
composition and lipid organization19. Although FLG mutations are a strong risk 
factor in the pathogenesis of AE, the results of this study indicate that in adult AE 
changes in the SC lipids seem to be the dominant factor in the reduced skin barrier. 
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etherton syndrome (NeS) is a rare genetic skin disease that is 
characterized by erythroderma, hair shaft defects and severe atopic 
manifestations. The disease is caused by mutations in the serine protease 
inhibitor Kazal-type 5 (SPINK5) gene, which encodes the protease inhibitor 
lympho-epithelial Kazal-type–related inhibitor (LEKTI). Lack of LEKTI causes 
epidermal proteases hyperactivity which results in stratum corneum (SC) 
detachment. NeS patients have an impaired skin barrier function. Besides barrier 
proteins, SC lipids are also crucial for the skin barrier. The lipids primarily consist 
of ceramides (CERs), free fatty acids (FFAs) and cholesterol. To date, hardly any 
information is available on the SC lipid composition and organization in SC of 
patients with NeS. Therefore, the aim of the present study is to determine the SC 
lipid composition and organization in NeS patients. 
We investigated the SC lipids by means of mass spectrometry, infrared 
spectroscopy and X-ray diffraction. We studied the lipid subclasses as well as the 
chain length distributions. A decreased FFA chain length and an increased level of 
mono-unsaturated FFAs was observed in SC of NeS patients compared to controls. 
Furthermore, the level of short-chain CERs was increased in NeS patients and in a 
subgroup of patients we observed a strong reduction in long-chain CER levels. The 
changes in lipid composition modified the lipid organization: we observed an 
increased disordering of the lipids in SC of NeS patients compared to controls. This 
study shows that there are striking changes in the lipid composition in NeS that 






Netherton syndrome (NeS) is a rare skin disorder with an occurrence of 1-3 in 
200.000 births and a fatality rate of around 20% in the first year of life by 
hypernatremic dehydration, electrolyte imbalances, perturbed thermoregulation, 
failure to thrive and recurrent infections1-5. NeS is characterized by erythroderma, 
hair shaft defects (bamboo hair) and severe atopic manifestations6. In addition, 
NeS patients show a drastically reduced skin barrier function7-9. The skin barrier is 
primarily located in the outermost layer of the skin, the stratum corneum (SC). The 
SC consists of flattened corneocytes embedded in a highly ordered lipid matrix. The 
organization and composition of this lipid matrix seems crucial for the barrier 
function of the skin, but hardly any information is available on the SC lipids 
regarding NeS patients. Therefore, the aim of the present study is to unravel the 
composition and organization of the SC lipid matrix in NeS. 
SC lipids mainly consist of ceramides (CERs), cholesterol (CHOL) and free 
fatty acids (FFAs). To date, 12 CER subclasses with a wide variation in chain length 
distribution have been identified in human SC10,11. FFAs mainly consist of  
saturated carbon-chains with lengths varying between 16 and 36 carbon atoms, of 
which the most abundant chain lengths are 24 and 26 carbon atoms12,13. In  
healthy SC, lipids form two lamellar phases with repeat distances of approximately 
6 and 13 nm referred to as the short periodicity phase (SPP) and long periodicity 
phase (LPP), respectively14,15. Within the lamellae the lipids form a dense 
(orthorhombic, highly ordered lipid chains) lateral organization although lipid 
domains with a less dense (hexagonal, less ordered lipid chains) lipid  
organization also co-exist. Both the lipid composition and lipid organization are 
crucial for a proper SC barrier function. Recent studies show the important role  
of the SC lipids in the skin barrier function of atopic eczema (AE) patients16,17,  
a skin disease often linked to NeS because of its shared symptoms18,19.  
We demonstrated a modified chain length distribution of CERs in SC of AE 
patients. This change resulted in an altered SC lipid organization, which in turn 
correlated with an impaired skin barrier function.  
NeS is caused by mutations in the serine protease inhibitor Kazal-type 5 
(SPINK5) gene. These mutations result in loss of function of lympho-epithelial 
Kazal-type-related inhibitor (LEKTI)20. LEKTI is described in relation to  
proteins involved in proliferation and differentiation of keratinocytes. In addition, 
several LEKTI-domains can efficiently inhibit the enzyme activity of  
various subtypes of kallikreins (KLKs): KLK5, KLK7 and KLK14. Lack of  
active LEKTI domains leads to increased activity of these KLKs, thereby affecting 
various biological processes that will have a detrimental effect on the skin barrier: 
i) KLKs 5 and 7 are involved in the desquamation process, that is the 




SC21-26. Reduction in the activity of LEKTI, which inhibits the activity of 
these enzymes, causes epidermal proteases hyperactivity resulting in SC 
detachment27. 
ii) KLKs 5 and 14 induce cutaneous inflammation through  
proteinase-activated receptor 2 (PAR2) and NF-κB pathway activation 
in vitro28, leading to up-regulation of pro-Th2 cytokine thymic stromal 
lymphopoietin (TSLP), IL1-α, IL8, and TNF-α8,23,29,30. The production of 
these cytokines can in turn affect the SC lipid synthesis and thereby the 
skin barrier31,32. Besides, PAR2 activation can lead to abnormal lamellar 
body secretion that also results in disrupted lipid lamellae and a 
reduced skin barrier function7. 
iii) KLKs act as catalysts for the proteolysis of the enzymes  
β-glucocerebrosidase and acid sphingomyelinase33. Both enzymes are 
involved in the synthesis of CERs that play an important role in the 
barrier function of the SC. 
iv) Increased activity of KLK5 (as a result of decreased inhibition by 
LEKTI) leads to hyperactivity of the epidermal protease elastase 2 
(ELA2). This results in abnormal processing of filaggrin, a keratin 
filament-associated protein highly associated with atopic eczema34. 
Filaggrin breakdown products, the natural moisturizing factor (NMF), 
are suggested to be important for maintaining the acidic nature of the 
SC: an increase in pH induces premature degradation of 
corneodesmosomes leading to a disrupted barrier and cohesion of the 
skin35. In addition, an increase in pH can lead to altered catalytic 
activities of lipid processing enzymes that require an acidic pH for their 
optimal catalytic activity36. Besides these effects of KLKs on the 
different aspects of the metabolic pathways, KLKs may activate each 
other or induce self-activation, thereby exacerbating the effects30,37,38. 
NeS patients show different expression of proteins like loricrin, involucrin and the 
transglutaminases. This disturbs the assembly of the cornified envelope 
surrounding the corneocytes and may also reduce the SC barrier function39-41. 
Altogether, this results in a drastically reduced barrier function in patients with 
NeS as measured by transepidermal water loss (TEWL)7-9. 
To date, little is known about the SC lipid composition in NeS. A study of 
Bonnart et al. with transgenic mice overexpressing ELA2 as a model for NeS 
reported a threefold increase in TEWL demonstrating a decreased skin barrier 
function34. For the first time, the lipids in total epidermis were analyzed. They 
observed an increased level of total glucosylceramides and reduction of 
sphingomyelin, and significant decrease in FFA levels. In addition, it was reported 
that the lipids form irregular loose stacks of lamellae7,34,42. However, no data were 




the lipids. In addition, no quantitative information about the lamellar phases were 
provided and no information is available on the lateral packing. Therefore, the aim 
of this study was to perform an in depth analysis of the lipid composition and 
organization in SC of patients with NeS.  
Our results show that in SC of NeS patients there is a strong increase in short 
chain CERs and FFAs as well as an increase in unsaturated FFAs. Furthermore, the 
lipid chains are more disordered and the lamellar lipid organization is altered. A 
subgroup of patients showed no lamellar lipid profile at all, and these patients also 
had the most drastic changes in their SC lipid composition. 
Materials and methods 
Study population 
The study was conducted in accordance with the Declaration of Helsinki and was 
approved by the Ethical Committee of Toulouse. Eight patients with classical 
features of Netherton syndrome were included in the study. They were from 
different ethnic backgrounds and their age ranged from 8 to 39 years at the time  
of the study. Patients included four males and four females. Patients  and , and 
  and  are siblings, respectively. Each patient presented congenital ichthyosiform 
erythroderma, trichorrhexis invaginata and eczematous like lesions. Four of  
them had ichthyosis linearis circumflexa (patients , ,  and ). All patients  
had elevated IgE in their serum. Each patient showed negative LEKTI 
immunostaining on skin biopsy. SPINK5 mutations leading to premature 
termination codons were identified in each patient.  
For comparison, SC was analyzed from epidermis of 5 Caucasian subjects 
(36.2±12.2 years; 3 males), which was obtained after abdominal- or mammaplasty 
reduction at the hospital. SC was isolated by trypsin digestion, a procedure that 
does not affect the lipid organization in SC43 and is described previously44. 
 
Lipid classification and nomenclature 
FFAs are classified according to their shorthand lipid number designation in which 
the chain length and degree of unsaturation is denoted45. For example, 
octadecenoic acid (oleic acid) is denoted as C18:1. CERs consist of a sphingosine 
base linked to a fatty acid (acyl) chain. In human SC, both chains can vary in the 
number of carbon atoms. This results in a wide distribution in total chain length, 
that is, the total number of carbon atoms in both chains. In addition, both chains 
can have additional functional groups at specific locations. This results in  
12 identified subclasses10,11 that are classified according to the nomenclature of 
Motta et al.46: CER [AdS], [AH], [AP], [AS], [EOdS], [EOH], [EOP], [EOS], [NdS], 






Figure 1. CER nomenclature and molecular structure. CERs are composed of a sphingoid base 
(depicted in blue) linked via an amide bond to an acyl chain (gray). Both chains show a variable carbon 
chains length indicated by the red arrows. This results in a wide distribution of the total CER chain 
length, i.e. the chain length of the sphingoid base and acyl chain combined. Both chains can have 
additional functional groups at the carbon positions marked in red. This results in 4 different sphingoid 
bases (dihydrosphingosine [dS], sphingosine [S], phytosphingosine [P], 6-hydroxysphingosine [H]) and 
3 different acyl chains (non-hydroxy fatty acid [N], α-hydroxy fatty acid [A] and esterified  
ω-hydroxy fatty acid [EO]). Together, this results in the presence of 12 subclasses denoted as: [NdS], 
[AdS], [EOdS], [NS], [AS], [EOS], [NP], [AP], [EOP], [NH], [AH], [EOH]. As an example, a CER with a 
non-hydroxy fatty acid of 16 carbon atoms long and a phytosphingosine base of 18 carbon atoms will be 
denoted as CER [NP] C34.  
 
SC lipid extraction and analysis 
An enhanced procedure of the commonly used Bligh and Dyer47 method was 
performed to extract the lipids from the SC sheets of both NeS patients and control 
subjects. Afterwards, lipids were analyzed by liquid chromatography coupled  
to mass spectrometry (LC-MS) to profile the CERs and FFAs. A detailed protocol  
of the lipid extraction and lipid analysis is described elsewhere11,47. Briefly, a  
three-step sequential extraction procedure of chloroform/methanol/water (1:2:½; 
1:1:0 and 2:1:0) was performed to extract all extracellular SC lipids. To  
enable proper analysis by LC-MS, samples were reconstituted in 
chloroform/methanol/heptane (2½:2½:95) to a final concentration of 1.0 mg/mL. 
Two 10 µl injections of each lipid sample were performed to analyze sequentially 
FFAs and CERs, using an Alliance 2695 high performance liquid chromatography 




spectrometer (TSQ Quantum, Thermo Finnigan, San Jose, CA, USA) equipped with 
an atmospheric pressure chemical ionization (APCI) source. FFAs were separated 
using a C18 reverse phase column (Purospher Star LiChroCART, Merck, 
Darmstadt, Germany) and analyzed in negative ion mode, while separation of CERs 
was achieved using a normal phase column (polyvinylalcohol-Sil, YMC, Kyoto, 
Japan) while analyzing in positive ion mode. Xcalibur software version 2.0 was 
used for data acquisition.  
 
Small angle X-ray diffraction measurements 
SC sheets were analyzed by small angle X-ray diffraction (SAXD) performed at the 
European Synchrotron Radiation Facility (ESRF, Grenoble, France) using station 
BM26B. SC was hydrated over a 27% NaBr solution during 24h before the 
measurements. SC sheets were oriented parallel to the primary X-ray beam in 
order to obtain high quality diffraction patterns. SAXD patterns were detected with 
a Frelon 2000 charged-coupled device (CCD) detector at room temperature for a 
period of 10 minutes using a microfocus beam, similarly as described elsewhere48. 
The exposure time to the X-rays was kept to a minimum and samples showed no 
evidence of radiation damage. From the scattering angle, the scattering vector ( ) 
was calculated by q=4π sin θ/λ, in which λ is the wavelength of the X-rays at the 
sample position and θ the scattering angle. The repeat distance of a lamellar phase 
can be calculated from the diffraction peaks by d=n·2π/qn, in which n is the order 
of the peak. This means that a shift in peak position to higher q values results in a 
shorter repeat distance. 
 
Conformational ordering of the lipids 
A high conformational ordering is an indication that the lipids adopt the properties 
of a crystalline phase, while with a low conformational ordering the lipids form  
a liquid phase. To obtain information on the conformational ordering,  
Fourier transform infrared spectroscopy (FTIR) spectra were recorded using a 
Varian 670-IR spectrometer (Varian Inc., Santa Clara, USA) equipped with a broad 
band liquid nitrogen cooled mercury-cadmium-telluride (MCT) detector and an 
external sample compartment containing a GladiATR (Pike, Madison, USA) 
attenuated total reflection (ATR) accessory with a single reflection diamond.  
The spectra of patients were collected in ATR mode and transmission mode  
(as a control), and no difference between both methods was observed. SC samples 
were hydrated over a 27% NaBr solution during 24h. SC was mounted between  
two ZnSe windows when measured in transmission mode. Samples were put  
under a purge of continuous dry air starting 30 minutes before data  
acquisition. Spectra were acquired as a co-addition of 256 scans at 1 cm-1  
resolution during 4 minutes. When measuring in ATR mode, 150 spectra  




(Varian Inc., Santa Clara, USA) was used for data acquisition. 
 
Statistical analysis 
Statistical analysis was performed using SPSS Statistics. Non-parametric  
Mann-Whitney tests were performed when comparing 2 groups, unless explicitly 
noted elsewhere. Differences were considered either weakly significant (P<0.1), 
moderately significant (P<0.05) or highly significant (P<0.005) and are denoted 
throughout the manuscript as *, ** and ***, respectively. 
Results 
Decreased FFA chain length and increased degree of 
unsaturation in patients with Netherton syndrome 
Figure 2 shows data on the FFA composition of NeS patients (purple) compared to 
the control subjects (green). The presence of FFAs <20 carbon atoms, being 
abundantly present in patients, were not taken into account in the present study as 
these FFAs are most probably present due to contamination of topical treatments 
of the NeS patients. It is impossible to distinguish between native FFAs and those 
from topical formulations. The relative abundance of saturated FFAs and  
mono-unsaturated FFAs (MUFAs) is shown in Figure 2a. In NeS patients there is a 
lower level of saturated FFAs compared to SC of controls (71.3±24.1% and 
97.0±1.1%, respectively) and a higher level of MUFAs compared to controls 
(28.7±24.1% and 3.0±1.1%, respectively). Figure 2b shows the relative chain length 
distribution of saturated FFAs in NeS patients (purple) and in controls (green).  
The most abundant chain lengths in controls are C24:0 and C26:0. The large 
standard deviations of the NeS patients are caused by inter subject variation  
and are not due to methodological variation.  
Compared to control subjects, SC lipids in NeS patients show a shift to a 
shorter FFA chain length: there is a significant increase in FFA C20:0 and C21:0 
and a significant decrease in FFAs C24:0, C25:0 and C26:0. Figure 2c shows the 
chain length distribution of MUFAs. No odd chain length MUFAs were detected in 
SC from either NeS patients or controls. SC of NeS patients show a significant level 
of MUFAs C20:1, C22:1, C24:1. On the contrary, control subjects did not show a 
detectable level of MUFAs (C20:1, C22:1, C24:1) and only very low levels of C26:1, 
C28:1, C30:1 and >C30:1. From the abundance of both the saturated FFAs and 
MUFAs, the average chain length for each patient and control was calculated. These 
results are provided in Figure 2d and show that the average FFA chain length is 
significantly reduced in NeS patients versus controls (23.4±0.9 and  





Figure 2. (a) Scatter dot plot showing the relative abundance of saturated FFAs (left) and  
mono-unsaturated FFAs (MUFAs, right). (b) and (c) present bar graphs showing the relative abundance 
of respectively saturated FFAs and MUFAs. The total abundance of saturated FFAs and MUFAs together 
was set to 100%. (d) Scatter dot plot showing the average FFA chain length. Controls (n=5) and NeS 
patients (n=8) are presented as green and purple bars/dots, respectively. Error bars represent SD 
values. Means are indicated by gray horizontal dashed lines and their corresponding values (±SD).  
ND means ‘not detected’. Individual NeS patients are labeled - . * indicates weakly significant 




Altered levels of acyl-CERs and short-chain CERs in SC of NeS 
patients 
The CER profiles of 5 controls and 8 NeS patients were studied. The CER profiles of 
two representative examples of controls and 4 examples of NeS patients are 
presented in the 3D ion chromatograms in Figure 3. An overview of 3D ion 
chromatograms of the remaining NeS patients and control subjects is provided in 
Supplemental Figure 1. Figures 3a and b show two examples of the CER profiles of 
control SC. As there was very little difference in the profile of all control subjects, 
these two pictures closely resemble those of all 5 controls. There are at least 12 CER 
subclasses depicted, as reported before11. Within each CER subclass, a large 
number of peaks can be observed. Each peak indicates a CER specie with a 
different chain length: the difference in molecular mass of two sequential CER 
species within one subgroup is 14 mass units, representing a reduction of one  
CH2-group. A wide distribution in ther total carbon chain length is observed in all 
12 CER subclasses in human SC. The CERs with higher mass values in the upper 
part of the 3D mass spectrogram belong to the CER [EO] subclasses (also noted as 
acyl-CERs) and show a chain length distribution between 63-78 carbon atoms. The 
α-hydroxy [A] and non-hydroxy [N] CER subclasses have shorter chains and 
therefore lower masses. The carbon chain lengths of these subclasses are between 
34-52 and 32-56 carbon atoms, respectively. The 3D ion chromatograms of NeS 
patients are provided in Figures 3c, d, e and f.  
In general, of all CER subclasses CER [NP] was most significantly  
reduced while CER subclasses [AS], [NS] and [AH] were least affected. 
Furthermore, there is a shift in the lipid chain length distribution of NeS patients to 
lower mass values compared to controls: increased peak intensities in the 
molecular range between 550 and 650 are observed in chromatograms of  
NeS patients (labeled as red peaks in Figure 3).  
The chromatograms of Figures 3c and d are representative for 5 NeS patients 
( , , ,  and ). In the SC of these patients all CER subclasses are observed. 
There is a clear shift to a higher abundance of short-chain CERs. This is particularly 
the case for CER subclasses [NS], [AS] and [AH], for which a very high peak was 
observed corresponding to CERs with a very short total carbon chain length of 34 
carbon atoms (referred to as C34 CERs). Figures 3e and f show the ion 
chromatograms representative for the other 3 NeS patients ( ,  and ). These 
patients show a clearly distinguishable pattern compared to the other NeS patients: 
there is a narrow chain length distribution in [A] and [N] subclasses. In addition, 
the level of acyl-CERs is drastically decreased and the C34 CERs are strongly 
increased. NeS subject  also shows a clearly distinguishable pattern in the CER 
subclasses, but in contrast to the other 3 patients, acyl-CERs were present in this 






Figure 3. 3D ion chromatograms of control SC (a and b) and NeS patients (c, d, e and f). Retention 
time (3.6-8.3 min), mass (480-1200 amu) and relative intensity of each peak are shown on the x-, y- and 
‘z’-axis, respectively. Chromatograms are normalized to their most abundant peak. The chromatograms 
of the NeS patients show a decreased chain length of the CERs. In addition, in (e) and (f) there is a 
decrease in acyl-CERs ([EO] CERs) and a narrower chain length distribution in all other CER 
subclasses. NeS patients also show an increase in short chain CERs, in particular CERs with a chain 
length of 34 carbon atoms (C34 CERs), which are indicated in the chromatograms by red peaks. The  
3D ion chromatograms of all controls and NeS patients are listed in Supplemental Figure 1. 
  
Quantitative results on the relative abundance of acyl-CERs and short-chain  
CERs are shown in Figures 4a and b, respectively. Control subjects show on  
average a relative abundance of 8.4±1.9% acyl-CERs. This abundance was 
comparable for 5 out of 8 NeS patients, but 3 patients show a drastic reduction  
to ~2.5%. Regarding the abundance of very short chain CERs with a mass  
lower than 600 amu (corresponding to a total chain length of ~38 carbon atoms), 








Figure 4. Dot plots showing the relative abundance of (a) acyl-CERs and (b) short chain CERs  
(C32-C38) in SC of controls () and NeS patients (). Gray dashed horizontal lines and  
the corresponding values indicate mean values (±SD). Gray horizontal solid lines indicate averages  
for two different subgroups observed: 5 NeS patients with normal acyl-CER levels and 3 NeS patients 
with reduced acyl-CER levels. Individual NeS patients are labeled - . *** indicates highly  
significant (P<0.005). 
 
A closer examination of the mass spectra led to the observation of unidentified 
peaks present in many CER subclasses with a mass of exactly 2 amu lower 
compared to the identified CERs. As an example, this is illustrated in the mass 
chromatogram of Figure 5a in which a subsection of the mass spectrum of CER 
[NP] is shown. These peaks correspond to CERs with one degree of unsaturation. 
The increase in unsaturated CERs in NeS is high, and the example of CER [NP] is 
illustrated in Figure 5b: the 3D ion chromatograms show the same subsection of 
CER [NP] in a control sample and a NeS patient. No unsaturated CERs were 
observed in control subjects, and the most abundant peak in this subsection 
corresponded to a saturated CER with a chain length of 48 carbon atoms. On the 
contrary, multiple peaks corresponding to unsaturated CERs of different chain 
length were observed in the NeS patient. In this subsection of CER [NP], 
unsaturated C48:1 was the most abundant peak. When comparing all the lipid 
profiles it becomes apparent that NeS subject  does show the highest abundance 






Figure 5. (a) Mass chromatograms of a subsection (730-815 amu) of CER [NP] in a representative 
control subject (upper chromatogram) and NeS patient (lower chromatogram). Peak labels indicate the 
mass (amu) and to which CER chain length and degree of unsaturation it corresponds. Red lines 
indicate the unsaturated CERs observed in NeS patients. Although [M+H]+ was the main ion observed, 
also the [M+H-H2O]+ is detected and shown in the chromatograms as dashed lines. These have a mass 
that is 18 amu lower than their main [M+H]+ counterpart. Figure (b) shows the 3D ion chromatograms 
of Figure (a). Saturated and unsaturated chromatograms are presented separately in the left and right 
column respectively. Chromatograms are normalized to their highest peak in the sample and marked by 
*: i.e. CER [NP] C48:0 in the control subject and CER [NP] C48:1 in the NeS patient. 
 
Altered lamellar lipid organization in Netherton syndrome 
Figure 6 shows diffraction patterns of controls and NeS patients. The positions of 
the peaks are indicative for the periodicity of the lipid lamellae: a shift to higher  
q-values in the figure is indicative for a shorter periodicity (d) of the lipid lamellae. 
Figure 6a shows diffraction patterns of control SC. In previous studies the 
diffraction patterns were analyzed and attributed to the two lamellar phases with 
repeat distances of around 13 (LPP) and 6 nm (SPP). All controls show clear peaks 
at scattering vector values (q) of 1.00±0.01 and 1.45±0.01 nm-1. The 1.00 nm-1 
diffraction peak is attributed to the 2nd order peak of the LPP and the 1st order peak 
of the SPP, while the 1.45 nm-1 peak is attributed to the 3rd order of the LPP.  
In addition, some controls also show the 1st order of the LPP as a weak shoulder at  
a q-value located at ~0.50 nm-1. Figures 6b and 6c show diffraction patterns of NeS 




showed acyl-CERs present in their 3D ion chromatograms of Figure 3 and 
Supplemental Figure 1 are depicted in Figure 6b. The presence of a diffraction peak 
at 0.5 nm-1, but also the presence of peak '2' and '3' in patients , ,  and  
suggests that the LPP is present. The diffraction pattern of patient  is very similar 
to that of the controls, although the peak position indicated by ‘2’ is shifted to 
slightly higher q-values suggesting a reduction in the repeat distances of  
the lamellar phases. The other diffraction patterns show distinct differences. In  
the SAXD pattern of SC from patients ,  and  the peak indicated as ‘3’ has a 
higher intensity compared to that in the controls and shifted to either lower or 
higher q-values. The most likely explanation for this increased intensity and 
changed shape of the peak is the formation of additional phases. The diffraction 
pattern of patient  does not show any diffraction peak. Figure 6c shows the SAXD 
curves of the NeS patients (numbers ,  and ) who have a low level of acyl-CERs 
present in the 3D ion chromatograms in Figure 3. No peaks are observed in the 
diffraction patterns of these NeS patients.  
 
 
Figure 6. SAXD patterns of controls (a) and NeS patients (b and c). The positions of the peaks (q) are 
indicative for the periodicity of the lipid lamellae. Figure (b) shows NeS patients with a normal level of 
acyl-CERs, while Figure (c) presents diffraction patterns of NeS patients with a reduced level of  
acyl-CERs. From the scattering angle, the scattering vector (q) was calculated by q=4π sin θ/λ, in which 
λ is the wavelength of the X-rays at the sample position and θ the scattering angle. Individual NeS 




Higher degree of disordering of the lipid chains in NeS 
Figure 7 shows the CH2 symmetric stretching peak position of the SC lipids in 
controls (green) and NeS patients (purple). A higher peak position indicates a 
higher degree of conformational disordering of the lipid chains. The average peak 
position of the NeS patients is 2850.0±0.6 cm-1, which is significantly higher 
compared to the control samples, showing an average value of 2849.4±0.1 cm-1. In 
addition, a larger variability between NeS patients compared to controls was 
observed when performing a non-parametric Levene’s test (P<0.05). 
 
 
Figure 7. CH2 symmetric stretching peak position in SC of controls () and NeS patients (). Means 
are indicated by gray horizontal dashed lines and their corresponding values (±SD). A higher peak 
position indicates a higher degree of conformational disordering of the lipid chains. Individual NeS 
patients are labeled - .* indicates weakly significant (P<0.1). 
Discussion  
In this study we investigated the SC lipid composition and organization in 8 NeS 
patients and compared this to control SC. Recently, Bonnart et al. studied the lipid 
composition in transgenic mice overexpressing ELA2 as a model for NeS34. They 
found a decreased level of FFAs and an increased total level of glucosylceramides 
and a reduction of sphingomyelin. Electron microscopy studies revealed the 
presence of unprocessed lipids in the intercellular space of the SC. However, no 
further details on lipid subclasses and chain length distributions were provided, 
which is the focus of the present study. In addition, we analyzed the lipid 
organization. Both the lipid composition and organization in SC of NeS patients 
show large deviations from that in control subjects. More precisely, we show that in 
SC of NeS patients there is an increase in MUFAs and in short-chain FFAs. Similar 
changes were observed in the CER composition: increased levels of unsaturated 
CERs as well as short-chain CERs were abundantly present in SC of NeS patients 
compared to control subjects. We also observed changes in the lipid organization  




lipid chains as well as an altered lamellar organization. In a subgroup of  
NeS patients almost no acyl-CERs were present.  
These changes in the lipid composition correlated to changes in the lipid 
organization. NeS patients ( , ,  and ) with normal levels of acyl-CERs in their 
SC revealed a diffraction pattern indicating the presence of the LPP. In contrast, 
NeS patients with low levels of acyl-CERs ( ,  and ) did not show any proper  
SC lamellar organization as no diffraction peaks were observed in the 
corresponding SAXD profile. The exception is NeS patient : despite a high level of 
acyl CERs present in the SC, no peaks were detected in the SAXD profile of  
this patient. However, this patient shows a clearly distinguishable profile in  
most CER subclasses and has the highest level of short chain CERs and  
unsaturated CERs. In addition, the highest level of MUFAs as well as the  
shortest average FFA chain length were observed in this patient. The  
abundant presence of shorter and unsaturated chains enhances disordering of  
the lipid organization and may therefore explain the lack of regularly stacked  
lipid lamellae49. Finally, only one patient ( ) showed a diffraction profile very 
similar to the controls. This patient exhibits the least deviation in SC lipid 
composition compared to the control subjects.  
It has been reported that NeS patients show a drastic reduction in  
skin barrier function, as indicated by increased TEWL values7-9. As the lipids  
play a crucial role in the skin barrier function an altered lipid composition and thus 
a change in lipid organization may contribute to the increased TEWL values in  
NeS patients: in previous studies using model lipid systems we observed  
that both an absence of acyl-CERs as well as short chain FFAs results in an 
increased permeability49,50. Furthermore, very recently we also reported  
an excellent correlation between a reduction in chain length of CERs and  
an increase in TEWL in patients with AE, demonstrating that the lipids may  
play a role in the impaired skin barrier function17. 
NeS and AE are both inflammatory diseases with some genetic association. 
Patients with NeS show many symptoms comparable to AE patients18,19. Therefore, 
a comparison in lipid profiling between NeS and AE is also of interest. Several 
changes in lipid composition in NeS were also observed in SC of patients with AE, 
but in the latter less pronounced. These changes are: 
i) a reduction in the level of acyl-CERs;  
ii) increased levels of CER [AS] and CER [NS] and a reduced level of  
CER [NP];  
iii) increased levels in C34 CERs; 
iv) a shift to shorter chain lengths in FFAs and CERs  





In AE, these changes in lipid composition correlate very well with an increased 
TEWL16,17,51. Therefore, also in NeS these changes in lipid composition and 
organization may contribute to the impaired skin barrier. In AE we observed that 
changes in the SC lipids were more pronounced in lesional skin compared to  
non-lesional skin, which may indicate that either inflammation or the presence of 
surface bacteria may play a role in changes in the lipid composition. 
Several changes in epidermal processing may contribute to a change in  
the lipid composition in NeS: 
i) An increased pH in SC of NeS patients, which may be caused by ELA2 
hyperactivity and lower NMF levels. This may lead to alterations in SC 
CER subclass levels in NeS33,36,52 as the activity of both 
sphingomyelinase and β-glucocerebrosidase is highly dependent on the 
pH in their microenvironment. Furthermore, a pH increase induces 
high serine proteases activity that in turn degrades lipid processing 
enzymes33. Up regulation of KLK activity has also been reported to 
affect these enzymes33. As CER [AS] and CER [NS] both have 
sphingomyelin as precursor, an imbalance in the activity of these 
enzymes may increase the relative levels of these ceramides.  
ii) Park et al. showed a downregulation of elongases 1, 4 and 6 (ELOVL1, -4 
and -6) and a subsequent reduction in CER chain length in a murine 
atopic eczema model53 demonstrating that these enzymes may be 
involved in the reduction of CER chains in this model. In addition, it  
is known that ELOVL4 knockout mice show a strong reduction in  
long chain FFAs especially beyond C24, increased presence of 
unsaturated FFAs, and absence of acyl-CERs54. Therefore, the reduction 
in chain length of the lipids in SC of NeS patients may be related to  
a decreased activity of ELOVLs.  
In conclusion, this study indicates for the first time that the SC lipid composition 
and organization are both altered in NeS patients. These alterations in SC lipids 
may at least partly explain the skin barrier dysfunction in NeS. It is of interest to 
study the activity of the abovementioned enzymes in NeS patients in vivo as the 
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The primary function of the skin is to form an effective barrier of the human body 
against allergens, irritants and microorganisms and to prevent excessive water loss 
from the body. The skin barrier function strongly relies on the outermost layer of 
the skin, the stratum corneum (SC), which consists of dead corneocytes embedded 
in a highly organized extracellular lipid matrix. The main penetration pathway of 
most substances through the SC is suggested to take place via the intercellular lipid 
matrix1-3. Therefore, the lipids are thought to play a crucial role in the skin barrier 
function. This lipid matrix consists mainly of ceramides (CERs), cholesterol 
(CHOL) and free fatty acids (FFAs) in an approximately equimolar ratio4. CERs 
consist of a sphingoid base linked to a fatty acid. To date, 12 CER subclasses have 
been identified in human SC5,6. They differ from each other by their head-group 
architecture and acyl chain length. The acyl-CERs have a unique structure as they 
contain a very long acyl chain linked to linoleic acid. FFAs mainly consist of 
saturated carbon-chains with lengths varying between 14 and 32 carbon atoms, of 
which the most abundant chain lengths are 24 and 26 carbon atoms7,8. 
SC lipids are arranged in layers, referred to as lamellae. These lamellae are 
stacked on top of each other and are oriented approximately parallel to the skin 
surface. In human SC, two lamellar phases are formed with repeat distances of  
6 and 13 nm, referred to as the short periodicity phase (SPP) and long periodicity 
phase (LPP), respectively9. Within these layers the lipids form a very dense, highly 
ordered packing – the so-called orthorhombic organization – but a subpopulation 
of lipids forms also a less dense (hexagonal) and even a liquid organization. In 
healthy human SC the lipids are mainly arranged in a dense orthorhombic packing. 
In diseased skin, like atopic eczema (AE), the SC lipid composition and 
organization may be altered. AE is a chronic relapsing inflammatory skin disease 
that is characterized by dryness, erythema and pruritus10,11. It affects almost 20% of 
Caucasian children and 2-10% of adults, and its prevalence is increasing rapidly, 
especially in developed countries12-16. The exact cause of AE is unknown, but in 
previous studies it has been shown that AE is strongly associated with mutations in 
the filaggrin gene (FLG)17,18. Filaggrin is a skin barrier protein that plays a role  
in the alignment of keratin filaments19. Furthermore, filaggrin is the precursor of 
the amino acid derived components of the natural moisturising factor (NMF), 
which is important for SC hydration20. 
AE patients have a decreased skin barrier function in non-lesional as well as 
lesional skin, as monitored with transepidermal water loss (TEWL)21-25.  
However, the role of FLG mutations in the reduced skin barrier function is yet 
inconclusive26-31. Therefore, other factors such as an altered SC lipid composition 





The main objective of this thesis is to determine the SC lipid composition, lipid 
organization and lipid/protein ratio in AE patients and control subjects and to 
determine how these changes in lipid properties are associated with the impaired 
skin barrier function and disease severity of AE patients. 
 
The main questions to be answered in this thesis are: 
i) Are the lipid composition and lipid organization altered in non-lesional 
and lesional SC of AE patients compared to control subjects? 
ii) Is there a correlation between an altered SC lipid organization and  
lipid composition in AE patients and control subjects? 
iii) Are the changes in the SC lipid properties associated with the  
impaired skin barrier function and disease severity? 
iv) Are the changes in SC lipid properties associated with the presence  
of FLG mutations and NMF levels? 
v) Is the SC lipid/protein level altered in AE and does this correlate  
with skin barrier function? 
vi) Are the SC lipid properties altered in the related skin disease Netherton 
syndrome? 
 
In chapter 2 the lamellar lipid organization and the level of CER subclasses of 
control SC and non-lesional SC of six AE patients is described. In two AE patients 
the lamellar lipid organization was altered: shorter periodicities of the lamellar 
phases in the SC were noticed compared to controls. The level of long chain  
acyl-CERs was also reduced in these two patients. These results indicate that the 
presence of long chain acyl-CERs may play a role in shortening of the repeat 
distances of the lipid lamellar phases in AE patients. The association of the level of 
long chain acyl-CERs and presence of the LPP was previously reported for in vitro 
SC lipid mixtures32. These results showed that a more detailed analysis of the lipid 
organization and composition in patients with AE is warranted. 
 
In the study described in chapter 3 a comprehensive analysis of CER composition 
and lipid organization in non-lesional SC of AE patients and control subjects  
was performed. SC was harvested by tape-stripping in order to determine  
the lipid composition. A biopsy was taken in order to obtain information  
on the lamellar lipid organization. The lateral organization of the lipids  
and the NMF levels were examined non-invasively. In addition, the  
skin barrier function and clinical state of the disease were examined. The  
results show that the levels of several CER subclasses were altered in  
non-lesional SC of AE patients compared to controls. The level of acyl-CERs  
was reduced while the level of CERs with an extreme short chain length (total chain 




SC of AE patients. These changes in CER composition contributed to a reduced 
average CER chain length in AE SC compared to control SC.  
Not only the CER composition was modified, but also changes in the lipid 
organization were observed: the lamellar lipid organization was altered in a 
subclass of AE patients, indicating lamellar phases with a shorter repeat distance. 
Within these lamellae the lipids were organized in a less dense structure in AE 
patients compared to controls. The reduced average chain length of the CERs was 
associated with these changes in lipid organization. The reduced CER chain length 
as well as the modified lipid organization correlated with the impaired skin barrier 
function and disease severity, but were independent of the presence of  
FLG mutations. However, the changes in lipid composition and organization 
correlated with the levels of NMF, the degradation product of filaggrin. These 
results indicate that SC lipids play a role in the skin barrier dysfunction in  
non-lesional SC of patients with AE.  
 
Chapter 4 describes a study in which electron diffraction (ED) is used to examine 
the lateral lipid organization of non-lesional SC of AE patients and controls.  
This method is used in combination with tape-stripping. With ED it is possible  
to sample the local lateral packing (an area of ~1 μm2 is exposed to the electron 
beam) and obtain information on the relative occurrence of orthorhombic (dense) 
and hexagonal (less dense) lipid domains as well as lipid domains containing  
a combination of both types of lipid organization. The results showed an  
increased presence of the hexagonal lipid organization in non-lesional SC of  
AE patients at the expense of the orthorhombic lipid organization. These  
changes correlated with a reduced skin barrier function, but are independent of  
the presence of FLG mutations.  
 
In chapter 5 a detailed analysis of the FFA composition as well as the lipid 
organization in non-lesional as well as lesional SC of AE patients and control SC is 
reported. We focused particularly on the chain length distribution of the FFAs as 
the results described in chapter 3 indicate that CER chain length is important for 
a proper lipid organization and skin barrier function. We observed that the level of 
very long chain FFAs are strongly reduced while the level of shorter FFAs are 
increased in SC of AE patients compared to that in SC of control subjects. These 
alterations were more pronounced in lesional skin sites but already present in  
non-lesional AE skin sites. These changes resulted in a significant reduction of the 
average FFA chain length in SC in lesional and non-lesional skin of AE patients 
compared to controls. Not only the FFA chain length was altered, but also an 
increased level of unsaturated FFAs and a reduced level of hydroxy-FFAs were 
observed in SC of AE patients. Again, this was more pronounced in lesional skin 




FFA chain length distribution was associated with the chain length distribution of 
CERs. We observed that changes in FFA chain length composition strongly 
correlated with changes in CER chain length. Furthermore, the reduced levels of 
acyl-CERs and increased levels of C34 CERs were more prominent in SC of lesional 
skin than in non-lesional skin sites of patients with AE. 
The changes in lipid composition resulted in an altered lateral lipid 
organization; an increased level of lipids formed a hexagonal (less dense) 
organization and the lipid chains were more disordered in SC of AE patients 
compared to controls. Also here, these alterations were more pronounced in 
lesional AE SC compared to non-lesional SC. Both, the chain length distribution of 
the lipids and the lipid organization correlated excellently with the impaired skin 
barrier function, but no association with FLG mutations was observed. 
The results described in this chapter clearly demonstrate that not only the 
CERs, but also changes in the chain length distribution of FFAs contribute to 
changes in lipid organization and impaired skin barrier function in AE patients.  
 
In chapter 6 the use of Raman spectroscopy in order to determine the 
lipid/protein level in SC is reported. The lipid/protein ratio was determined by 
calculating the ratio of the integrated signal intensity from 2866 to 2900 cm-1  
(lipid signal) and from 2910 to 2966 cm-1 (protein signal). In addition, the dry SC 
mass per surface area of non-lesional and lesional AE skin sites was determined 
and compared to control SC. The results show that the dry SC mass per skin area  
is altered to some extent in lesional skin sites in AE patients compared to control 
subjects. In contrast, we observed a reduction in lipid/protein ratio already in  
non-lesional skin and this reduction was more pronounced in lesional SC of AE 
patients compared to controls. The lipid/protein ratio showed a very strong 
association with the skin barrier function. This demonstrates that besides the lipid 
composition and organization, the lipid/protein ratio is another important 
determinant of the skin barrier function. 
 
Chapter 7 describes the lipid composition and organization in 8 patients suffering 
from Netherton syndrome (NeS), an inflammatory skin disease related to AE.  
The disease is caused by mutations in the serine protease inhibitor  
Kazal-type 5 (SPINK5) gene, which encodes the protease inhibitor  
lympho-epithelial Kazal-type–related inhibitor (LEKTI). Lack of LEKTI causes 
epidermal proteases hyperactivity which results in severe SC detachment. As hardly 
any information is available on the SC lipid properties of these patients, our aim 
was to investigate whether the SC lipid composition and organization are altered in 
NeS patients. The results show that in SC of NeS patients there are drastic changes 
in the composition of CER subclasses, such as a reduction in the level of acyl-CERs. 




lengths and a strong increase in the level of unsaturated FFAs. Not only the  
lipid composition changed, but also changes in the lipid organization  
were detected: the lipid chains were more disordered. A subgroup of patients 
showed no lamellar ordering, and these patients also had the most  
drastic reduction of acyl-CERs in their SC. 
This study showed changes in the SC lipid profiles in NeS that are  
similar, but much more pronounced than in patients with AE. These changes in  
SC lipids are expected to contribute to the barrier dysfunction in NeS, as observed 
for patients with AE. 
Conclusions 
The studies described in this thesis demonstrate that there is an altered lipid 
composition in non-lesional as well as lesional SC of AE patients. Not only the 
levels of CER and FFA subclasses are altered in AE, also the levels of long-chain 
CERs and long-chain FFAs are decreased, while the level of short-chain CERs and 
short-chain FFAs are increased. These coordinated changes in lipid composition 
result in an altered lipid organization that is associated with an impaired skin 
barrier function. However, besides the altered lipid composition, the lipid/protein 
ratio is decreased in SC of AE patients. The reduced lipid/protein level also 
correlates strongly with the impaired skin barrier function. Then the question 
arises whether the changes in lipid composition correlate with the decreased lipid 
level. Preliminary results indicate a correlation coefficient of r=0.79 between the 
average lipid chain length and lipid/protein ratio, indicative for a common factor 
underlying the altered lipid composition and the lipid/protein level. This factor is 
yet unknown and may be subject of future studies. 
A direct intra-subject comparison between lesional and non-lesional skin 
revealed that the alterations in SC lipid properties are more pronounced in lesional 
SC in most cases. This suggests that the lipid biosynthesis is most affected  
in lesional skin which may be a result of inflammation, altered pH or  
increased levels of cutaneous microbes. 
Changes in SC lipid properties of NeS patients were comparable to  
those found in AE but were more pronounced, indicating similarities between  
these two atopic skin diseases. 
Our results show that the SC lipid composition, lipid organization  
and lipid/protein ratio are important determinants of the impaired skin  
barrier function in AE patients and are also related to the severity of the disease.  
A possible future treatment aiming to repair the skin barrier in patients with AE 
may focus on normalizing the lipid composition. This can be achieved in  




are present in reduced levels in SC or by affecting the lipid biosynthesis in  
the epidermis. This may improve the lipid organization and skin barrier function  
of these patients. 
Perspectives 
The studies described in this thesis demonstrate the importance of the SC lipids in 
the impaired skin barrier function of AE; the altered SC lipid composition results in 
an altered lipid organization which results in a decreased skin barrier function. 
 
Barrier repair in AE 
 
Use of in vitro lipid mixtures to study the effect of individual 
lipids on the lipid organization and permeability 
In order to obtain more insight in the effect of an altered lipid composition on the 
lipid organization, in vitro lipid mixtures can be used to study in more detail the 
effect of individual lipid classes on the lipid organization. Of special interest is an 
increase in the level of C34 CERs, a reduction in the level of acyl-CERs, an 
increased level of short chain FFAs and an increased level of unsaturated FFAs. Not 
only the modulation in lipid organization, but also changes in the permeability 
across the lipid matrix are of interest to examine. Such studies can be carried out 
with in vitro lipid mixtures sprayed on a porous membrane. It may be possible to 
monitor the lipid barrier function by transepidermal water loss also used in vivo to 
monitor the skin barrier function. In addition, it is of interest to measure the 
diffusion of compounds across the same lipid membrane model. Then even the 
question can be tackled whether the skin barrier as measured by transepidermal 
water loss (inside-out) is correlated with the penetration of substances inducing 
allergic response (outside-in). Currently hardly any information is available on 
these issues.  
 
Future treatments to normalize the lipid composition in AE 
patients  
This can be achieved in two ways; that is by supplementation of those lipids  
that are present in reduced levels in SC or by affecting the lipid biosynthesis in  
the epidermis.  
 
a. Topical supplementation of lipids. Based on the results obtained in this 
thesis formulations can be designed to supplement the SC of AE patients with those 




important determinant for skin barrier modulation, formulations should include 
lipids that increase the average lipid chain length. To determine whether this 
approach is successful, fundamental studies are required in order to determine 
whether the applied lipids indeed diffuse into the SC and subsequently modulate 
the lipid organization. This can be achieved by an extensive assessment of the lipid 
composition and organization before and after such a treatment. This should 
answer the question whether the formulations form an additional layer onto the 
skin surface or that the formulations diffuse into the skin provoking changes in the 
lipid properties within the SC. 
 
b. Lipid metabolism as an important target in AE. The altered lipid 
composition observed in SC of AE patients demonstrates changes in the lipid 
metabolism in the skin of AE patients. Two major changes in lipid composition 
were observed: changes in the levels of CER subclasses, and a reduction in the 
chain lengths of CERs and FFAs. Regarding the changes in CER subclasses, we 
found increased levels of those CERs that not only have glucosylceramides, but also 
sphingomyelin as precursors. This suggests a misbalance in activity between acid 
sphingomyelinase that catalyses the hydrolysis of the phosphorylcholine from 
sphingomyelin, and β-glucocerebrosidase that cleaves the glucose group from 
glucosylceramides. Therefore, it is of great interest to study the activity and level of 
the enzymes acid sphingomyelinase and β-glucocerebrosidase. 
The reduced chain lengths of CERs and FFAs may indicate reduced 
expression or activity of enzymes that elongate the lipid chains. As our studies 
showed that the changes in chain lengths of FFAs and CERs were highly correlated, 
normalization of elongation of the FFAs will most probably also normalize the 
chain lengths of the CERs. The elongation of FFAs from C14-C16 to longer chain 
lengths occurs by the elongase family. There are 7 elongases (ELOVL1-7) identified, 
all having a specific preference for a certain chain length of the FFA. ELOVL4 is 
observed in the epidermis on a protein level and plays a crucial role in the 
elongation of FFAs ≥C2433,34. This has been reported by two studies in which a 
strong reduction in very long chain FFAs was observed in ELOVL4 knockout 
mice33,35. However, also other members of this ELOVL family may be of interest. In 
particular ELOVL1 and ELOVL6 that may be responsible for the elongation of fatty 
acids with chain lengths between 16 to 20 carbons. Future studies may therefore 
focus on the expression level and activity of ELOVLs in AE patients. 
A less pronounced change in lipid composition is the increased level of 
unsaturated FFAs in SC of AE patients. It would be very desirable to examine the 
expression and activity of enzymes involved in desaturation of fatty acids, the 
stearoyl-coenzyme A desaturases (SCDs). As mono-unsaturated fatty acids with 
chain lengths of 16 carbon and 18 carbon atoms are most abundantly present in SC 




Effect of FLG mutations on skin barrier properties 
 
To date, the presence of FLG mutations is a well-known predisposing factor for AE, 
however we did not observe correlations between alterations in the SC lipids  
and presence of these mutations.  
In our studies 4 subjects were included that had a homozygous mutation and 
1 subject was included that had 2 heterozygous (compound heterozygous) 
mutations. Therefore, we were not able to compare the SC lipid properties of AE 
patients that had heterozygous, homozygous and compound heterozygous 
mutations. This may be an interesting target for future studies. Another approach 
to study in more detail whether FLG mutations do affect SC lipid composition and 
organization is to examine subjects with and without these mutations with any 
history of inflammation. In this way solely the effect of filaggrin mutations in lipid 
composition could be assessed without the interference of inflammation. Candidate 
subjects are control subjects carrying FLG mutations or infants with AE, without 




The study with NeS patients was carried out with a small group of patients. The 
results, however, demonstrate an altered SC lipid composition and organization. In 
the present study no TEWL was measured. Therefore, no relation between lipid 
organization, composition and skin barrier function could be assessed. It would be 
desirable to carry out such a study in a larger group of patients. Not only TEWL, 
but also expression levels of various proteases including LEKTI as well as lipid 
processing enzymes are of interest to examine. This might give more insight in the 
effect of proteases on lipid processing enzymes, lipid composition and organization 
in SC of patients with NeS. Studying this more severe atopic skin disease in greater 
detail may give more insights that can be of great help in understanding the disease 
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De huid beschermt het lichaam doeltreffend tegen ongewenste stoffen en overmatig 
vochtverlies. De barrièrefunctie is sterk afhankelijk van de buitenste laag van de 
huid, het stratum corneum (SC), ook wel hoornlaag genoemd. Het SC bestaat uit 
dode cellen, de zogenoemde corneocyten. Deze zijn omringd door een lipiderijke 
(vetrijke) matrix. Deze lipiden zijn zeer geordend. Corneocyten zijn tamelijk 
ondoordringbaar voor stoffen: het transport van de meeste stoffen door het SC 
heeft daardoor plaats via deze lipiden1-3. De SC-lipiden spelen daardoor een 
cruciale rol in de barrièrefunctie van de huid.  
De lipiden bestaan hoofdzakelijk uit ceramides (CER’s), cholesterol (CHOL) 
en vrije vetzuren (FFA’s)4. CER’s zijn opgebouwd uit een sphingosinebase 
gekoppeld aan een vetzuur. Tot op heden zijn er 12 CER-subklassen geïdentificeerd 
in menselijk SC5,6. De subklassen verschillen van elkaar in de structuur van de 
kopgroep en de ketenlengte. Er is één subklasse CER’s met een unieke structuur: de 
acyl-CER’s. Deze CER’s hebben een lange koolstofketen die verbonden is aan 
linolzuur (een onverzadigd vetzuur met 18 koolstofatomen). FFA’s bestaan 
voornamelijk uit verzadigde koolstofketens met lengtes variërend van 14 tot 32 
koolstofatomen, waarbij die van 24 en 26 koolstofatomen het meest voorkomen7,8.  
De lipiden in het SC zijn gerangschikt in lagen, waar ze zogeheten lamellaire 
structuren vormen. De lagen liggen ongeveer evenwijdig aan het huidoppervlak. In 
SC van gezonde mensen vormt het grootste gedeelte van de lipiden binnen de 
lipidelagen een zeer dichte, geordende (orthorhombische) structuur. Een klein 
gedeelte van de lipiden vormt een minder dichte (hexagonale) structuur.  
De lipidesamenstelling en lipidestructuur van het SC kunnen veranderd zijn 
in huid met een verminderde barrièrefunctie, zoals bij patiënten met 
constitutioneel eczeem (AE). AE is een chronische huidontsteking die gekenmerkt 
wordt door een droge, rode, jeukende huid9,10. Bijna 20% van de kinderen in 
westerse landen en 2-10% van de volwassenen heeft AE en dit aantal neemt gestaag 
toe11-15. De precieze oorzaak van AE is niet bekend, maar in eerdere studies is 
aangetoond dat AE sterk geassocieerd is met mutaties in het filaggrine-gen 
(FLG)16,17. Filaggrine is een eiwit dat een belangrijke rol speelt in de structuur en 
functie van het SC18. Filaggrine wordt afgebroken in een aantal componenten die 
belangrijk zijn voor de hydratatie van het SC. Men noemt deze componenten samen 
de natuurlijke hydratatiefactor (NMF)19. 
Patiënten met AE hebben een verminderde huidbarrière in zowel 
onaangedane (normaal uitziende) als aangedane (rood uitziende) huid.  
Deze patiënten hebben een verhoogd waterverlies door de huid20-24. Hoewel 
filaggrine belangrijk is voor de structuuropbouw van het SC, is nog niet  
aangetoond dat FLG mutaties ook bepalend zijn voor de verminderde 




een veranderde SC-lipidesamenstelling en SC-lipidestructuur, een belangrijke rol 
spelen in de vermindering van de huidbarrière bij patiënten met AE. 
De belangrijkste doelstelling van dit promotieonderzoek is het bepalen van 
de lipidesamenstelling, lipidestructuur en lipide-eiwitverhouding in SC van 
patiënten met AE en in controles met gezond SC. Daarnaast is onderzocht hoe deze 
veranderingen in lipide-eigenschappen gerelateerd zijn aan de verminderde 
barrièrefunctie van de huid en de ernst van het eczeem bij patiënten met AE. 
 
De belangrijkste vragen die worden beantwoord in dit proefschrift zijn: 
i) Zijn de SC-lipidesamenstelling en SC-lipidestructuur veranderd in 
onaangedane huid en aangedane huid van patiënten met AE vergeleken 
met SC van gezonde mensen? 
ii) Bestaat er een verband tussen de veranderde SC-lipidesamenstelling  
en SC-lipidestructuur in patiënten met AE en gezonde mensen? 
iii) Zijn de veranderingen in de lipide-eigenschappen van het  
SC gerelateerd aan een verminderde huidbarrière en de ernst  
van het eczeem? 
iv) Zijn de veranderingen in de lipide-eigenschappen van het  
SC gerelateerd aan de aanwezigheid van FLG-mutaties en het  
NMF-gehalte? 
v) Is de lipide-eiwitverhouding veranderd in SC van patiënten met AE en 
heeft deze gevolgen voor de huidbarrièrefunctie? 
vi) Zijn de lipide-eigenschappen van SC veranderd bij patiënten met een 
aan AE gerelateerde huidziekte, te weten het syndroom van Netherton 
(NeS)? 
 
In hoofdstuk 2 wordt de lamellaire lipidestructuur en de verhouding tussen de 
CER-subklassen beschreven in het SC van onaangedane huid van zes patiënten met 
AE en zes gezonde proefpersonen. Bij twee patiënten met AE is de lamellaire 
lipidestructuur veranderd: de repeterende eenheid van de lamellaire lipidelagen in 
het SC is kleiner vergeleken met die in SC van gezonde huid. De hoeveelheid  
acyl-CER’s die een zeer lange koolstofketen hebben, was lager bij beide patiënten. 
Deze resultaten tonen aan dat de aanwezigheid van acyl-CER’s een rol speelt bij het 
verlagen van de repeterende eenheid van de lipidelagen in SC van patiënten met 
AE. Een verband tussen de hoeveelheid acyl-CER’s en de lengte van de lamellaire 
lipidelagen is eerder aangetoond in SC-lipidemengsels31. Uit deze resultaten blijkt 
dat een meer gedetailleerde analyse van de lipidestructuur en lipidesamenstelling 






In hoofdstuk 3 wordt een uitgebreide analyse van de CER-samenstelling en de 
lipidestructuur beschreven in niet-aangedaan SC van patiënten met AE en in 
controles. De lipidesamenstelling van het SC is bepaald met behulp van  
tape-stripping: het aanbrengen, aandrukken en verwijderen van plakband  
met stukjes van het SC. De lamellaire lipidestructuur is door middel van  
een biopsie bepaald. De lipidestructuur binnen de lipidlagen en het NMF-gehalte 
van het SC zijn ook onderzocht. Tevens zijn de huidbarrièrefunctie en de ernst  
van het eczeem bepaald. 
Uit deze studies is gebleken dat de verhouding tussen verschillende  
CER-subklassen in het SC van onaangedane huid van patiënten met AE  
is veranderd ten opzichte van die van de gezonde proefpersonen. Vooral de  
acyl-CER’s zijn verlaagd, terwijl de aanwezigheid van CER’s met een extreem korte 
koolstofketen (een totale ketenlengte van 34 koolstofatomen, aangeduid als  
C34-CER’s) sterk blijkt te zijn toegenomen in het SC van patiënten met AE. Deze 
veranderingen in CER-samenstelling zorgen ervoor dat de gemiddelde  
CER-ketenlengte in het SC van patiënten met AE is verlaagd ten opzichte van  
die in gezonde proefpersonen.  
Naast de veranderde CER-samenstelling, blijkt ook de lipidestructuur te zijn 
gewijzigd. De repeterende eenheid van de lamellaire lipidestructuur is kleiner in 
een subgroep van patiënten met AE. De lipiden hebben, binnen deze lipidenlagen, 
een minder dichte structuur (een groter gedeelte van de lipiden is meer hexagonaal 
georganiseerd) bij patiënten met AE.  
De kortere ketenlengte van de CER’s correleert met veranderingen in de 
lipidestructuur. De kortere CER-ketenlengte en de veranderingen in de 
lipidestructuur komen overeen met een verminderde huidbarrière en de ernst van 
het eczeem, maar zijn onafhankelijk van de aanwezigheid van FLG-mutaties.  
De veranderingen in lipidesamenstelling en lipidestructuur correleren wel met  
het NMF-gehalte, het afbraakproduct van filaggrine. Deze resultaten tonen de  
rol aan van SC-lipiden in de verminderde huidbarrière van onaangedane huid  
in patiënten met AE. 
 
Hoofdstuk 4 beschrijft een studie waarin elektronendiffractie (ED) is gebruikt om 
de lipidestructuur te bepalen in onaangedaan SC van patiënten met AE en SC van 
controles. Deze methode wordt gebruikt in combinatie met tape-stripping. Het is 
met ED mogelijk de lokale lipidestructuur (=~1 μm2) te bestuderen en informatie te 
verkrijgen over de aanwezigheid van orthorhombische (dicht gestructureerde) en 
hexagonale (minder dicht gestructureerde) lipidedomeinen, alsmede over 





Uit de resultaten blijkt dat er meer hexagonale dan orthorhombisch georganiseerde 
lipiden zijn in onaangedaan SC van patiënten met AE, vergeleken met controles. 
Deze veranderingen correleren met een verminderde huidbarrièrefunctie, maar zijn 
onafhankelijk van de aanwezigheid van FLG-mutaties. 
 
In hoofdstuk 5 wordt een gedetailleerde analyse van de FFA-samenstelling en de 
lipidestructuur in het SC van onaangedane en aangedane huid van patiënten met 
AE en van gezonde proefpersonen beschreven. Het onderzoek is voornamelijk 
geconcentreerd op de ketenlengte-verschillen tussen de lipiden van gezonde 
personen en patiënten met AE. Immers, uit de resultaten vermeld in hoofdstuk 3 
is gebleken dat de CER-ketenlengte invloed heeft op de lipidestructuur en 
huidbarrière. Aangetoond is dat de relatieve hoeveelheid FFA’s met lange 
koofstofketens sterk verlaagd is in het SC van patiënten met AE, terwijl FFA’s met 
kortere ketenlengtes juist verhoogd zijn, in vergelijking met het SC van gezonde 
proefpersonen. Deze veranderingen zijn duidelijker te zien in aangedane AE-huid, 
maar zijn ook waargenomen in onaangedane huid van patiënten met AE. Deze 
veranderde FFA-samenstelling resulteert in een aanzienlijke vermindering van de 
gemiddelde ketenlengte van de FFA’s in aangedaan en niet-aangedaan SC van 
patiënten met AE ten opzichte van gezonde proefpersonen. De FFA-ketenlengte is 
niet alleen gewijzigd, daarnaast is het gehalte aan onverzadigde FFA’s verhoogd en 
blijkt het gehalte aan hydroxy-FFA’s verlaagd in het SC van patiënten met AE.  
Ook deze veranderingen zijn nadrukkelijker aanwezig in aangedaan SC ten  
opzichte van niet-aangedaan SC.  
Het resultaten van het onderzoek tonen aan dat er een sterke samenhang 
bestaat tussen de FFA- ketenlengteverdeling en de ketenlengteverdeling van  
CER’s. De verlaagde relatieve hoeveelheden acyl-CER’s (met lange ketens)  
en verhoogde relatieve hoeveelheden C34-CER’s (met korte ketens) manifesteerden 
zich meer in het SC van aangedane huid dan in het SC van niet-aangedane  
huid van patiënten met AE. 
De veranderingen in lipidesamenstelling leiden tot een veranderde 
lipidestructuur binnen de lipidelagen: meer lipiden vormen een hexagonale 
(minder dichte) structuur en de lipideketens waren minder geordend in het SC van 
patiënten met AE in vergelijking met gezonde proefpersonen. Ook hier waren de 
veranderingen duidelijker aanwezig in aangedane huid ten opzichte van 
onaangedane huid. De ketenlengteverdeling van de lipiden en de lipidestructuur 
correleren uitstekend met de verminderde huidbarrièrefunctie, maar wederom was 
er geen associatie met FLG-mutaties. 
De resultaten in dit hoofdstuk tonen aan, dat de veranderingen in SC  
CER’s èn die in de ketenlengteverdeling van FFA’s bijdragen tot veranderingen  
in de lipidestructuur en van invloed zijn op de verminderde huidbarrière  




Hoofdstuk 6 gaat in op het gebruik van Raman-spectroscopie om de  
lipide-eiwitverhouding in het SC te bepalen. Deze is bepaald door de verhouding 
van het oppervlakte van de piek, gelegen tussen 2866-2900 cm-1 (lipidesignaal)  
en die van de piek, gelegen tussen 2910-2966 cm-1 (eiwitsignaal) in het spectrum  
te berekenen. Bovendien is het droge SC-gewicht per oppervlakte-eenheid 
vastgesteld van onaangedane en aangedane huid van patiënten met AE en  
van gezonde proefpersonen.  
Uit de resultaten blijkt dat het droge SC-gewicht enigszins is verminderd in 
aangedane huid van patiënten met AE ten opzichte van de controles. De  
lipide-eiwitverhouding in onaangedane huid van patiënten met AE is aanzienlijk 
lager ten opzichte van die in gezonde proefpersonen. Deze verlaging is nog 
duidelijker in aangedane huid van patiënten met AE. De lipide-eiwitverhouding 
heeft een zeer sterke associatie met de huidbarrièrefunctie. Hieruit blijkt dat naast 
de lipidesamenstelling en lipidestructuur, óók de lipide-eiwitratio van grote invloed 
is op de verminderde huidbarrièrefunctie van deze patiënten.  
 
Hoofdstuk 7 beschrijft de lipidesamenstelling en de lipidestructuur van acht 
patiënten met NeS, een inflammatoire huidziekte die gerelateerd is aan AE. NeS 
wordt veroorzaakt door mutaties in het zogenoemde serine protease inhibitor 
Kazal-type 5 (SPINK5)-gen. Dit gen codeert de proteaseremmer LEKTI, de  
lymfo-epitheliale Kazal-type gerelateerde inhibitor. Gebrek aan LEKTI veroorzaakt 
hyperactiviteit van epidermale proteasen (enzymen die lagen van de huid kunnen 
‘knippen’), wat resulteert in het vroegtijdig loslaten van het bovenste gedeelte  
van het SC. Er is op dit moment weinig bekend over de SC-lipiden bij deze 
patiënten. Wij wilden daarom onderzoeken of de SC-lipidesamenstelling en de  
SC-lipidestructuur zijn veranderd bij patiënten met NeS.  
Uit de resultaten blijkt, dat er sprake is van grote veranderingen in de 
samenstelling van de CER-subklassen in het SC van patiënten met NeS. Er is een 
duidelijke vermindering van de relatieve hoeveelheid van acyl-CER’s. Daarnaast is 
er een sterke toeneming van de C34-CER’s, een verhoging in FFA’s met kortere 
ketens en een sterke toeneming van het gehalte aan onverzadigde FFA’s. Er zijn ook 
veranderingen in de lipidestructuur aangetoond: de lipideketens zijn minder 
geordend. Bovendien had een aantal patiënten geen juist gerangschikte lipidelagen 
in hun SC en hadden deze patiënten de meest extreme vermindering acyl-CER’s. 
Uit deze studie komt naar voren dat de veranderingen in  
SC-lipidesamenstelling bij patiënten met NeS vergelijkbaar zijn met die bij 
patiënten met AE. Echter, bij patiënten met NeS zijn deze veranderingen veel 
prominenter. Deze veranderingen in SC-lipiden kunnen ook bijdragen aan de 
huidbarrièredysfunctie bij patiënten met NeS, zoals waargenomen bij patiënten 





Uit deze onderzoeksresultaten blijkt, dat er sprake is van een veranderde 
lipidesamenstelling van zowel onaangedaan als aangedaan SC bij patiënten met AE. 
Er zijn niet alleen veranderingen in de relatieve hoeveelheid CER en  
FFA-subklassen in SC van patiënten met AE. Tevens zijn de relatieve hoeveelheden 
CER’s en FFA’s met lange ketens verlaagd, terwijl CER’s en FFA’s met korte ketens 
relatief zijn verhoogd. Deze veranderingen resulteren in een wijziging in de 
lipidestructuur die leidt tot een verminderde huidbarrière. Verder is de  
lipide-eiwitverhouding verlaagd in het SC van patiënten met AE, wat ook sterk is 
gerelateerd aan de verminderde barrièrefunctie van de huid.  
Uit een directe vergelijking tussen aangedane en onaangedane huid bij één 
patiënt blijkt dat de veranderingen in lipide-eigenschappen van het SC 
prominenter aanwezig zijn in SC van aangedane huid. Dit doet vermoeden dat de 
lipidesynthese het meest veranderd is in aangedane huid. Aangezien het hier om 
een vergelijking binnen één patiënt gaat, kan deze verandering in lipidesynthese 
niet veroorzaakt worden door genetische factoren. De lipidesamenstelling en dus 
ook de lipidestructuur veranderen mogelijk ten gevolge van ontsteking, veranderde 
zuurgraad (pH) of verhoogde aanwezigheid van bacteriën op de huid. 
De veranderingen in de SC-lipide-eigenschappen waren meer expliciet bij 
patiënten met NeS, in vergelijking met patiënten met AE. Dit toont aan dat er 
overeenkomsten zijn tussen deze twee atopische huidaandoeningen. 
De resultaten wijzen uit dat de lipidesamenstelling, lipidestructuur en  
lipide-eiwitverhouding in het SC belangrijke factoren zijn met betrekking tot de 
verminderde huidbarrière en de ernst van het eczeem bij patiënten met AE. Een 
behandeling ten behoeve van verbetering van de huidbarrière van patiënten met 
AE, zou zich mogelijk kunnen richten op het normaliseren van de 
lipidesamenstelling. Twee fundamenteel verschillende manieren zouden hier voor 
in aanmerking kunnen komen: aanvulling van de lipiden in het SC of het bewerken 
van de lipidesynthese in de epidermis. Zo zouden de lipidestructuur en de 
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Dan is het nu toch echt zover dat ik de allerlaatste woorden van mijn proefschrift 
aan het schrijven ben! Dit werk was niet mogelijk geweest zonder de hulp van 
velen. Daarom wil ik iedereen bedanken die heeft bijgedragen aan de 
totstandkoming van dit proefschrift. Collega’s, studenten, en de bedrijven die deel 
uitmaakten van de gebruikerscommissie. Iedereen droeg zijn of haar steentje bij, en 
dat was echt onmisbaar!  
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Jullie hebben de basis gelegd voor wie ik nu ben en hebben mij altijd alle  
kansen gegeven.  
Margot en Marc, mijn zus en broertje, ook van jullie heb ik altijd steun gekregen  
als ik het even niet zag zitten. Marc, jij gaat nu je eigen promotieonderzoek  
doen, heel veel succes, voor tips kan je bij mij terecht! Margot, wat is het super  
een zus zoals jij te hebben! 
Ook mijn schoonfamilie mag hier niet ontbreken.  De hulp met de Nederlandse 
samenvatting en stellingen was zeer fijn, bedankt hiervoor! De gezellige avonden 
gevuld met eten en films kijken moeten er zeker blijven, Merijn. 
 
En tenslotte, Thijs. Onze vrijdag de 13e was alles behalve een ongeluksdag! Precies 
een jaar later kregen we de sleutel van ons fijne huis gelegen aan de Vliet in 
Voorschoten. Na een dag hard werken is het altijd heerlijk om naar huis te gaan. 
Voorbereidingen treffen voor onze bruiloft en verhuizing waren zeer ontspannende 
bezigheden naast de dagelijkse promotiestress. Ik heb heel veel aan jouw 
relativeringsvermogen: telkens slaag jij erin om mij dingen in het juiste perspectief 
te laten zien. En last but not least: jij hebt ervoor gezorgd dat de artikelen 
samengebundeld werden tot één geheel: dit proefschrift. Ik ben je ontzettend 
dankbaar voor alles! 
